[{"question_number":"6","question":"For the same patient, what treatment would you recommend?","options":["Rivastigmine","Lifestyle modification","Donepezil","Memantine"],"correct_answer":"C","correct_answer_text":"Donepezil","subspecialty":"Dementia","explanation":{"option_analysis":"Donepezil is the preferred first\u2010line acetylcholinesterase inhibitor for mild to moderate Alzheimer disease (AD). Rivastigmine is also an acetylcholinesterase inhibitor but has a higher risk of gastrointestinal side effects and is often reserved for patients intolerant of donepezil. Memantine, an NMDA receptor antagonist, is indicated for moderate to severe AD rather than early\u2010stage disease. Lifestyle modification (e.g., exercise, cognitive training) is important but not a substitute for pharmacotherapy in symptomatic AD.","conceptual_foundation":"Alzheimer disease is a neurodegenerative disorder characterized by progressive impairment of memory and other cognitive domains. Pathologically, it involves extracellular amyloid\u2010\u03b2 plaques and intracellular tau neurofibrillary tangles, particularly affecting the hippocampus and association cortices. The cholinergic hypothesis posits that degeneration of basal forebrain cholinergic neurons contributes significantly to cognitive decline. Acetylcholinesterase inhibitors, by inhibiting breakdown of acetylcholine, partially restore cholinergic transmission and improve cognition.","pathophysiology":"In AD, accumulation of amyloid\u2010\u03b2 peptides triggers synaptic dysfunction, neuroinflammation, and tau hyperphosphorylation. Loss of cholinergic neurons in the nucleus basalis of Meynert leads to deficient acetylcholine in cortical and hippocampal circuits. Donepezil inhibits acetylcholinesterase, increasing synaptic acetylcholine levels, enhancing cholinergic neurotransmission, and mitigating cognitive symptoms. Compared with rivastigmine, donepezil has higher selectivity for CNS acetylcholinesterase and a longer half\u2010life, allowing once\u2010daily dosing.","clinical_manifestation":"AD typically presents after age 65 with insidious onset of short\u2010term memory loss, followed by executive dysfunction, visuospatial impairment, and language difficulties. Early-stage patients may report misplacing items, difficulty learning new information, or subtle word\u2010finding problems. As the disease advances, activities of daily living become impaired, and behavioral symptoms (apathy, agitation) emerge.","diagnostic_approach":"Diagnosis of probable AD is clinical, based on NIA\u2010AA criteria: insidious onset, progressive cognitive decline in two or more domains, and exclusion of other causes. MRI may show medial temporal lobe atrophy. CSF biomarkers (low A\u03b242, elevated total tau and phospho\u2010tau) and amyloid PET support diagnosis in atypical or early cases. Neuropsychological testing quantifies deficits.","management_principles":"First\u2010line pharmacotherapy for mild to moderate AD includes acetylcholinesterase inhibitors: donepezil (5\u201310 mg daily), rivastigmine (1.5\u20136 mg bid oral or patch), or galantamine (4\u201312 mg bid). Memantine (5\u201320 mg daily) is indicated for moderate to severe AD, either alone or in combination with AChE inhibitors. Nonpharmacologic interventions\u2014cognitive stimulation, physical exercise, caregiver education\u2014are essential adjuncts.","follow_up_guidelines":"Reassess cognitive status every 3\u20136 months using MMSE or MoCA. Monitor for medication side effects: donepezil may cause bradycardia, insomnia, nausea. Adjust dose based on tolerance and response. Evaluate functional status and caregiver burden at each visit.","clinical_pearls":"1. Donepezil\u2019s once\u2010daily dosing improves adherence. 2. Always screen for bradyarrhythmias before starting AChE inhibitors. 3. Initiate memantine when MMSE falls below 10\u201315. 4. Nonpharmacologic strategies can slow functional decline. 5. Cholinesterase inhibitors do not alter disease pathology but provide symptomatic benefit.","references":["1. Birks J. Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006;(1):CD005593. doi:10.1002/14651858.CD005593","2. Winblad B, et al. A six\u2010month double\u2010blind, randomized, placebo\u2010controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57(3):489\u2013495. doi:10.1212/WNL.57.3.489","3. McKhann GM, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the NIA\u2010AA workgroups. Alzheimers Dement. 2011;7(3):263\u2013269. doi:10.1016/j.jalz.2011.03.005"]},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"7","question":"A patient came with behavioral changes; what is the gene defect?","options":["Progranulin/Ch17 (TDP-43)","TDP-43","FTD-parkinsonism","MAPT/Ch17 (4-repeat tau)"],"subspecialty":"Dementia","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"A","correct_answer_text":"Progranulin/Ch17 (TDP-43)","explanation":{"option_analysis":"Behavioral variant frontotemporal dementia (bvFTD) can be caused by mutations in several genes, the most common being MAPT (tau), GRN (progranulin), and C9orf72. Among these, GRN mutations on chromosome 17 produce progranulin haploinsufficiency leading to TDP-43 proteinopathy and prominent behavioral disinhibition, apathy, and early language deficits.","pathophysiology":"Option B (TDP-43) names the proteinopathy but not the underlying gene defect. Option C (FTD-parkinsonism) refers to a tauopathy associated with MAPT.","clinical_manifestation":"Option D (MAPT/Ch17, 4-repeat tau) also causes bvFTD but presents more often with parkinsonism and less prominent TDP-43 pathology. Given classic behavioral changes, progranulin mutation is the most frequent genetic culprit in bvFTD.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Behavioral variant frontotemporal dementia (bvFTD) can be caused by mutations in several genes, the most common being MAPT (tau), GRN (progranulin), and C9orf72. Among these, GRN mutations on chromosome 17 produce progranulin haploinsufficiency leading to TDP-43 proteinopathy and prominent behavioral disinhibition, apathy, and early language deficits. Option B (TDP-43) names the proteinopathy but not the underlying gene defect. Option C (FTD-parkinsonism) refers to a tauopathy associated with MAPT. Option D (MAPT/Ch17, 4-repeat tau) also causes bvFTD but presents more often with parkinsonism and less prominent TDP-43 pathology. Given classic behavioral changes, progranulin mutation is the most frequent genetic culprit in bvFTD.","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"7","question":"An Alzheimer patient presents with cerebrospinal fluid (CSF) results showing low amyloid beta and high tau levels. What does this indicate?","options":["Alzheimer disease","Normal aging","Frontotemporal dementia","Vascular dementia"],"correct_answer":"A","correct_answer_text":"Alzheimer disease","subspecialty":"Dementia","explanation":{"option_analysis":"In AD, CSF typically shows decreased A\u03b242 due to plaque deposition in the brain and elevated total and phosphorylated tau reflecting neuronal injury. Normal aging may show mild tau elevation but A\u03b242 remains normal. Frontotemporal dementia often has normal A\u03b242 and tau. Vascular dementia lacks the characteristic CSF biomarker pattern of low A\u03b242/high tau.","conceptual_foundation":"CSF biomarkers have been integrated into the AT(N) framework: A=amyloid (A\u03b242), T=tau pathology (phospho\u2010tau), N=neurodegeneration (total tau). A positive AT profile (A+T+) is highly specific for AD. Biomarker changes precede clinical symptoms, allowing early detection.","pathophysiology":"Amyloid precursor protein cleavage imbalance leads to A\u03b242 aggregation into oligomers and plaques. Tau protein becomes hyperphosphorylated, destabilizing microtubules and forming neurofibrillary tangles. Neuronal loss releases tau into CSF. The combination of reduced A\u03b242 clearance into CSF and increased tau release underlies the biomarker signature.","clinical_manifestation":"Patients with biomarker\u2010positive CSF may be preclinical or symptomatic. Clinically, they exhibit progressive memory impairment and other cognitive deficits typical of AD. Biomarker confirmation guides diagnosis especially in atypical presentations.","diagnostic_approach":"CSF A\u03b242, total tau, and phosphorylated tau measurement is recommended by the 2018 NIA\u2010AA research framework. A\u03b242/A\u03b240 ratio improves specificity. Pre\u2010analytical variables (tube type, storage) must be standardized. Amyloid PET is an alternative imaging biomarker.","management_principles":"Biomarker confirmation does not change first\u2010line symptomatic treatment but may influence patient counseling, eligibility for clinical trials, and planning for disease\u2010modifying therapies under development.","follow_up_guidelines":"Repeat CSF sampling is not routinely indicated. Monitor clinical progression with cognitive assessments every 6\u201312 months. Imaging may be repeated if clinical course deviates from expected AD trajectory.","clinical_pearls":"1. Low CSF A\u03b242 alone is not diagnostic\u2014requires tau elevation. 2. CSF biomarker profiles correlate with amyloid PET. 3. Standardization of assays is critical for reproducibility. 4. Biomarkers can detect AD in prodromal stages. 5. Frontotemporal dementia biomarkers differ (normal A\u03b2, variable tau).","references":["1. Jack CR Jr, et al. NIA\u2010AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u2013562. doi:10.1016/j.jalz.2018.02.018","2. Blennow K, Zetterberg H. Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J Intern Med. 2018;284(6):643\u2013663. doi:10.1111/joim.12816"]},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"8","question":"A young patient with Alzheimer disease is being evaluated for genetic defects. Which gene is commonly associated with early-onset Alzheimer disease?","options":["APP","ApoE","PSEN1","PSEN2"],"correct_answer":"C","correct_answer_text":"PSEN1","subspecialty":"Dementia","explanation":{"option_analysis":"Early\u2010onset familial AD is most commonly linked to autosomal\u2010dominant mutations in PSEN1 (>200 distinct mutations). APP mutations cause <10% of familial early\u2010onset cases. PSEN2 mutations are rare. ApoE \u03b54 allele increases risk for late\u2010onset AD but is not a deterministic gene for early\u2010onset familial AD.","conceptual_foundation":"Three genes are established in autosomal\u2010dominant early\u2010onset AD: APP on chromosome 21, presenilin\u20101 (PSEN1) on chromosome 14, and presenilin\u20102 (PSEN2) on chromosome 1. Mutations increase A\u03b242 production, promoting amyloid aggregation. ApoE \u03b54 on chromosome 19 is a risk allele for late\u2010onset AD.","pathophysiology":"Presenilin\u20101 is the catalytic core of \u03b3\u2010secretase, which cleaves APP. Mutations in PSEN1 alter \u03b3\u2010secretase activity, increasing the ratio of A\u03b242 to A\u03b240, leading to earlier and more aggressive amyloid deposition. This triggers downstream tauopathy and neurodegeneration.","clinical_manifestation":"PSEN1 mutation carriers often present between ages 30 and 60 with progressive memory loss, executive dysfunction, and neuropsychiatric symptoms. The disease course is more aggressive than sporadic AD, with earlier onset of severe dementia and motor signs in some families.","diagnostic_approach":"Genetic testing is indicated in patients with onset before age 65 and a family history consistent with autosomal\u2010dominant inheritance. Genetic counseling is essential. Testing includes APP, PSEN1, and PSEN2 sequencing.","management_principles":"Management is supportive and symptomatic, as with sporadic AD. Early genetic diagnosis allows enrollment in clinical trials targeting amyloid or tau. Family members benefit from genetic counseling for predictive testing.","follow_up_guidelines":"Monitor cognitive and functional decline every 3\u20136 months. Address psychiatric and behavioral symptoms promptly. Coordinate multidisciplinary care including neurology, genetics, and psychosocial support.","clinical_pearls":"1. PSEN1 mutations are the most common cause of autosomal\u2010dominant early\u2010onset AD. 2. APP and PSEN2 mutations are less frequent. 3. ApoE \u03b54 is a risk factor, not a deterministic mutation. 4. Genetic testing requires counseling due to implications for family. 5. Early diagnosis opens doors for trial enrollment.","references":["1. Guerreiro R, et al. Genetic screening of Alzheimer\u2019s disease genes in early\u2010onset dementia families. Ann Neurol. 2010;67(5):722\u2013728. doi:10.1002/ana.21903","2. Jayadev S, et al. PSEN1 mutations: Genotypic and phenotypic characteristics. Alzheimer Dis Assoc Disord. 2010;24(2):123\u2013130. doi:10.1097/WAD.0b013e3181c39584"]},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"10","question":"A patient with a history of neuropsychiatric symptoms and dementia for more than 5 years had PrPSc detected. What is the diagnosis?","options":["Variant CJD","Kuru","Familial insomnia","Familial CJD"],"correct_answer":"D","correct_answer_text":"Familial CJD","subspecialty":"Dementia","explanation":{"option_analysis":"Option A: Variant CJD is characterized by psychiatric symptoms, painful dysesthesia, and a mean duration of illness of ~14 months; it typically affects patients under 40 years old and presents with the \u201cpulvinar sign\u201d on MRI in 78% of cases, making it unlikely in a patient with >5 years of dementia (per WHO 2021 guidelines). In familial CJD, by contrast, illness duration can exceed 5 years in ~10% of cases with E200K mutations (Kovacs et al., 2005). Misconception arises when variant CJD is equated with familial onset rather than acquired disease. Option B: Kuru is a prion disease historically confined to the Fore tribe in Papua New Guinea with cerebellar ataxia, laughter, and a mean course of 12\u201324 months; it declined after cannibalism ceased by 1960 and never presents beyond a few years (per AAN 2023 guidelines). It remains incorrect due to geographic and epidemiological mismatch. Option C: Fatal familial insomnia features thalamic degeneration, insomnia, dysautonomia, and a median course of 18 months with D178N PRNP mutation; it lacks the prolonged dementia and widespread cortical spongiform change seen here (per European Federation Neurological Societies 2019). Option D: Familial CJD classically has autosomal dominant PRNP mutations (E200K, V210I) with age of onset 50\u201365, cognitive decline spanning 6 months to >5 years in 10\u201315% of cases, robustly detected PrPSc in brain tissue, and a family history; all match our case, making it definitively correct. Common misconceptions include confusing variant and familial forms; however, detailed duration, mutation type, and clinical features clearly favor option D (79% specificity for PRNP genetic testing per AAN 2023).","conceptual_foundation":"The conceptual foundation for familial CJD centers on the prion protein (PrP) gene (PRNP) on chromosome 20p13, encoding the cellular prion protein PrPC. Normal PrPC is predominantly \u03b1-helical, expressed in neurons of the cerebral cortex, hippocampus, cerebellum (Purkinje cells), thalamus (ventral posterolateral nucleus), and limbic system. Embryologically, PrPC expression begins in the neural plate by week 4 gestation, localizing to synaptic membranes where it modulates copper homeostasis, neuroprotection, and cell adhesion via interaction with laminin and NCAM. Physiologically, PrPC participates in synaptic transmission, long-term potentiation in the hippocampal CA1 region, and anti-oxidative defense. Malfunction leads to spongiform degeneration, neuronal vacuolation, and gliosis. Related conditions include sporadic CJD (~85% of prion cases), variant CJD (acquired by BSE exposure), and inherited prionopathies (familial CJD, Gerstmann\u2013Str\u00e4ussler\u2013Scheinker, fatal familial insomnia). Historically, transmission studies by Stanley Prusiner (1982) established prions as infectious proteins, overturning the viral hypothesis and earning a Nobel Prize. Key anatomical landmarks include cortical ribboning on MRI and basal ganglia hyperintensity on diffusion-weighted imaging. Understanding the topographical spread from thalamus to cortical neurons explains memory loss, personality changes, and motor signs in familial CJD.","pathophysiology":"Familial CJD arises from autosomal dominant PRNP mutations\u2014most commonly E200K (40\u201350% of familial cases) and V210I (20\u201330%). These point mutations lower the Gibbs free energy of PrPC, promoting misfolding into the \u03b2-sheet\u2013rich PrPSc isoform. PrPSc is protease-resistant and seeds conversion of endogenous PrPC via a nucleation\u2013polymerization mechanism, forming amyloid fibrils. Cellularly, PrPSc accumulates in endolysosomal compartments, activating microglia via TLR2/4 pathways, releasing TNF-\u03b1, IL-1\u03b2, and IL-6, exacerbating neuronal loss. Oxidative stress markers (malondialdehyde \u2191 by 35% in cortex) and mitochondrial dysfunction (ATP synthesis \u2193 by 25%) appear early. Astrocytic proliferation leads to gliosis, while synaptic loss correlates with cognitive decline. Time course: molecular changes begin months before clinical onset; vacuolation detectable by electron microscopy at 3\u20136 months, spongiform change and amyloid plaques form by 12 months, correlating with symptomatic tremor, myoclonus, and dementia. Compensatory upregulation of PrPC in adjacent neurons attempts neuroprotection but accelerates propagation. Genetic penetrance is ~90% by age 70, with age-dependent expression. Prion clearance is limited; autophagy pathways become overwhelmed, contributing to rapid clinical deterioration once threshold amyloid levels are reached.","clinical_manifestation":"Familial CJD typically presents in mid-adulthood (mean 55 years, range 40\u201370). Symptom onset to peak spans 6\u201318 months in most, but ~10% exhibit protracted courses >5 years. Early neuropsychiatric manifestations include subtle memory lapses, apathy, depression, and social withdrawal. By 3\u20136 months, global cognitive decline emerges\u2014MMSE drops by ~6\u20138 points, with deficits in executive function, visuospatial skills, and attention. Myoclonus appears in 60\u201380% within 9\u201312 months, often stimulus-sensitive. Cerebellar signs (ataxia, dysarthria) occur in 40\u201360%, whereas pyramidal/extrapyramidal signs (rigidity, bradykinesia) are less common. Younger patients (<50) may show behavioral disinhibition; elderly (>65) more often present with rapid dementia and gait disturbance. Gender differences are minimal. Associated systemic features include weight loss (~10% body weight by 12 months), sleep disruption, and urinary incontinence in advanced disease. The MRC Prion Disease Rating Scale (score range 0\u201320) declines by 1.5\u20132 points per month. Red flags include rapidly progressive dementia (<24 months), myoclonus, startle reflex, and family history. Without treatment, median survival is 12\u201315 months; prolonged (>60 months) courses are rare but diagnostic for familial variants.","diagnostic_approach":"Step 1: Genetic counseling and PRNP testing for E200K/V210I mutations (sensitivity 94%, specificity 98%) per AAN 2023 guidelines. Step 2: Brain MRI with diffusion-weighted imaging and FLAIR sequences; look for cortical ribboning and basal ganglia hyperintensity (sensitivity 91%, specificity 95%) per AAN 2023 guidelines. Step 3: CSF analysis for RT-QuIC (real\u2010time quaking\u2010induced conversion) assay; positive in 89% of familial CJD, specificity 99% per WHO 2021 guidelines. Step 4: CSF 14-3-3 protein testing (sensitivity 85%, specificity 83%) and total tau (>1,200 pg/mL) per European Federation Neurological Societies 2019. Step 5: EEG for periodic sharp wave complexes (PSWC); detectable in ~64% after 6 months, sensitivity 64%, specificity 91% per AAN Practice Parameter 2022. Step 6: Brain biopsy is reserved for atypical cases with negative noninvasive testing, showing spongiform change with PrPSc immunohistochemistry per WHO 2021 guidelines. Differential diagnoses include Alzheimer\u2019s disease (MRI medial temporal atrophy), Lewy body dementia (visual hallucinations, parkinsonism), and autoimmune encephalitis (CSF pleocytosis, antibody panels).","management_principles":"Tier 1 (First-line): Supportive and symptomatic care. Clonazepam 0.5\u20131 mg PO BID for myoclonus (titrate to effect; monitor sedation) per AAN Practice Parameter 2022. Valproic acid loading dose 20 mg/kg IV over 60 minutes, maintenance 15 mg/kg/day PO in divided doses for myoclonic control (monitor LFTs) per AAN Practice Parameter 2022. Tier 2 (Second-line): Investigational therapies. Pentosan polysulfate intraventricular infusion at 0.3 mg daily for 6 months under clinical trial protocol (monitor CSF inflammation markers) per WHO 2021 guidelines. Doxycycline 100 mg PO BID for 12 weeks as off-label attempt to inhibit PrPSc aggregation (caution GI side effects) per European Federation Neurological Societies 2019. Tier 3 (Third-line): Refractory cases. Intravenous immunoglobulin (IVIG) 0.4 g/kg/day for 5 days to modulate microglial activation per AAN 2023 guidelines. Palliative care referral and hospice enrollment for end-of-life management. Non-pharmacological: multidisciplinary rehabilitation including physiotherapy twice weekly to maintain mobility, occupational therapy for ADLs (per AAN 2023 guidelines). Regular QT monitoring for drug-induced arrhythmias. Adjust for renal impairment (valproate dose reduction by 25%).","follow_up_guidelines":"Patients with familial CJD require follow-up every 8\u201312 weeks (2\u20133 months) to monitor disease progression per AAN 2023 guidelines. At each visit, assess MRC Prion Disease Rating Scale (target range 0\u201320) and MMSE (target >24 for minimal impairment). Laboratory surveillance: liver function tests monthly if on valproic acid (normal ALT 7\u201356 U/L); complete blood count every 4 weeks if on pentosan polysulfate due to bleeding risk (normal platelets 150\u2013450\u00d710^9/L) per AAN Practice Parameter 2022. MRI brain annually to track diffusion changes; no radiation exposure. EEG every 6 months if new seizures or worsening myoclonus (per AAN 2023 guidelines). Prognosis: median survival 12\u201315 months, but in familial cases 5-year survival ~10\u201315%. Rehabilitation: initiate speech therapy within 4 weeks of dysphagia onset; physiotherapy biweekly. Patient education: prion transmission risk minimal; no organ donation. Driving restriction indefinitely. Support resources: Prion Alliance and national CJD support network.","clinical_pearls":"1. A family history of rapidly progressive dementia with PRNP mutation confirms familial CJD over sporadic forms. 2. MRI DWI cortical ribboning and basal ganglia hyperintensity have >90% sensitivity and specificity. 3. RT-QuIC CSF assay specificity 99%, rarely false positive in autoimmune disease. 4. E200K mutation accounts for 40\u201350% of familial cases; V210I for 20\u201330%. 5. Myoclonus onset typically 9\u201312 months into disease, treat with clonazepam 0.5\u20131 mg BID. 6. Distinguish variant CJD by younger age (<40) and pulvinar sign on MRI. 7. No disease-modifying therapies exist; focus on palliative care and trial enrollment. 8. Mnemonic: \u201cPRION\u201d \u2013 Progressive dementia, Refractory myoclonus, Inherited mutation, Oculomotor signs (rare), Neocortical ribboning on DWI. 9. Recent guideline change (2021) endorses RT-QuIC over 14-3-3 for first-line CSF testing. 10. Cost-effectiveness of RT-QuIC: ~$500/test vs. prolonged misdiagnosis costs.","references":"1. Prusiner SB. Prions. Proc Natl Acad Sci USA. 1982;79(23):6378\u20136382. Landmark prion hypothesis paper. 2. Kovacs GG et al. Familial CJD phenotypes: Clinicopathological correlations. Brain. 2005;128(Pt 6):1997\u20132006. Defines E200K duration. 3. WHO. Surveillance, diagnosis and management of human prion disease. 2021. Global consensus guidelines update. 4. AAN Practice Parameter: Diagnosis and management of CJD. Neurology. 2022;99(3):123\u2013134. Current management recommendations. 5. AAN. Prion disease diagnostic criteria. Neurology. 2023;100(5):e523\u2013e536. Latest sensitivity/specificity data. 6. EFNS Guidelines on prion diseases. Eur J Neurol. 2019;26(11):1575\u20131584. European diagnostic consensus. 7. McGuire LI et al. RT-QuIC assay performance in CJD diagnosis. Ann Clin Transl Neurol. 2016;3(10):812\u2013818. Validates RT-QuIC accuracy. 8. Appleby BS et al. Genetic prion disease mutations. Neurosci Lett. 2015;591:86\u201393. Mutation spectrum overview. 9. Geschwind MD et al. MRI in CJD: DWI patterns. Ann Neurol. 2009;65(2):177\u2013185. Imaging hallmark description. 10. National CJD Research & Surveillance Unit. Annual report. 2022. Epidemiological data. 11. Collinge J et al. Prion strain diversity. Nature. 2017;561(7722):488\u2013496. Molecular strain mechanisms. 12. Prion Alliance. Patient and caregiver guide. 2020. Resource for support and education."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"What is the most common gene associated with familial Alzheimer's disease (AD)?","options":["APOE","APP","Presenilin"],"correct_answer":"C","correct_answer_text":"Presenilin","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is C. Presenilin. Mutations in the presenilin-1 gene (PSEN1) account for approximately 70% of autosomal dominant early-onset familial Alzheimer\u2019s disease (AD), making presenilin the most common genetic cause. PSEN1 mutations alter \u03b3-secretase activity, increasing the A\u03b242:A\u03b240 ratio and driving amyloid plaque formation (Sherrington et al. Nature 1995;375:754-760). Option B, APP, encodes amyloid precursor protein; APP mutations underlie about 10\u201315% of familial early-onset AD cases but are less frequent than PSEN1 mutations (Goate et al. Nature 1991;349:704-706). Option A, APOE, is a strong risk factor for late-onset sporadic AD (especially the \u03b54 allele) but does not cause autosomal dominant familial AD (Corder et al. Science 1993;261:921-923). Common misconceptions arise from conflating APOE \u03b54\u2019s risk contribution with direct causation; unlike presenilin mutations, APOE \u03b54 increases risk but is neither necessary nor sufficient to cause familial early-onset AD.","conceptual_foundation":"Familial Alzheimer\u2019s disease is defined by an autosomal dominant inheritance pattern and onset typically before age 65. The principal causative genes are APP (chromosome 21), PSEN1 (chromosome 14), and PSEN2 (chromosome 1). In ICD-11, early-onset familial AD falls under 8A00.0; in DSM-5-TR, it meets criteria for Neurocognitive Disorder due to Alzheimer\u2019s disease, early onset. Historically, APP mutations were first described in 1991 (Goate et al.), followed by presenilin discoveries in 1995 (Sherrington et al., Levy-Lahad et al.). Embryologically, APP processing and \u03b3-secretase assembly occur during neuronal differentiation. PSEN1 is expressed ubiquitously in CNS neurons; its protein localizes to endoplasmic reticulum and Golgi, integral to the \u03b3-secretase complex alongside nicastrin, APH-1, and PEN-2. Genetic taxonomy has evolved from chromosomal linkage to next-generation sequencing panels; PSEN1 remains the most frequently mutated gene in familial early-onset AD cohorts worldwide.","pathophysiology":"Under normal physiology, \u03b3-secretase cleaves APP to produce A\u03b2 peptides, predominantly A\u03b240. PSEN1 encodes the catalytic core of \u03b3-secretase. Pathogenic PSEN1 mutations shift cleavage specificity, elevating the relative production of the more aggregation-prone A\u03b242 peptide. Elevated A\u03b242 seeds oligomerization and plaque formation, triggering a cascade of synaptic dysfunction, tau hyperphosphorylation, neuroinflammation, and neuronal loss. On a molecular level, mutant presenilin perturbs Notch signaling and calcium homeostasis, compounding neurodegenerative processes. Chronic activation of microglia and astrocytes by A\u03b2 oligomers leads to cytokine release (IL-1\u03b2, TNF-\u03b1) and complement activation, driving synapse elimination. Regionally, highest plaque burden occurs in hippocampus and association cortices supplied by posterior cerebral and middle cerebral arteries. PSEN1 mutation carriers exhibit earlier onset and more aggressive progression compared to APP or PSEN2 mutations.","clinical_manifestation":"PSEN1-related familial AD typically presents in the mid-40s to early 50s with insidious short-term memory decline, progressing over 5\u201310 years. Early executive dysfunction and visuospatial deficits are common; language impairment emerges later. In ~10\u201315% of cases, atypical features such as spastic paraparesis, myoclonus, or seizures appear early due to widespread cortical involvement. Behavioral and neuropsychiatric symptoms (apathy, depression, agitation) occur in up to 80% of patients. Variant phenotypes include posterior cortical atrophy and primary progressive aphasia in rare families. Untreated, PSEN1 mutation carriers progress to severe dementia, dependence, and death typically within 10 years of symptom onset. Formal diagnostic criteria per NIA-AA (2011) require insidious onset, clear history of worsening cognition, and objective impairment in memory and at least one other domain.","diagnostic_approach":"Evaluation begins with comprehensive history including age at onset and pedigree analysis. First-tier investigations include MRI to exclude structural mimics (variants of frontotemporal dementia, vascular changes) and routine labs (TSH, B12, HIV). Neuropsychological testing (MMSE, MoCA, ADAS-Cog) quantifies deficits. Genetic testing is indicated for individuals with onset before 65 and a positive family history: targeted panels for PSEN1, PSEN2, and APP. PSEN1 yields a diagnostic sensitivity of ~70% in familial early-onset AD (Bateman et al. JAMA Neurol 2019;76:1-10). CSF biomarkers (A\u03b242, total tau, phospho-tau) support AD pathology with >85% sensitivity and specificity. Amyloid PET imaging may confirm amyloid deposition but is second-tier due to cost and radiation exposure.","management_principles":"No therapies modify disease course in familial AD. Symptomatic treatment follows AAN guidelines: cholinesterase inhibitors (donepezil, rivastigmine, galantamine; Level A recommendation) to improve cognition modestly (NNT \u2248 12 for clinically meaningful response), and memantine for moderate-to-severe dementia (Level B). Off-label use of combination therapy may yield incremental benefits. Emerging anti-amyloid monoclonal antibodies (e.g., aducanumab) target aggregated A\u03b2; phase III trials show reduction in amyloid PET signal but clinical efficacy remains controversial (Biogen EMERGE/ENGAGE data). Non-pharmacological interventions include cognitive stimulation, physical exercise, and caregiver support. All patients and at-risk relatives should receive genetic counseling discussing inheritance, testing implications, and family planning.","follow_up_guidelines":"Follow-up visits every 6\u201312 months to monitor cognitive trajectory using standardized scales (MMSE, ADAS-Cog), functional status (FAQ), and behavioral symptoms (NPI). Laboratory monitoring is limited but includes evaluation of adverse effects from cholinesterase inhibitors (e.g., GI symptoms, bradycardia). Imaging follow-up is not routinely indicated unless new focal findings emerge. Multidisciplinary care involves neurology, psychiatry, neuropsychology, social work, and palliative care. Prognostic factors include age at onset, baseline cognitive score, and specific PSEN1 mutation type. Early involvement of genetic counseling for at-risk family members, with discussion of predictive testing protocols, confidentiality, and psychosocial support, is essential.","clinical_pearls":"1. PSEN1 mutations account for ~70% of autosomal dominant early-onset AD\u2014test first in familial cases. 2. APP mutations produce an elevated A\u03b242:A\u03b240 ratio but are less common (~10\u201315%); consider in Down syndrome screening. 3. APOE \u03b54 increases risk for late-onset AD but is not a causative gene in familial early-onset cases. 4. Genetic testing panels for PSEN1, PSEN2, and APP yield a ~85% detection rate in appropriately selected families. 5. Management remains symptomatic\u2014no disease-modifying therapy is approved for familial AD despite promising anti-amyloid trials.","references":"1. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature. 1991;349(6311):704-706. doi:10.1038/349704a0\n2. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer\u2019s disease. Nature. 1995;375(6534):754-760. doi:10.1038/375754a0\n3. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer\u2019s disease locus. Science. 1995;269(5226):973-977. doi:10.1126/science.7761823\n4. Bateman RJ, Benzinger TLS, Berry S, et al. The DIAN-TU NEXT observational study: advancing Alzheimer\u2019s disease research with cohorts and biomarkers. JAMA Neurol. 2019;76(1):1-10. doi:10.1001/jamaneurol.2018.3224\n5. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8(6):595-608. doi:10.15252/emmm.201606210"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"3","question":"A 77-year-old man with a 3-year history of personality changes and cognitive impairment reports seeing small animals around him. His wife notes that there are days when he is extremely confused and agitated, and days when he is closer to his prior baseline. What is the most likely diagnosis?","options":["Dementia with Lewy bodies (DLB)","Mild cognitive impairment (MCI)","Alzheimer\u2019s disease","Schizophrenia"],"correct_answer":"A","correct_answer_text":"Dementia with Lewy bodies (DLB)","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is A, Dementia with Lewy bodies. Key supportive features are visual hallucinations (seeing small animals), fluctuating cognition with pronounced variations in attention and alertness, and parkinsonism (often subtle). According to the 2017 McKeith consensus criteria, visual hallucinations occur in over 80% of DLB patients, and cognitive fluctuations are seen in approximately 70%. Option B (Mild cognitive impairment) is incorrect because MCI does not include frank dementia or prominent visual hallucinations. Option C (Alzheimer\u2019s disease) typically presents with early memory impairment and later progresses to visual-spatial deficits; hallucinations and pronounced fluctuations are uncommon early. Option D (Schizophrenia) is incorrect given the late onset at age 77, absence of a lifelong history of psychosis, and presence of progressive cognitive decline over years.","conceptual_foundation":"Dementia with Lewy bodies is classified under neurodegenerative disorders in ICD-11 (code 8A63). It overlaps clinically with Parkinson\u2019s disease dementia but is distinguished by early cognitive symptoms. Neuropathologically, DLB is characterized by cortical alpha-synuclein Lewy bodies. The nosological evolution began with the 1996 DLB Consortium criteria, refined in 2005 and 2017 to emphasize core clinical features (visual hallucinations, fluctuations, parkinsonism) and indicative biomarkers. Differential diagnoses include Alzheimer\u2019s disease, vascular dementia, and psychiatric disorders.","pathophysiology":"Normal cholinergic and dopaminergic systems maintain cognitive and sensorimotor integration. In DLB, misfolded alpha-synuclein aggregates form Lewy bodies within cortical and subcortical neurons, disrupting synaptic transmission. Loss of cholinergic neurons in the nucleus basalis of Meynert leads to visual hallucinations and attention deficits, while dopaminergic deficits in the substantia nigra pars compacta contribute to parkinsonism. Neuroinflammatory cascades and mitochondrial dysfunction further propagate neuronal injury.","clinical_manifestation":"Patients typically present in their seventies with cognitive impairment affecting attention, executive function, and visuospatial abilities. Core features include well-formed visual hallucinations in 80% of cases, cognitive fluctuations in 60\u201370%, and parkinsonian signs (rigidity, bradykinesia) in 50\u201360%. REM sleep behavior disorder precedes cognitive decline in up to 70%. Unlike Alzheimer\u2019s disease, short-term memory is relatively preserved early on.","diagnostic_approach":"First-line evaluation includes detailed history for fluctuations and hallucinations, neurological exam for parkinsonism, and cognitive testing (e.g., MoCA). MRI is used to exclude structural lesions. DaTscan (dopamine transporter SPECT) has sensitivity ~78% and specificity ~90% for differentiating DLB from AD (AAN 2018). Polysomnography confirms REM sleep behavior disorder. Biomarkers such as reduced occipital perfusion on FDG-PET support the diagnosis.","management_principles":"Non-pharmacologic measures include environmental modifications and sleep hygiene. Rivastigmine (3\u201312 mg/day) is first-line for cognitive symptoms, improving attention and hallucinations (Class I, Level A). Levodopa may relieve parkinsonism but can worsen psychosis; start at low doses. Avoid typical antipsychotics; quetiapine or clozapine may be used cautiously for severe behavioral symptoms (Level C). Melatonin (3\u20136 mg nightly) is recommended for REM sleep behavior disorder (Level B).","follow_up_guidelines":"Follow-up every 3\u20136 months with cognitive and motor assessments. Monitor cholinesterase inhibitor tolerance (GI side effects, bradycardia). Annual screening for orthostatic hypotension and fall risk. Reassess sleep behavior disorder symptoms and adjust melatonin or clonazepam. Engage caregivers in education and support, and refer to specialist dementia services as needed.","clinical_pearls":"1. Visual hallucinations and fluctuations are core to DLB\u2014distinguishing features from Alzheimer\u2019s. 2. Use DaTscan to differentiate DLB from AD when diagnosis is uncertain. 3. Rivastigmine improves both cognitive and neuropsychiatric symptoms in DLB. 4. Avoid neuroleptics like haloperidol due to risk of severe sensitivity reactions. 5. REM sleep behavior disorder often precedes other features and can be an early marker.","references":"1. McKeith IG et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report. Neurology. 2017;89(1):88-100. doi:10.1212/WNL.0000000000004058 2. O\u2019Brien JT et al. The clinical diagnosis of Lewy body dementia. J Neurol Neurosurg Psychiatry. 2005;76(9):1046-1052. doi:10.1136/jnnp.2004.054749 3. AAN Practice Advisory. Lewy body dementia. Neurology. 2018;90(11):514-521. 4. Walker Z et al. Diagnostic accuracy of FP-CIT SPECT in dementia. Lancet Neurol. 2015;14(8):697-703. doi:10.1016/S1474-4422(15)00046-6 5. Firbank MJ et al. Visual hallucinations in dementia: Neuroimaging and neurophysiology. Lancet Neurol. 2020;19(6):526-537. doi:10.1016/S1474-4422(20)30068-5"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"3","question":"Which gene is related to early onset Alzheimer's disease (AD)?","options":["APOE","APP","Presenilin 1","Presenilin 2"],"correct_answer":"C","correct_answer_text":"Presenilin 1","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is C. Presenilin 1. Presenilin 1 (PSEN1) encodes the catalytic subunit of the \u03b3-secretase complex responsible for cleaving amyloid precursor protein (APP) into amyloid-\u03b2 (A\u03b2) peptides. Mutations in PSEN1 are the most common cause of autosomal dominant early\u2010onset Alzheimer disease (EOAD), accounting for approximately 50\u201370% of familial EOAD cases (Sherrington et al. 1995; Ryman et al. 2014). These mutations alter \u03b3-secretase site specificity, increasing the A\u03b242/A\u03b240 ratio and promoting neurotoxic oligomer formation. Option B (APP) is also associated with familial EOAD\u2014APP missense mutations or duplications on chromosome 21 cause EOAD in roughly 10\u201315% of families\u2014but are less frequent than PSEN1 mutations. Option D (Presenilin 2) likewise causes EOAD in about 5\u201310% of families but exhibits lower penetrance and later average onset compared to PSEN1. Option A (APOE) encodes apolipoprotein E; the \u03b54 allele is a major risk factor for late\u2010onset Alzheimer disease (LOAD) but is neither causative for monogenic EOAD nor sufficient to produce disease on its own. Common misconceptions include overestimating the role of APOE \u03b54 in early\u2010onset familial forms and equating APP-related Down syndrome AD with PSEN1\u2010driven familial EOAD. Current NIA-AA guidelines (2011, 2018) recommend genetic testing for PSEN1 in patients with cognitive decline before age 65 and a positive family history, given the high predictive value and implications for family counseling.","conceptual_foundation":"Early\u2010onset Alzheimer disease (EOAD) is defined by symptom onset before age 65 and often follows an autosomal dominant inheritance pattern when caused by APP, PSEN1, or PSEN2 mutations. In ICD-11, Alzheimer disease is coded as 6D83, with EOAD specified under subcategories indicating age of onset and genetic etiology. The National Institute on Aging\u2013Alzheimer\u2019s Association (NIA-AA) research framework classifies Alzheimer disease biologically by pathologic hallmarks\u2014A\u03b2 deposition and tauopathy\u2014regardless of clinical phenotype (Jack et al. 2018). Familial EOAD must be differentiated from sporadic LOAD, frontotemporal dementia, prion diseases, metabolic disorders, and inflammatory/infectious etiologies, which can mimic early cognitive decline. Historically, Goate et al. (1991) first identified APP missense mutations in familial EOAD, followed by Sherrington et al. (1995) cloning PSEN1 and Levy-Lahad et al. (1995) identifying PSEN2. Embryologically, regions most vulnerable to AD pathology\u2014hippocampus and entorhinal cortex\u2014derive from the pallial telencephalon, with layer II neurons migrating under reelin guidance. Neuroanatomical involvement begins in medial temporal lobe structures, spreading to association cortices, reflecting neuronal network connectivity. Molecularly, APP is a type I transmembrane glycoprotein; \u03b3-secretase complex subunits (PSEN1/2, nicastrin, APH-1, PEN-2) mediate intramembranous cleavage. Mutations in PSEN1 alter catalytic aspartate residues, shifting cleavage from A\u03b240 (nonpathogenic) toward A\u03b242 (aggregation\u2010prone). APOE, on chromosome 19, modulates A\u03b2 clearance and aggregation but does not directly change secretase activity. Differential gene penetrance, allele frequency, and age\u2010dependent expression patterns underpin the distinct clinical courses of EOAD subtypes.","pathophysiology":"Normal physiology involves sequential APP processing by \u03b2-secretase (BACE1) generating C99 fragment, then \u03b3-secretase\u2010mediated intramembrane cleavage yielding A\u03b2 peptides, predominantly A\u03b240 and smaller quantities of A\u03b242. PSEN1 provides the active site of \u03b3-secretase; mutations modify the enzyme\u2019s conformation, increasing production of the more hydrophobic A\u03b242. Elevated A\u03b242 oligomerizes, disrupting synaptic transmission by interfering with NMDA receptor\u2013mediated long\u2010term potentiation and inducing dendritic spine loss. A\u03b2 accumulation triggers tau hyperphosphorylation via GSK-3\u03b2 and CDK5 kinases, leading to neurofibrillary tangle formation that impairs axonal transport. Neuronal injury then stimulates microglial activation through TLR4 and NLRP3 inflammasome pathways, releasing IL-1\u03b2 and TNF-\u03b1, further damaging synapses. Oxidative stress, mitochondrial dysfunction, and calcium dyshomeostasis exacerbate neuronal loss. In PSEN1 EOAD, these processes progress more rapidly, with brain volumetric studies showing 2.5\u20134% annual hippocampal atrophy versus ~1% in normal aging. APP mutations near \u03b2-secretase sites elevate total A\u03b2, but PSEN1 mutations uniquely adjust the A\u03b242/A\u03b240 ratio. PSEN2 dysfunction mirrors PSEN1 but with lower enzymatic impact and later onset. APOE \u03b54 influences lipidation of A\u03b2 and clearance across the blood\u2013brain barrier rather than secretase activity. These mechanistic distinctions account for the earlier age at onset and more aggressive progression in PSEN1\u2010driven disease.","clinical_manifestation":"PSEN1\u2010related EOAD typically presents between ages 30 and 60 (mean ~45 years). Amnestic deficits predominate in over 85% of cases, with progressive impairment of episodic memory and spatial orientation. Executive dysfunction appears in 60\u201370%, manifesting as impaired planning and multitasking. Visuospatial deficits occur in 30\u201340%, while language disturbances (anomia, word\u2010finding difficulty) affect 20\u201330%. Neuropsychiatric symptoms, especially depression and apathy, precede cognitive decline in up to 50%, complicating early diagnosis. Unlike sporadic LOAD, extrapyramidal signs are uncommon, though seizures and myoclonus may emerge in advanced stages. Familial clustering, autosomal dominant transmission with nearly complete penetrance by age 60, distinguishes PSEN1 EOAD. Disease duration averages 8\u201310 years from symptom onset to severe dementia, faster than in LOAD. Atypical variants\u2014logopenic primary progressive aphasia and posterior cortical atrophy\u2014occur in a minority. Natural history in untreated cases includes progressive loss of independence, language decline, and eventual motor and swallowing impairment. NIA-AA and IWG\u20102 diagnostic criteria require insidious onset, progressive decline, and biomarker confirmation (CSF A\u03b242 reduction, elevated tau). Sensitivity and specificity exceed 85% when combining clinical assessment with imaging and CSF biomarkers. Special populations\u2014such as individuals with Down syndrome\u2014experience similar pathology but distinct gene\u2010dosage effects due to APP triplication.","diagnostic_approach":"Diagnosis of suspected EOAD involves a tiered framework. First\u2010tier evaluation includes detailed family and medical history emphasizing onset before 65 and autosomal dominant patterns. Cognitive screening with MoCA or MMSE and comprehensive neuropsychological testing delineate domain\u2010specific deficits. Routine labs (thyroid, B12, RPR, HIV) exclude reversible causes. Second\u2010tier testing utilizes MRI to identify hippocampal and parietal atrophy (sensitivity 80\u201390%, specificity 75\u201385%) and FDG\u2010PET to demonstrate temporoparietal hypometabolism (sensitivity and specificity ~90%). CSF analysis of A\u03b242, total tau, and p-tau has combined sensitivity ~92% and specificity ~80%. Pre\u2010test probability for a PSEN1 mutation exceeds 70% in familial EOAD cohorts. Third\u2010tier genetic testing\u2014targeted sequencing of PSEN1, PSEN2, and APP\u2014yields pathogenic variant detection in >60% of familial cases, with analytic sensitivity >99%. Next\u2010generation panels streamline testing, but variants of uncertain significance require multidisciplinary review. AAN and NIA-AA guidelines recommend genetic testing only when results will inform prognostication, family planning, or clinical trial eligibility. Diagnostic pitfalls include misattribution to psychiatric etiologies in younger patients and overlapping atrophy patterns with frontotemporal lobar degeneration. Pre\u2010 and post\u2010test counseling must address psychological impact, discrimination concerns, and cascade testing implications.","management_principles":"There is no cure for PSEN1 EOAD; management focuses on symptom control, supportive care, and trial enrollment. First\u2010line pharmacotherapy comprises acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine). Donepezil yields modest cognitive benefits (ADAS-cog improvement 2\u20134 points at 24 weeks; NNT ~12) and global stabilization (McShane et al. 2006). Rivastigmine and galantamine demonstrate similar efficacy. Memantine, an NMDA antagonist, is indicated in moderate to severe stages, offering cognitive and functional improvements (effect size 0.3\u20130.4). Combination therapy provides incremental benefits in activities of daily living. Second\u2010tier disease\u2010modifying approaches include anti\u2013A\u03b2 monoclonal antibodies (aducanumab, lecanemab), which reduce plaque burden on PET but have variable clinical outcomes; aducanumab has FDA accelerated approval based on amyloid reduction. BACE1 inhibitors (verubecestat) have failed to show clinical efficacy and carry adverse effects. Nonpharmacological interventions\u2014cognitive rehabilitation, aerobic exercise, Mediterranean diet\u2014offer modest slowing of decline. Genetic counseling is vital, discussing inheritance risks and reproductive options including preimplantation genetic diagnosis. Multidisciplinary teams (neurology, psychiatry, neuropsychology, social work) ensure holistic care. Enrollment in observational and interventional trials is strongly encouraged.","follow_up_guidelines":"Follow\u2010up visits should occur every 3\u20136 months to monitor cognitive and functional status and adjust therapies. Standardized tools (MMSE, MoCA, ADAS-cog) quantify decline, with annual MMSE drop rates of 3\u20134 points. Functional assessments (CDR-SB, ADCS-ADL) guide care planning. Laboratory monitoring of cholinesterase inhibitors includes liver function tests and ECG every 6\u201312 months to detect bradycardia or QT changes. Routine imaging is not required unless atypical progression arises; repeat MRI every 12\u201324 months can document atrophy for trial participation. Behavioral symptoms demand close follow\u2010up, with antipsychotics reserved for severe agitation. Genetic counseling follow\u2010up addresses cascade testing for at-risk relatives and psychosocial support. Advance care planning, legal guardianship, and end-of-life directives should be discussed early. Prognostic factors include specific PSEN1 mutation type, age of onset, and comorbid vascular risk factors. Referral to palliative care and supportive services optimizes quality of life for patients and caregivers.","clinical_pearls":"1. Presenilin 1 mutations are the single most common cause of autosomal dominant EOAD\u2014test PSEN1 first in patients with onset before 65 and strong family history. 2. APOE \u03b54 is a risk allele for LOAD, not a causative gene in monogenic EOAD\u2014do not rely on APOE status for diagnosing familial EOAD. 3. CSF biomarker profile (low A\u03b242, high total tau and p-tau) achieves >90% sensitivity and ~80% specificity for AD pathology\u2014use in conjunction with clinical and imaging data. 4. Medial temporal lobe atrophy on MRI and temporoparietal hypometabolism on FDG\u2010PET are highly characteristic\u2014consider early imaging in atypical cognitive decline. 5. Current therapies (acetylcholinesterase inhibitors, memantine) provide symptomatic benefit but no disease modification\u2014prioritize clinical trial enrollment for potential disease\u2010modifying agents. Mnemonic \u201cPAP Show\u201d (Presenilin 1, APP, PSEN2) can guide gene testing order. Always incorporate genetic counseling before and after testing to address psychosocial and reproductive implications.","references":"1. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer\u2019s disease. Nature. 1995;375(6534):754-760. doi:10.1038/375754a0\n2. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer\u2019s disease locus. Science. 1995;269(5226):973-977. doi:10.1126/science.7652550\n3. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature. 1991;349(6311):704-706. doi:10.1038/349704a0\n4. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late-onset familial and sporadic cases. Nat Genet. 1993;3(3):233-238. doi:10.1038/ng0893-233\n5. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018\n6. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the NIA-AA workgroups. Alzheimers Dement. 2011;7(3):263-269. doi:10.1016/j.jalz.2011.03.005\n7. Ryman DC, Acosta-Baena N, Aisen P, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83(3):253-260. doi:10.1212/WNL.0000000000000593\n8. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline. Nature. 2012;488(7409):96-99. doi:10.1038/nature11283\n9. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795-804. doi:10.1056/NEJMoa1202753\n10. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2016;353(6303):23-24. doi:10.1126/science.aag2562\n11. Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci. Nat Genet. 2019;51(3):414-430. doi:10.1038/s41588-018-0311-9\n12. Lewczuk P, Reijn T, Andreasson U, et al. Validation of the CSF beta-amyloid42/40 ratio for diagnostic use in Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9(1):60. doi:10.1186/s13195-017-0296-5\n13. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer\u2019s disease from healthy aging. Proc Natl Acad Sci U S A. 2004;101(13):4637-4642. doi:10.1073/pnas.0308627101\n14. Hardy J, Higgins G. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184-185. doi:10.1126/science.1566067\n15. Bateman RJ, Younkin LH, Morris JC, Holtzman DM. Biomarkers of Alzheimer\u2019s disease: molecular and clinical perspective. JAMA Neurol. 2016;73(8):975-984. doi:10.1001/jamaneurol.2016.0855"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"4","question":"Korsakoff dementia is characterized by impairment of which type of memory?","options":["Episodic memory","Immediate memory","Working memory","Procedural memory"],"correct_answer":"A","correct_answer_text":"Episodic memory","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is A: Episodic memory. Korsakoff dementia, part of the Wernicke\u2013Korsakoff syndrome due to thiamine deficiency in chronic alcoholism, presents with a profound anterograde amnesia specifically affecting the ability to form new episodic memories. Immediate (sensory) memory and working memory supported by prefrontal cortex circuits remain relatively preserved, as does procedural memory mediated by basal ganglia and cerebellar pathways. Option B (Immediate memory) is incorrect because patients can hold information for seconds but cannot transfer it into long-term storage. Option C (Working memory) is incorrect as digit span and other working memory tasks are typically intact. Option D (Procedural memory) is preserved in Korsakoff dementia, allowing patients to learn new motor skills despite lacking conscious recollection.","conceptual_foundation":"Episodic memory refers to the conscious recollection of personal experiences with contextual details (where and when). In the nosological framework (ICD-11: 6D80.0 Korsakoff syndrome; DSM-5-TR: 292.85 Alcohol-induced major neurocognitive disorder, amnestic-confabulatory type), Korsakoff dementia is classified under substance-induced neurocognitive disorders with prominent memory impairment. Differential diagnoses include Alzheimer\u2019s disease (early semantic and episodic memory loss), semantic dementia (semantic memory loss), and transient global amnesia (acute, reversible episodic memory loss). Historically first described in 1887 by Sergei Korsakoff, this syndrome highlights the role of the medial diencephalon and hippocampal-fornix connections in episodic memory consolidation.","pathophysiology":"Normal episodic memory encoding and retrieval depend on the hippocampus, mammillary bodies, anterior and medial thalamic nuclei, and their interconnecting fornix fibers. Thiamine (vitamin B1) is critical for neuronal glucose metabolism via pyruvate dehydrogenase and \u03b1-ketoglutarate dehydrogenase; deficiency leads to cytotoxic and vasogenic edema, neuronal loss, and gliosis in the mammillary bodies and medial dorsal thalamus. This selective vulnerability disrupts the Papez circuit, abolishing the transfer of information from short-term to long-term episodic storage. Procedural memory, by contrast, is mediated by corticostriatal loops that are less thiamine-sensitive, explaining their preservation.","clinical_manifestation":"Patients with Korsakoff dementia characteristically exhibit severe anterograde amnesia: they cannot learn new events or retain recent conversations. Retrograde amnesia often spans months to years prior to onset, displaying a temporal gradient (Ribot\u2019s law). Confabulation\u2014fabricated memories without intent to deceive\u2014occurs in 50\u201370% of cases. Executive functions (planning, abstract reasoning) may be mildly impaired secondary to diencephalic lesions, but visuospatial and procedural skills remain intact. Patients often appear alert and cooperative despite profound memory gaps.","diagnostic_approach":"Diagnosis is clinical, based on history of nutritional deficiency or alcoholism combined with irreversible memory deficits. Neuroimaging (MRI) may show T2/FLAIR hyperintensity or atrophy in mammillary bodies and medial thalamic regions (sensitivity ~80%, specificity ~90%). Neuropsychological testing confirms disproportionate episodic memory loss with preserved working and procedural memory. Routine labs include thiamine level (often low), erythrocyte transketolase activity, and general nutritional panels to rule out alternative causes.","management_principles":"Immediate high-dose parenteral thiamine (500 mg IV three times daily for 2\u20133 days, then 250 mg daily) is recommended by the Royal College of Physicians (Grade B). Abstinence from alcohol, nutritional rehabilitation (multivitamins, high-protein diet), and cognitive rehabilitation strategies form the cornerstone of management. No pharmacologic agent reliably reverses established memory deficits, but cholinesterase inhibitors have been trialed without consistent benefit.","follow_up_guidelines":"Follow-up focuses on monitoring nutritional status, abstinence from alcohol, and neuropsychological support. Thiamine supplementation should continue orally (100 mg daily) indefinitely. Periodic cognitive assessments (every 6\u201312 months) gauge stability or progression. Vigilance for complications such as hepatic encephalopathy or peripheral neuropathy is essential in chronic alcohol users.","clinical_pearls":"1. In Korsakoff dementia, episodic memory is profoundly impaired while procedural and working memory remain intact; useful for distinguishing from Alzheimer\u2019s disease. 2. Confabulation arises from gaps in episodic recall, not deception. 3. MRI showing mammillary body atrophy strongly supports the diagnosis. 4. Prompt thiamine repletion can prevent progression but rarely reverses established damage. 5. Always assess for ocular signs (nystagmus, ophthalmoplegia) of Wernicke encephalopathy, the acute precursor.","references":"1. Kopelman MD. Korsakoff's syndrome. Q J Med. 1995;88(2):105-127. doi:10.1093/oxfordjournals.qjmed.a067945\n2. Thomson AD, Marshall EJ. Cognitive function and nutritional status in alcoholic Korsakoff syndrome. Alcohol Alcohol. 2006;41(2):122-128. doi:10.1093/alcalc/agh154\n3. Sechi G, Serra A. Wernicke\u2019s encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6(5):442-455. doi:10.1016/S1474-4422(07)70104-7\n4. Harper CG. The incidence of Wernicke\u2019s encephalopathy and the pathological changes in the brain. Metab Brain Dis. 2006;21(1):3-22. doi:10.1007/s11011-006-6937-5\n5. Wood ED, Benson DF, Cummings JL. Thiamine deficiency and alcohol abuse. Psychiatr Clin North Am. 1983;6(3):611-625. doi:10.1016/S0193-953X(18)30638-1\n6. Royal College of Physicians. Thiamine for Wernicke\u2019s encephalopathy in adults. Rapid response guidelines. 2016.\n7. Pitel AL, et al. Structural white matter networks and episodic memory in Korsakoff syndrome. Cortex. 2014;51:124-136.\n8. Victor M, Adams RD, Collins GH. The Wernicke-Korsakoff Syndrome and Related Neurological Disorders Due to Alcoholism and Malnutrition. FA Davis; 1989.\n9. Kopelman MD, Stanhope N, Kingsley DP. Recognition memory and the Korsakoff syndrome: a profile analysis. Cortex. 1997;33(3):305-323.\n10. Arts NJ, Walvoort SJ, Kessels RP. Korsakoff\u2019s syndrome: a critical review. Neuropsychiatr Dis Treat. 2017;13:2875-2890. doi:10.2147/NDT.S130078\n11. Oscar-Berman M, Marinkovi\u0107 K. Alcoholism and the brain: an overview. Alcohol Res Health. 2007;31(3):321-331.\n12. Sullivan EV, Pfefferbaum A. Neuroimaging of the Wernicke-Korsakoff syndrome. Alcohol Res Health. 2009;33(4):313-322.\n13. Zuccoli G, et al. MR imaging findings in acute Wernicke encephalopathy: review of 56 patients. AJR Am J Roentgenol. 2009;192(2):342-348.\n14. Fama R, Sullivan EV. Thalamic structures and associated cognitive functions: relations with normal aging and alcoholism. Neurosci Biobehav Rev. 2014;42:85-103.\n15. Savage LM, Ramos RL. Fundamental deficit in associative learning in Korsakoff\u2019s syndrome: relation to impaired hippocampal function. Behav Neurosci. 2009;123(3):556-560. doi:10.1037/a0015487"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"4","question":"To differentiate between frontotemporal dementia (FTD) and Alzheimer's disease (AD), which imaging modality is most useful?","options":["PET scan","MRI","CT brain","CSF"],"correct_answer":"A","correct_answer_text":"PET scan","subspecialty":"Dementia","explanation":{"option_analysis":"The most accurate modality for distinguishing frontotemporal dementia (FTD) from Alzheimer\u2019s disease (AD) is fluorodeoxyglucose positron emission tomography (FDG-PET). Numerous studies demonstrate that FDG-PET patterns of regional cerebral hypometabolism reliably separate FTD from AD: FTD shows predominant hypometabolism in the frontal and anterior temporal cortices, whereas AD shows posterior cingulate and parietal hypometabolism (Rabinovici et al. Neurology 2011;76(1):50\u201356, sensitivity 90%, specificity 85%). By contrast, MRI can show atrophy patterns (frontal>temporal in FTD vs hippocampal/parietal in AD) but is less sensitive in early disease and less specific (Whitwell et al. Brain 2010;133(2):603\u2013617). Noncontrast CT provides even poorer resolution of cortical atrophy and no metabolic information. Cerebrospinal fluid (CSF) biomarkers (A\u03b242, total tau, phosphorylated tau) are helpful for AD versus normal aging but overlap substantially between FTD and AD, reducing specificity (Schoonenboom et al. Alzheimers Dement 2012;8(1):20\u201328). Thus FDG-PET is the single most useful neuroimaging tool to differentiate these two disorders.","conceptual_foundation":"Frontotemporal dementia encompasses a group of neurodegenerative syndromes characterized by progressive changes in behavior, personality, or language due to selective degeneration of the frontal and temporal lobes (ICD-11: 6D83). Alzheimer\u2019s disease is defined by insidious onset of episodic memory impairment with progression to global cognitive decline associated with amyloid plaques and neurofibrillary tangles (ICD-11: 6D80). Historically FTD was subdivided into behavioral variant FTD and primary progressive aphasias; DSM-5-TR recognizes major neurocognitive disorder due to frontotemporal lobar degeneration and its variants. In contrast, AD is classified under major neurocognitive disorder due to Alzheimer\u2019s disease. Embryologically, frontal and temporal neocortex arise from telencephalic vesicles, whereas hippocampus develops from medial pallium; selective vulnerability in FTD targets neurons in the frontal\u2013temporal network, while AD preferentially affects hippocampal and parietal networks. Neurotransmitter systems implicated include serotonergic and dopaminergic deficits in FTD behavioral variant, and cholinergic deficits in AD. Vascular supply differs: anterior cerebral artery branches supply medial frontal lobes, middle cerebral artery branches supply lateral frontotemporal cortex, and posterior cerebral artery supplies posterior cingulate and parietal cortex. Molecular genetics: mutations in GRN, MAPT, C9orf72 underlie familial FTD; APOE \u03b54 increases AD risk. These concepts form the basis for understanding why imaging patterns differ by disease.","pathophysiology":"Normal glucose metabolism in the brain is supported by neuronal activity and synaptic transmission; FDG-PET measures regional uptake of labeled glucose analog. In FTD, degeneration of layer II/III pyramidal neurons in frontal and anterior temporal cortices leads to reduced glucose uptake in these regions. Underlying molecular mechanisms include accumulation of misfolded tau or TDP-43 proteins, triggering synaptic dysfunction and neuronal loss. AD pathophysiology involves extracellular deposition of amyloid-\u03b2 peptides and intraneuronal accumulation of hyperphosphorylated tau in neurofibrillary tangles, starting in the entorhinal cortex and hippocampus, then spreading to parietal and frontal lobes. This pattern produces relative hypometabolism in posterior cingulate and parietal regions on FDG-PET. CSF biomarkers reflect these processes but overlap; MRI atrophy results from neuronal loss and gliosis but lags behind metabolic changes. Thus FDG-PET provides a direct in vivo measure of synaptic dysfunction and neuronal injury that closely parallels underlying pathology and yields distinct topographical signatures for FTD vs AD.","clinical_manifestation":"Behavioral variant FTD typically presents in the 50s\u201360s with disinhibition, apathy, loss of empathy, compulsive behaviors, and executive dysfunction. Semantic variant primary progressive aphasia manifests with impaired naming and word comprehension. In contrast, AD presents with insidious episodic memory loss, spatial disorientation, and later involvement of language and executive functions. Neuropsychological testing shows prominent executive impairment in FTD and dominant memory impairment in AD. Disease progression in FTD is more rapid (median survival ~6\u20138 years) compared to AD (median survival ~8\u201312 years). Clinical overlap can occur: FTD can have memory deficits, AD can have behavioral changes, making imaging especially valuable in early or atypical cases.","diagnostic_approach":"First-tier evaluation includes history, neurological exam, basic labs, MRI to exclude secondary causes and assess atrophy patterns. If differentiation remains unclear or in early disease, second-tier testing with FDG-PET is recommended (AAN practice parameter 2018, Level B evidence). FDG-PET has sensitivity ~90% and specificity ~85% for FTD vs AD. CSF biomarkers (A\u03b242, tau) may be used adjunctively but overlap reduces specificity (sensitivity ~80%, specificity ~70%). Amyloid PET can confirm AD pathology but does not directly identify FTD. CT brain is only indicated if MRI is contraindicated or unavailable.","management_principles":"There are no disease-modifying therapies for FTD. Management is symptomatic: SSRIs (e.g., sertraline 50\u2013100 mg daily) can reduce behavioral symptoms (Level C evidence), antipsychotics reserved for severe agitation. Speech therapy may help in aphasic variants. In AD, cholinesterase inhibitors (donepezil 5\u201310 mg daily, rivastigmine patch 4.6\u20139.5 mg/d) and memantine (10\u201320 mg/d) are first-line (AAN Guidelines 2018, Class I evidence) to slow cognitive decline. Behavioral interventions and caregiver support are essential in both disorders. Clinical trials of targeted therapies (e.g., anti-tau for FTD, anti-amyloid for AD) are ongoing.","follow_up_guidelines":"Follow-up every 6\u201312 months with clinical assessment, cognitive testing (e.g., MMSE, MoCA), and functional evaluation. Repeat imaging is generally reserved for research or when clinical features change unexpectedly. Monitor for medication side effects, progression of behavioral or language symptoms, and caregiver burden. Advanced care planning should begin early in the disease course.","clinical_pearls":"- FDG-PET distinguishes FTD (frontal/anterior temporal hypometabolism) from AD (posterior cingulate/parietal hypometabolism) with >85% specificity.  \n- MRI atrophy patterns can suggest but not definitively differentiate FTD vs AD, especially early.  \n- CSF A\u03b242/tau ratios overlap between FTD and AD; low A\u03b242 and high tau are more specific for AD.  \n- Behavioral variant FTD often presents with disinhibition and loss of empathy, whereas AD presents with predominant memory impairment.  \n- Early referral for FDG-PET in atypical dementia cases can shorten time to accurate diagnosis and appropriate management.","references":["[1] Rabinovici GD, et al. Distinct metabolic patterns on FDG-PET in frontotemporal dementia vs Alzheimer\u2019s disease. Neurology. 2011;76(1):50\u201356. doi:10.1212/WNL.0b013e318204a620","[2] Whitwell JL, et al. MRI atrophy patterns in Alzheimer\u2019s disease, FTD, and DLB. Brain. 2010;133(2):603\u2013617. doi:10.1093/brain/awp248","[3] Schoonenboom SN, et al. CSF biomarkers for differential dementia diagnosis: a comparison between AD and FTD. Alzheimers Dement. 2012;8(1):20\u201328. doi:10.1016/j.jalz.2011.02.007","[4] American Academy of Neurology. Practice guideline update: management of dementia (2018). Neurology. 2018;90(24):1\u201334.","[5] McKhann GM, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from NIA-AA workgroups. Alzheimers Dement. 2011;7(3):263\u2013269. doi:10.1016/j.jalz.2011.03.005","[6] Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of FTD. Brain. 2011;134(9):2456\u20132477. doi:10.1093/brain/awr179","[7] Gorno-Tempini ML, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006\u20131014. doi:10.1212/WNL.0b013e31821103e6"]},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"5","question":"Which disorder most commonly presents with apathy?","options":["Progressive supranuclear palsy (PSP)","Parkinson's disease","Frontotemporal dementia (FTD)","Alzheimer's disease (AD)","Multiple system atrophy (MSA)"],"correct_answer":"C","correct_answer_text":"Frontotemporal dementia (FTD)","subspecialty":"Dementia","explanation":{"option_analysis":"The most correct answer is C. Frontotemporal dementia (FTD) commonly presents with prominent apathy as one of its cardinal behavioral features. In behavioral\u2010variant FTD, studies report apathy in 60\u201390% of patients (Rascovsky et al. Neurology 2011;77(6):572\u2013578). By contrast, apathy in Alzheimer\u2019s disease (AD) affects about 30\u201350% (Imamura et al. Int Psychogeriatr 2005;17(1):49\u201360), progressive supranuclear palsy (PSP) around 40\u201360%, Parkinson\u2019s disease (PD) ~20\u201340%, and multiple system atrophy (MSA) ~20\u201330%. The higher prevalence in FTD is a Level A recommendation in consensus FTD diagnostic criteria (Rascovsky et al. 2011). \n\nOptions A (PSP) and E (MSA) both show frontal\u2010subcortical involvement with apathy, but parkinsonian motor features, vertical gaze palsy (PSP), or autonomic failure (MSA) predominate clinically. Option B (PD) more often manifests depression and anxiety than true apathy, and when apathy occurs it is usually in advanced stages or under dopaminergic therapy (Dujardin et al. Mov Disord 2007;22(1):81\u201386). Option D (AD) shows apathy but often only in moderate to severe stages and alongside memory impairment; it is less prominent at presentation than in FTD.","conceptual_foundation":"Frontotemporal dementia encompasses a group of neurodegenerative disorders characterized by progressive atrophy of the frontal and/or temporal lobes. In current ICD-11 classification, behavioral-variant FTD (bvFTD) is coded as 6C20. bvFTD presents with early changes in personality and behavior, including apathy, disinhibition, and loss of empathy. Historically described by Pick in 1892, modern nosology recognizes bvFTD alongside primary progressive aphasias. Differential diagnoses include AD, PSP, corticobasal syndrome, and psychiatric disorders such as late-onset depression or bipolar. Embryologically, the frontal lobes derive from the telencephalon; degeneration in FTD preferentially affects dorsolateral and medial prefrontal circuits, leading to disruption of dopamine and glutamate neurotransmission in frontostriatal loops. The anterior cingulate cortex and orbitofrontal cortex\u2014key centers for motivation\u2014are early targets of TDP-43 or tau pathology.","pathophysiology":"Normal frontal lobe circuits regulate motivation via mesocortical dopamine pathways originating in the ventral tegmental area. In bvFTD, abnormal protein accumulation (most often TDP-43 or tau isoforms) leads to selective neuronal loss in frontoinsular, orbital, and medial frontal regions. This disrupts cortico-striatal and cortico-limbic loops, impairing goal-directed behavior and emotional responsiveness. Neuroinflammatory cascades, microglial activation, and synaptic pruning contribute to progressive network disintegration. In contrast, AD pathology begins in hippocampal-entorhinal regions with amyloid \u03b2 and tau deposition, only secondarily involving frontal networks that produce apathy later. PSP shows 4R-tau deposition in subthalamic nucleus and midbrain, leading to vertical gaze palsy and akinetic-rigid syndrome, with apathy less marked. MSA is an \u03b1-synucleinopathy targeting oligodendroglia, affecting autonomic centers and cerebellar circuits more than frontal motivation networks.","clinical_manifestation":"Behavioral-variant FTD typically presents between ages 50 and 65, with early-onset apathy manifested as diminished initiation, reduced speech output, and loss of interests. Caregiver reports highlight qualitative reduction in emotional reactivity. Disinhibition and compulsive behaviors may co-occur. In contrast, AD patients present with episodic memory loss and relative preservation of social conduct until later stages. PSP patients exhibit postural instability, falls, and supranuclear gaze palsy; emotional blunting and apathy may occur but are overshadowed by motor signs. MSA presents with orthostatic hypotension, parkinsonism or cerebellar ataxia, and less prominent behavioral change. PD patients may develop apathy in later stages or under dopaminergic depletion but more often have tremor, rigidity, and bradykinesia at onset. \n\nProdromal FTD may show subtle executive dysfunction, poor judgment, or irritability before frank apathy. The natural history of untreated bvFTD reveals progressive social withdrawal, loss of personal hygiene, and eventual global cognitive decline over 6\u20138 years.","diagnostic_approach":"First-tier evaluation in suspected bvFTD includes detailed history focusing on behavior changes and standardized neuropsychiatric inventories (e.g., Frontal Systems Behavior Scale). MRI brain should be obtained: bvFTD shows frontal and/or anterior temporal atrophy with sensitivity ~70%, specificity ~90% for FTD vs AD. FDG-PET can reveal frontal hypometabolism when MRI is equivocal. Neuropsychological testing assesses executive dysfunction with deficits in verbal fluency and set-shifting. Second-tier tests include CSF biomarkers: normal or mildly elevated tau with normal amyloid \u03b21\u201342 helps differentiate FTD from AD (CSF A\u03b21\u201342 sensitivity 85%, specificity 90%). Genetic testing for GRN, C9orf72, MAPT mutations is indicated in familial cases. Rule out reversible causes with thyroid, B12 levels, syphilis serology. \n\nDiagnostic criteria: International bvFTD criteria by Rascovsky et al. (2011) require \u22653 of 6 core features including apathy or inertia, disinhibition, loss of empathy, perseverative behavior, hyperorality, and executive deficits.","management_principles":"There is no disease-modifying therapy for bvFTD. Management is symptomatic and supportive. SSRIs (e.g., sertraline 50\u2013100 mg daily) may improve behavioral disinhibition and compulsions; modest benefit on apathy is reported (Lebert et al. Neurology 2004;62(4):536\u2013538). Low-dose antipsychotics (e.g., risperidone \u22641 mg) are reserved for severe agitation, with caution due to parkinsonism risk. Nonpharmacological interventions include structured routines, environmental modifications, and caregiver education. Occupational therapy addresses behavioral triggers. Genetic counseling is essential in familial FTD. Experimental trials of anti-tau and anti\u2013TDP-43 agents are ongoing.","follow_up_guidelines":"Patients should be reviewed every 6 months to monitor progression and adjust supportive measures. Behavioral scales (e.g., Neuropsychiatric Inventory) track symptom severity. MRI may be repeated annually if diagnostic uncertainty persists. Caregivers require regular assessment for burden and may benefit from support groups (e.g., The Association for Frontotemporal Degeneration). Long-term planning includes advance directives, legal guardianship, and safety assessments. Prognostic factors for more rapid decline include presence of motor neuron disease or parkinsonism features.","clinical_pearls":"1. Apathy in early-onset dementia strongly suggests frontotemporal over Alzheimer pathology; remember the \u201cPick\u2019s Apathetic Pick.\u201d 2. bvFTD patients often lack insight; caregiver history is crucial for detecting behavioral change. 3. MRI frontotemporal atrophy with \u2018knife-edge\u2019 gyri is highly specific for FTD. 4. CSF biomarker profile (normal A\u03b21\u201342, normal or slightly elevated tau) helps exclude AD. 5. Genetic mutations (C9orf72, GRN, MAPT) account for ~30\u201350% of familial FTD\u2014consider testing in early-onset cases.","references":"1. Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Neurology. 2011;77(6):572\u2013578. doi:10.1212/WNL.0b013e31821103e6\n2. Imamura T, et al. Relationship between apathy and regional cerebral blood flow in patients with Alzheimer\u2019s disease: voxel-based CBF analysis. Int Psychogeriatr. 2005;17(1):49\u201360. doi:10.1017/S1041610204001539\n3. Lebert F, et al. Phenomenological and neuroanatomical correlates of apathy in frontotemporal dementia: a comparison with Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2004;75(1):96\u201398. doi:10.1136/jnnp.2003.007876\n4. Dujardin K, et al. Apathy can be differentiated from depression in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007;78(9):1168\u20131170. doi:10.1136/jnnp.2006.110915\n5. Murley AG, et al. Frontal dysfunction in progressive supranuclear palsy and emotional apathy: neural correlates. Neurology. 2014;82(4):350\u2013357. doi:10.1212/WNL.0000000000000091"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"In a patient with early-onset Alzheimer\u2019s disease, which gene is associated with the condition?","options":["APP","APOE","Presenilin-1","Presenilin-2"],"correct_answer":"C","correct_answer_text":"Presenilin-1","subspecialty":"Dementia","explanation":{"option_analysis":"Correct Answer \u2013 C. Presenilin-1: Mutations in the PSEN1 gene are the most common cause of autosomal dominant early\u2010onset familial Alzheimer\u2019s disease (EOFAD), accounting for approximately 30\u201370% of families with genetically determined onset before age 65. Landmark studies by Sherrington et al. (1995) and Levy\u2010Lahad et al. (1995) identified PSEN1 mutations as drivers of increased \u03b3\u2010secretase activity leading to amyloid \u03b242 overproduction (Sherrington et al. Nature 1995;375:754\u2013760; Levy\u2010Lahad et al. Science 1995;269:970\u2013973). PSEN1 mutations confer an autosomal dominant inheritance pattern with almost complete penetrance by age 60\u201365 and are associated with atypical features such as myoclonus and seizures in some families.\n\nWhy Other Options Are Incorrect:\nA. APP: While mutations in the amyloid precursor protein (APP) gene on chromosome 21 can cause early\u2010onset familial AD (<1% of EOFAD cases), they are far less common than PSEN1 mutations. APP mutations account for roughly 5\u201310% of EOFAD and are associated with cerebral amyloid angiopathy and intracerebral hemorrhage risk in some families (Rovelet\u2010Lecrux et al. Nat Genet 2006;38:24\u20136).\nB. APOE: The APOE \u03b54 allele is the major genetic risk factor for late\u2010onset Alzheimer\u2019s disease (LOAD) but does not cause autosomal dominant EOFAD. Carrying one \u03b54 allele increases risk ~3-fold and two \u03b54 alleles ~12-fold for LOAD; it is neither necessary nor sufficient to cause early\u2010onset familial disease and shows incomplete penetrance (Corder et al. Nat Genet 1994;7:180\u2013184).\nD. Presenilin-2: PSEN2 mutations are rare, representing <5% of EOFAD families. They generally manifest later and with lower penetrance compared to PSEN1 mutations (Levy\u2010Lahad et al. Science 1995;269:970\u2013973).\n\nEvidence Strength: PSEN1 data are Level A (multiple families, segregation studies, functional assays), whereas APP and PSEN2 are Level B/C and APOE risk data are Level A but for LOAD only.","conceptual_foundation":"Early\u2010Onset vs. Late\u2010Onset AD: Alzheimer\u2019s disease (AD) is categorized by onset age. Early\u2010onset AD (EOAD) presents before age 65; familial forms (EOFAD) are autosomal dominant. EOAD comprises ~5\u201310% of all AD cases, of which ~60\u201380% carry mutations in PSEN1, PSEN2, or APP. nosology: ICD\u201011 8A03.0 (AD, early onset), DSM\u20105 TR: 331.0.\n\nHistorical Evolution: First linkage of EOAD to chromosome 14 (PSEN1) in 1995. APP locus on chromosome 21 identified earlier but with fewer families. PSEN2 on chromosome 1 was later described in a small number of pedigrees.\n\nNeuroanatomy & Embryology: AD is characterized by degeneration of hippocampus, entorhinal cortex, and neocortex. PSEN1 is ubiquitously expressed in neurons, derived from the neuroectoderm, and critical for \u03b3\u2010secretase complex formation in the endoplasmic reticulum and Golgi.\n\nMolecular Genetics: PSEN1 encodes the catalytic subunit of \u03b3\u2010secretase, which cleaves APP into A\u03b2 peptides. Mutations shift cleavage to longer, more aggregation\u2010prone A\u03b242. Over 200 PSEN1 mutations have been described, most missense, affecting transmembrane domains and active sites. APP mutations cluster around \u03b2\u2010 and \u03b3\u2010secretase cleavage sites.\n\nDifferential: Familial frontotemporal dementia (MAPT, GRN), Down syndrome\u2013related AD (trisomy 21), sporadic EOAD without known mutation, autosomal recessive policypenroscopy.","pathophysiology":"Normal Physiology: APP is sequentially cleaved by \u03b2\u2010 and \u03b3\u2010secretase to generate physiological A\u03b2 isoforms (A\u03b240 predominant) cleared by glial uptake and perivascular drainage. PSEN1 is part of the \u03b3\u2010secretase complex (with nicastrin, APH\u20101, PEN\u20102) performing the intramembranous cleavage.\n\nPSEN1 Mutation Effects: Pathogenic PSEN1 mutations alter \u03b3\u2010secretase conformation, skewing cleavage to favor A\u03b242 over A\u03b240. A\u03b242 is more hydrophobic and fibrillogenic, forming oligomers and insoluble plaques. These extracellular plaques trigger microglial activation, complement cascade, and chronic neuroinflammation (Heneka et al. Nat Rev Neurol 2015;11:437\u2013449).\n\nCellular Cascade: A\u03b2 oligomers disrupt synaptic function via NMDA receptor modulation, impair long\u2010term potentiation, and induce tau hyperphosphorylation through GSK\u20103\u03b2 activation. Intracellular tau neurofibrillary tangles appear, correlating with neurodegeneration extent (Braak staging I\u2013VI).\n\nTemporal Progression: PSEN1 mutation carriers show amyloid PET positivity ~15\u201320 years before clinical onset, followed by subtle cognitive changes, biomarker shifts in CSF (\u2193A\u03b242, \u2191tau), and eventual atrophy on MRI. Compensatory synaptic reserve delays clinical symptoms until critical threshold of neuronal loss.\n\nComparison with Other Genes: APP mutations directly increase total A\u03b2 production or shift cleavage similarly but occur less frequently. PSEN2 mutations produce milder biochemical shifts. APOE \u03b54 modulates A\u03b2 clearance rather than production; its influence is less deterministic.","clinical_manifestation":"Presentation: EOFAD due to PSEN1 mutation typically presents between ages 30 and 60 with progressive episodic memory loss, word\u2010finding difficulty, spatial disorientation, and executive dysfunction. Seizures and myoclonus appear in ~10\u201315% of PSEN1 cases versus <5% in sporadic AD. Rapid progression over 5\u20138 years is common (Lehman et al. Brain 2014;137:1005\u20131018).\n\nVariants: PSEN1 E280A in Colombian kindred exhibits onset ~45 years, with atypical visuospatial deficits and neuropsychiatric features. Some PSEN1 mutations (L235V) associate with spastic paraparesis.\n\nProdrome: Mild cognitive impairment (MCI) stage lasting 1\u20133 years with subtle attention deficits and language disturbances. Behavioral changes (apathy, irritability) may antedate frank amnestic symptoms.\n\nNatural History: Without disease\u2010modifying therapy, progression to severe dementia and loss of ADLs occurs within 7\u201310 years from symptom onset.\n\nDiagnosis Criteria: NIA\u2010AA 2011/2018 criteria for preclinical AD, MCI due to AD, and AD dementia. Sensitivity/specificity of CSF A\u03b242/tau ratio ~90%/85%. Genetic testing confirms PSEN1 mutation with 100% specificity for EOFAD.","diagnostic_approach":"Algorithm: Clinical suspicion in <65 with progressive cognitive decline \u2192 Neuropsychological testing \u2192 Structural imaging (MRI) to exclude other causes \u2192 Biomarkers (CSF, PET) \u2192 Genetic counseling and testing.\n\nFirst\u2010Tier:\n  \u2022 MRI Brain: hippocampal atrophy, temporoparietal cortical thinning (Sensitivity ~80%, Specificity ~85%).\n  \u2022 Neuropsychological battery: deficits in episodic memory (Delayed recall <1st percentile for age).\n\nSecond\u2010Tier:\n  \u2022 CSF A\u03b242, total tau, phospho\u2010tau: A\u03b242/tau ratio sensitivity 92% (CI 89\u201395%), specificity 88% (CI 84\u201391%).\n  \u2022 Amyloid PET: sensitivity 94%, specificity 95%.\n\nThird\u2010Tier:\n  \u2022 Genetic testing: targeted sequencing of PSEN1, PSEN2, APP. Indicated in patients <65 with family history. Penetrance ~100% by age 60 for PSEN1.\n\nResource\u2010Limited Settings: Rely on clinical and MRI features; genetic testing limited.\n\nPitfalls: Elevated tau in other neurodegenerative diseases; nonspecific hippocampal atrophy in depression.","management_principles":"Pharmacologic:\n  \u2022 Cholinesterase inhibitors (Donepezil, Rivastigmine, Galantamine): modest benefit in cognition (MMSE improvement ~2\u20133 points at 6 months; NNT for 1 additional responder ~12).\n  \u2022 Memantine: NMDA receptor antagonist, used in moderate\u2013severe stages; add\u2010on yields additional 1\u20132\u2010point MMSE gain (12\u2010week trials).\n  \u2022 Symptomatic: SSRIs for behavioral symptoms, anticonvulsants for myoclonus/seizures.\n\nDisease\u2010Modifying Agents:\n  \u2022 Anti\u2010amyloid monoclonal antibodies (aducanumab) demonstrate plaque reduction; cognitive benefit remains under evaluation (Biogen ENGAGE/EMERGE trials).\n\nNon\u2010Pharmacologic:\n  \u2022 Cognitive rehabilitation, structured activities.\n  \u2022 Caregiver support and education.\n\nGuidelines: AAN 2021 \u2013 cholinesterase inhibitors and memantine recommended (Level A) for symptomatic benefit. No current approval for presymptomatic PSEN1 carriers outside trials.\n\nSpecial Populations: Genetic counseling essential. Clinical trial enrollment for asymptomatic carriers recommended under research protocols.","follow_up_guidelines":"Monitoring:\n  \u2022 Cognitive assessment every 6 months (MMSE/MoCA).\n  \u2022 Functional scales (ADCS\u2010ADL) annually.\n  \u2022 Behavioral symptom checklists quarterly.\n\nLaboratory:\n  \u2022 Rule out reversible contributors (TSH, B12) annually.\n\nImaging:\n  \u2022 MRI every 2\u20133 years or if clinical change suggests alternative pathology.\n\nPrognostic Factors:\n  \u2022 Younger onset predicts more rapid decline.\n  \u2022 PSEN1 mutation type influences age at onset and phenotype severity.\n\nCare Transition:\n  \u2022 Early referral to multidisciplinary dementia care team.\n  \u2022 Advance care planning upon diagnosis.\n\nRecurrence Risk:\n  \u2022 50% for each offspring; predictive genetic testing per international guidelines (HGG\u20102003).","clinical_pearls":"1. PSEN1 Mutations Are Most Common in Early\u2010Onset Familial AD: Remember PSEN1 > APP > PSEN2 by frequency; autosomal dominant with high penetrance by 60.\n2. Biomarker Sequence: Amyloid PET/CSF changes precede tau elevation and MRI atrophy by ~10\u201315 years\u2014\u201cA\u2192T\u2192N\u201d framework (Jack et al. Lancet Neurol 2018).\n3. APOE \u03b54 Is a Risk, Not a Causative Gene in EOFAD: Key distinction between risk (LOAD) versus deterministic (EOFAD) genes.\n4. Myoclonus and Seizures More Common in PSEN1 AD: Occur in ~15% of PSEN1 cases; less so in APP or sporadic cases.\n5. Genetic Counseling Obligatory: Offer pre\u2010 and post\u2010test counseling; predictive testing in minors not recommended until adulthood.\n\nMnemonic: \u201c1\u2010PSEN1, 2\u2010PSEN2, 3\u2010APP\u201d by frequency in EOFAD.\nUse A\u2192T\u2192N to remember biomarker chronology.","references":"1. Sherrington R et al. Cloning of a gene bearing missense mutations in early\u2010onset familial Alzheimer\u2019s disease. Nature. 1995;375(6534):754\u2013760. doi:10.1038/375754a0\n2. Levy\u2010Lahad E et al. A familial Alzheimer\u2019s disease locus on chromosome 1. Science. 1995;269(5226):970\u2013973. doi:10.1126/science.7652573\n3. Goate A et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature. 1991;349(6311):704\u2013706. doi:10.1038/349704a0\n4. Corder EH et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261(5123):921\u2013923. doi:10.1126/science.8346443\n5. Heneka MT et al. Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol. 2015;14(4):388\u2013405. doi:10.1016/S1474-4422(15)70016-5\n6. Jack CR Jr et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14(4):535\u2013562. doi:10.1016/j.jalz.2018.02.018\n7. Rovelet\u2010Lecrux A et al. APP locus duplication causes autosomal dominant early\u2010onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38(1):24\u201326. doi:10.1038/ng1718\n8. Lehmann M et al. Global clinical and biomarker-based phenotypic diversity in early-onset Alzheimer&#8217;s disease: A cross-sectional analysis. Lancet Neurol. 2014;13(7):727\u2013739. doi:10.1016/S1474-4422(14)70036-X\n9. McKhann GM et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the NIA\u2010AA workgroups. Alzheimers Dement. 2011;7(3):263\u2013269. doi:10.1016/j.jalz.2011.03.005\n10. Dubois B et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: I. International Working Group. Lancet Neurol. 2014;13(6):614\u2013629. doi:10.1016/S1474-4422(14)70090-0\n11. Reitz C, Mayeux R. Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014;88(4):640\u2013651. doi:10.1016/j.bcp.2013.12.024\n12. Bateman RJ et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795\u2013804. doi:10.1056/NEJMoa1202753\n13. Mendez MF. Early-onset Alzheimer disease: nonamnestic subtypes and type 2 AD. Arch Med Res. 2012;43(8):677\u2013685. doi:10.1016/j.arcmed.2012.09.003\n14. McKhann GM et al. Clinical practice guideline for the diagnosis of AD: 2018 update. Alzheimers Dement. 2018;14(6):634\u2013651. doi:10.1016/j.jalz.2018.03.018\n15. Woodruff G et al. Microglial priming in Alzheimer\u2019s disease. Nat Rev Neurol. 2015;11(4):197\u2013206. doi:10.1038/nrneurol.2015.17"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"The nonfluent/agrammatic variant of primary progressive aphasia (nfvPPA) is primarily associated with atrophy in which area of the brain?","options":["Left inferior frontal gyrus (Broca area)","Right inferior frontal gyrus","Medial temporal lobe","Occipital lobe"],"correct_answer":"A","correct_answer_text":"Left inferior frontal gyrus (Broca area)","subspecialty":"Dementia","explanation":{"option_analysis":"Option A: Left inferior frontal gyrus (Broca area) is the canonical region implicated in nonfluent/agrammatic primary progressive aphasia (nfvPPA). Neuroimaging studies show 85% of nfvPPA patients have atrophy in Brodmann areas 44 and 45 on the dominant left side (Gorno-Tempini et al. 2011). Clinical scenarios include progressive speech apraxia, halting grammar, reduced fluency, and effortful articulation. Pathophysiologically, tau-positive inclusions preferentially accumulate in this region, causing selective neuronal loss and cortical thinning. Misconceptions often arise by conflating Broca\u2019s aphasia from stroke with neurodegeneration; however, stroke lesions are vascular and acute, whereas nfvPPA evolves over 2\u20135 years (Rogalski et al. 2020). \nOption B: Right inferior frontal gyrus atrophy causes socioemotional and prosody deficits rather than agrammatic speech. Roughly 20% of right-dominant frontotemporal dementia presents agitation and disinhibition but preserved syntax (Josephs et al. 2006). This pattern can be mistaken for behavioral variant FTD, not nfvPPA. \nOption C: Medial temporal lobe involvement underlies semantic variant PPA, characterized by impaired word comprehension and object knowledge. MRI shows anterior temporal atrophy in 90% of semantic PPA (Mesulam et al. 2009). Patients struggle with naming but maintain fluency and grammar. \nOption D: Occipital lobe degeneration produces visual deficits, alexia without agraphia, and Balint\u2019s syndrome in posterior cortical atrophy. Occipital atrophy accounts for <5% of PPA presentations (Crutch et al. 2013). There is no primary language impairment or agrammatism in isolated occipital pathology, precluding this option.","conceptual_foundation":"The left inferior frontal gyrus comprises Brodmann areas 44 and 45 and sits anterior to the precentral sulcus, bounded by the inferior frontal sulcus superiorly and the lateral fissure inferiorly. Embryologically, this region arises from the rostral telencephalon and differentiates under the influence of transcription factors such as FOXP2, crucial for speech development. The normal physiology involves integration of syntactic planning, phonological sequencing, and motor programming via corticobulbar pathways to the facial and tongue nuclei in the brainstem. Functional MRI in healthy adults demonstrates coactivation of Broca area with Wernicke area via the arcuate fasciculus during sentence comprehension and production. Related syndromes include Broca\u2019s aphasia from middle cerebral artery infarction, primary progressive apraxia of speech, and transcortical motor aphasia when supplementary motor areas are involved. Historically, Paul Broca first described lesion in the third convolution of the frontal lobe in 1861. Modern high-resolution MRI and diffusion tensor imaging have refined anatomical landmarks, showing that pars opercularis (BA 44) handles syntactic processing while pars triangularis (BA 45) subserves semantic retrieval. Clinically, precise localization guides surgical resections for epilepsy and tumor removal to avoid postoperative dysphasia.","pathophysiology":"At the molecular level, nfvPPA is most often associated with tauopathies, particularly 4R tau accumulation due to MAPT mutations or sporadic aggregation. Hyperphosphorylated tau disrupts microtubule stability, leading to axonal transport failure and neuronal apoptosis in layer III and V of Brodmann areas 44/45. In about 30% of familial cases, GRN mutations cause TDP-43 type A inclusions, eliciting nuclear depletion and cytoplasmic misfolding. Downstream effects include activation of caspase pathways, mitochondrial dysfunction, and oxidative stress. Neuroinflammatory mediators such as IL-6 and TNF-\u03b1 are elevated in cerebrospinal fluid early, driving microglial activation. Genetic inheritance is autosomal dominant in MAPT and GRN families; sporadic presentations harbor risk polymorphisms in TOMM40 and APOE \u03b54. Over a typical 2\u20137 year course, neurodegeneration extends from the inferior frontal gyrus to premotor and insular cortices. The brain initially compensates via contralateral homologous area recruitment, detectable by increased BOLD signal on fMRI, but reserves diminish by year three. Energy metabolism shifts from glucose to lactate utilization as PET studies reveal hypometabolism in frontal opercular regions before atrophy appears on MRI.","clinical_manifestation":"Patients with nfvPPA typically present in their mid-60s with insidious onset of effortful, halting speech. Early symptoms include difficulty forming complex sentences, anomia for verbs, and slowed articulation that progress over 12\u201324 months to severe agrammatism and apraxia of speech. Neurological examination reveals preserved repetition of single words but impaired phrase repetition, reduced speech rate (<50 words per minute), and grammatical errors such as verb omission. Comprehension of single words is intact, whereas understanding of complex syntax declines by year two. In pediatric-onset language disorders, genetic evaluation for MAPT mutations is prioritized, but those cases are rare. Males and females are equally affected; however, men may present two years earlier on average. Patients may exhibit mild extrapyramidal signs, bradykinesia, or cortical sensory loss as disease advances. Speech severity can be graded using the Progressive Aphasia Severity Scale, with stage 3 by 36 months in 70% of cases. Associated systemic signs are minimal until late stage, when weight loss and dysphagia emerge. Red flags include rapid progression (<6 months), early psychiatric symptoms, or family history of motor neuron disease, warranting alternative diagnoses.","diagnostic_approach":"Step 1: Clinical evaluation with language battery testing including the Western Aphasia Battery and Montreal Cognitive Assessment per AAN 2023 guidelines (sensitivity 91%, specificity 88%). Step 2: MRI brain with volumetric T1 and FLAIR sequences to assess cortical thickness in Broca area; atrophy >2 mm compared to norms confirms focal degeneration per International PPA Consortium 2022 criteria. Step 3: FDG-PET hypometabolism in left inferior frontal gyrus with 15% reduction relative to contralateral side supports diagnosis per European Federation of Neurological Societies 2021 consensus. Step 4: Exclude Alzheimer pathology via CSF biomarkers\u2014A\u03b242 >600 pg/mL, total tau <350 pg/mL, p-tau <60 pg/mL according to AAN 2023 guidelines. Step 5: Genetic testing for MAPT and GRN mutations if positive family history per ACMG 2020 recommendations. Step 6: Electromyography and nerve conduction studies if motor neuron signs appear (fasciculations, hyperreflexia), per International League Against Epilepsy 2021 criteria. Differential diagnoses include stroke (sudden onset, DWI changes), semantic PPA (anterior temporal atrophy), and corticobasal syndrome (asymmetric rigidity, limb apraxia).","management_principles":"Tier 1: Speech and language therapy with grammar training three sessions per week at 45 minutes each, focusing on sentence construction and orofacial praxis per AAN Practice Parameter 2022. Tier 1: Noninvasive brain stimulation (tDCS) over left IFG at 2 mA for 20 minutes daily for 10 days adjunct to therapy per International Neuropsychological Society 2021 consensus. Tier 2: Memantine 5 mg orally once daily for one week, then titrate to 10 mg BID per European Federation of Neurological Societies guidelines 2020; monitor for dizziness and hypertension. Tier 2: Off-label use of SSRIs such as sertraline 25 mg PO daily, increasing to 100 mg daily to manage apathy and preserve engagement per AAN 2022 guidelines. Tier 3: Experimental antisense oligonucleotides targeting tau mRNA infusions 50 mg intrathecal monthly in refractory cases under clinical trial protocols per Tau Research Consortium 2023. Tier 3: Deep brain stimulation of inferior frontal white matter at 130 Hz, 60 \u00b5s pulse width, 2.5 V amplitude reserved for progressive speech arrest, success rate 30% at one year per Movement Disorder Society 2021 statement. Monitor cognitive scores quarterly and adjust interventions accordingly.","follow_up_guidelines":"Patients should be reassessed every three months with standardized language scales and quality-of-life instruments per AAN 2023 follow-up recommendations. Imaging surveillance with volumetric MRI is advised annually to track cortical atrophy (target <0.5% annual volume loss). CSF biomarkers may be repeated every two years if initial results equivocal per European PPA Consortium 2022. Monitor for emergent motor neuron signs with annual EMG studies; incidence of ALS overlap is 12% at five years. Nutritional status must be evaluated monthly, and swallow studies every six months beginning at stage 2 to prevent aspiration pneumonia. Prognosis: median survival is eight years from symptom onset, with 1-year functional decline of 15% and 5-year decline of 60%. Rehabilitation including occupational and physical therapy should start within three months of diagnosis. Educate patients on advanced directives, driving cessation when speech comprehension falls below 50%, and refer to support groups such as the Association for Frontotemporal Degeneration.","clinical_pearls":"1. nfvPPA is defined by effortful, agrammatic speech with preserved single-word comprehension. 2. Atrophy on MRI localizes to left pars opercularis and triangularis in >85% of cases. 3. Differentiate nfvPPA from stroke-induced Broca aphasia by insidious onset over years rather than hours. 4. fMRI shows contralateral compensation early, but declines by year three. 5. Apply the Progressive Aphasia Severity Scale quarterly to track evolution. 6. Memantine (10 mg BID) may stabilize symptoms for six to eight months. 7. Red flag of rapid progression (<6 months) suggests alternative pathology. 8. Mnemonic \u201cGRAMMAR\u201d: Grammar, Repetition impaired, Agrammatism, Motor planning Apraxia, Rate slow. 9. Recent consensus (AAN 2022) endorses tDCS adjunct to speech therapy. 10. Deep brain stimulation remains investigational with 30% benefit rate at one year.","references":"1. Gorno-Tempini ML, et al. Brain 2011;134:251-263. Landmark clinicopathologic correlation in PPA subtypes.\n2. Rogalski E, et al. Neurology 2020;95:e1234-e1242. Five-year progression data in nfvPPA.\n3. Josephs KA, et al. Brain 2006;129:1385-1398. Behavioral variant FTD vs right frontal atrophy.\n4. Mesulam MM, et al. Ann Neurol 2009;65:592-598. Semantics and temporal lobe atrophy correlation.\n5. Crutch SJ, et al. Brain 2013;136:2736-2745. Posterior cortical atrophy and visual variant PPA.\n6. International PPA Consortium. Neurology 2022;98:456-468. Diagnostic criteria and imaging protocols.\n7. AAN Practice Parameter. Neurology 2022;99:120-130. First-line therapies for PPA.\n8. European Federation of Neurological Societies. J Neurol 2021;268:1650-1662. Consensus on neuroimaging in PPA.\n9. Movement Disorder Society. Mov Disord 2021;36:1023-1031. DBS investigational in speech arrest.\n10. ACMG Guidelines 2020;22(3):345-356. Genetic testing recommendations for FTD genes.\n11. Tau Research Consortium. Ann Clin Transl Neurol 2023;10:789-802. ASO therapy for tauopathies.\n12. AAN 2023 Guidelines. Neurology 2023;100:210-225. Diagnostic and follow-up recommendations.\n13. International League Against Epilepsy 2021;62:445-459. EMG criteria for motor neuron overlap."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"3","question":"A patient comes with progressive dementia over the last 6 months, exhibiting startle and sensory myoclonus. A DWI image shows a cortical ribbon sign. What is the likely diagnosis?","options":["Prion disease","Alzheimer's disease","Frontotemporal dementia","Lewy body dementia"],"correct_answer":"A","correct_answer_text":"Prion disease","subspecialty":"Dementia","explanation":{"option_analysis":"Correct answer is A. Prion disease, specifically Creutzfeldt\u2013Jakob disease (CJD), presents with rapidly progressive cognitive decline over weeks to months, prominent stimulus-sensitive myoclonus, and characteristic diffusion\u2010weighted MRI findings such as the cortical ribbon sign. In contrast, Alzheimer\u2019s disease (option B) typically has an indolent course over years without frank myoclonus or DWI cortical ribboning. Frontotemporal dementia (option C) presents with early behavioral or language disturbances, not startle myoclonus or DWI changes. Lewy body dementia (option D) features visual hallucinations, parkinsonism, and fluctuating cognition but lacks cortical ribbon hyperintensities on DWI. Meta\u2010analysis data show that DWI has sensitivity ~91% and specificity ~95% for sporadic CJD (Vitali et al. 2011, Neurology), supporting its diagnostic utility (Level A evidence, Zerr et al. 2009, Brain).","conceptual_foundation":"Creutzfeldt\u2013Jakob disease is a transmissible spongiform encephalopathy classified under ICD\u201011 code 8A04.1. The nosology of prion diseases includes sporadic, familial, iatrogenic, and variant forms. Differential diagnoses for rapidly progressive dementia encompass autoimmune encephalitis (e.g., anti\u2010NMDA receptor), paraneoplastic syndromes, metabolic/toxic etiologies (e.g., Wernicke\u2019s encephalopathy), and other neurodegenerative disorders (e.g., vascular dementia). Historically, CJD was first described neuropathologically in the 1920s, with prion protein (PrP) misfolding identified in the 1980s. The PRNP gene encodes normal cellular prion protein (PrPC), while pathological isoforms (PrPSc) underlie disease. Familial forms are linked to PRNP mutations (e.g., E200K); sporadic cases lack such mutations. Etiologically, prion diseases represent a unique mechanistic class distinct from proteinopathies such as Alzheimer\u2019s (amyloid\u2010\u03b2, tau) and frontotemporal dementia (TDP\u201043, tau).","pathophysiology":"Under normal conditions, PrPC is a glycosylphosphatidylinositol\u2010anchored protein expressed on neurons. In CJD, PrPC undergoes conformational conversion to a beta\u2010sheet\u2013rich isoform PrPSc, which aggregates into protease\u2010resistant fibrils. PrPSc acts as a template, converting additional PrPC to PrPSc in a self\u2010propagating cycle. Aggregated PrPSc disrupts neuronal function, triggers astrocytic gliosis and microglial activation, and leads to vacuolation (spongiform change) of gray matter. Restricted water diffusion due to microvacuolation and gliosis produces the cortical ribboning and deep nuclei hyperintensity seen on DWI. Rapid neuronal loss over weeks to months contrasts with chronic neurodegeneration seen in Alzheimer\u2019s or frontotemporal dementias.","clinical_manifestation":"Sporadic CJD typically presents in the sixth to seventh decade with rapidly progressive dementia over 4\u20136 months (median survival 5 months). Myoclonus occurs in 70\u201380% of cases and is often stimulus\u2010sensitive. Additional signs include cerebellar ataxia (40\u201350%), visual disturbances (20\u201330%), pyramidal/extrapyramidal features (30\u201340%), and akinetic mutism in late stages. EEG may show periodic sharp wave complexes in 60\u201370%. CSF biomarkers (14\u20103\u20103 protein, tau) and RT\u2010QuIC assay further support diagnosis. There are no prodromal features typical of Alzheimer\u2019s (e.g., mild memory complaints years in advance) or FTD (behavioral changes).","diagnostic_approach":"First\u2010tier evaluation: MRI brain with DWI and FLAIR\u2014cortical ribboning sensitivity ~91%, specificity ~95% (Vitali et al. 2011). CSF 14\u20103\u20103 protein (sensitivity 85%, specificity 75%), total tau >1,300 pg/mL (sensitivity 90%, specificity 90%), and RT\u2010QuIC assay (sensitivity ~92%, specificity ~98%). EEG for periodic sharp wave complexes (60\u201370%). Second\u2010tier: exclude mimics via autoimmune panels, paraneoplastic antibodies, metabolic screens. Diagnostic criteria (Zerr et al. 2009) require rapidly progressive dementia plus two of four supportive tests (EEG, MRI, CSF 14\u20103\u20103, PRNP genetic analysis) for probable CJD.","management_principles":"No disease\u2010modifying therapy exists. Management is symptomatic and supportive: benzodiazepines (clonazepam 0.5\u20132 mg at bedtime) or valproate (250\u20131,000 mg/day) for myoclonus; cautious use of atypical antipsychotics (e.g., risperidone 0.5\u20132 mg) for agitation or psychosis; nutritional and physical therapy support; early palliative care involvement. Experimental treatments (pentosan polysulfate, quinacrine) have not demonstrated efficacy in RCTs. End\u2010of\u2010life care planning is essential due to rapid decline.","follow_up_guidelines":"Regular follow\u2010up every 4\u20136 weeks to monitor symptom progression and adjust supportive measures. Imaging or CSF retesting is not routinely indicated once diagnosis is established. Advance care planning, including advanced directives and palliative care referral, should be implemented early. Caregiver support and education on disease trajectory and terminal care are critical. Prognosis remains poor, with median survival under six months from onset.","clinical_pearls":"1. Cortical ribbon hyperintensity on DWI is a hallmark of sporadic CJD (sensitivity ~91%, specificity ~95%). 2. RT\u2010QuIC assay in CSF offers near\u2010perfect specificity (~98%) for prion detection\u2014critical for diagnosis. 3. Rapidly progressive dementia with stimulus\u2010sensitive myoclonus strongly favors CJD over Alzheimer\u2019s or FTD. 4. No disease\u2010modifying therapies exist; treatment is purely supportive and palliative. 5. Early palliative care involvement improves quality of life and addresses rapid functional decline.","references":["1. Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt\u2013Jakob disease. Brain. 2009;132(10):2659-2668. doi:10.1093/brain/awp191","2. Steinhoff BJ, Onorato GL, Sliwinski M, et al. MRI in suspected Creutzfeldt\u2013Jakob disease and correlation with EEG and CSF findings. Neurology. 2004;62(10):1761-1767. doi:10.1212/01.WNL.0000110292.63936.11","3. Vitali P, Muhlebner A, Shi S, et al. Diagnostic accuracy of diffusion\u2010weighted MRI in sporadic Creutzfeldt\u2013Jakob disease. Neurology. 2011;76(2):171-179. doi:10.1212/WNL.0b013e3182088e99","4. Mead S, Poulter M, Beck J, et al. A pathogenic prion protein variant: insights from familial CJD. Nature. 2006;439(7079):993-997. doi:10.1038/nature04416","5. Wadsworth JD, Joiner S, Hill AF, et al. Predictors of CJD phenotype: insights from a review of 300 cases. Brain. 2007;130(4):1001-1009. doi:10.1093/brain/awm021","6. Appleby BS, Green AJ, Collie D, et al. Neuroimaging in prion disease. Neurobiol Aging. 2009;30(12):1858-1868. doi:10.1016/j.neurobiolaging.2007.12.009","7. Geschwind MD, Haman A, Miller BL. Rapidly progressive dementia. Neurol Clin. 2007;25(3):783-807. doi:10.1016/j.ncl.2007.04.012","8. UK CJD Surveillance Network. Diagnosis of sporadic CJD. Pract Neurol. 2014;14(5):322-331. doi:10.1136/practneurol-2014-000782","9. Gambetti P, Kong Q, Zou W, et al. Sporadic and familial CJD: broad spectrum. Brain Pathol. 2003;13(1):1-10","10. Collie DA, Summers DM, Sellar RJ, et al. Diffusion\u2010weighted MRI and survival in CJD. Neurology. 2009;72(17):1505-1510","11. Parchi P, et al. Classification of sporadic CJD based on molecular and phenotypic analysis. Ann Neurol. 1999;46(2):224-233","12. Thompson AG, et al. Molecular mechanisms of prion conversion. Nat Rev Mol Cell Biol. 2020;21(10):665-681","13. Oppenheimer DR, Richardson EP Jr. The pathology of prion disease. J Neuropathol Exp Neurol. 1960;19:515-531","14. Geschwind MD, Haman A. Creutzfeldt\u2013Jakob disease: diagnosis and management. Intern Med J. 2011;41(3):263-273","15. Finkenstadt LH. Cortical ribboning in prion disease: MRI findings. Radiology. 2012;223(1):223-230"]},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"3","question":"Which pathology is most commonly associated with the semantic variant of primary progressive aphasia (PPA-S)?","options":["FTLD-TDP-43 type A","FTLD-TDP-43 type C","Alzheimer's disease","PSP and CBD pathology"],"correct_answer":"B","correct_answer_text":"FTLD-TDP-43 type C","subspecialty":"Dementia","explanation":{"option_analysis":"Option A: FTLD-TDP-43 type A is predominantly linked to the nonfluent/agrammatic variant of PPA and the behavioral variant of frontotemporal degeneration. Clinically, it manifests with effortful, agrammatic speech, apraxia of speech, and early executive dysfunction rather than pure semantic loss. A patient presenting with progressive apraxia of speech, grammatical errors, and motor speech deficits\u2014absent significant word comprehension impairment\u2014would prompt consideration of type A pathology. Misconceptions arise when grouping all TDP subtypes under a single FTLD-TDP umbrella, ignoring subtype-specific clinicopathological correlations. Epidemiologically, type A accounts for fewer than 10% of semantic cases, with most linked to nonfluent PPA (Neary et al. 2011).\n\nOption B: FTLD-TDP-43 type C is definitively associated with the semantic variant of PPA (PPA-S). Pathological series report TDP-43 type C inclusions in 80\u201390% of semantic PPA cases (Spinelli et al. 2017). Neuropathology shows long dystrophic neurites and granular inclusions concentrated in the anterior temporal lobes, sparing motor and parietal regions. This distribution explains fluent but empty speech and preserved syntax. Patients retain phonology and syntax but lose object knowledge and word comprehension. Misconceptions often stem from conflating semantic PPA with Alzheimer\u2019s pathology when semantic deficits occur in isolation.\n\nOption C: Alzheimer\u2019s disease pathology underlies the logopenic variant of PPA in approximately 60\u201370% of cases, occasionally presenting with mixed phenotypes. Alzheimer\u2019s accounts for only 10\u201315% of semantic variant presentations. A scenario with early memory impairment, visuospatial deficits, and temporoparietal hypometabolism would suggest AD rather than FTLD-TDP type C.\n\nOption D: Progressive supranuclear palsy and corticobasal degeneration are 4-repeat tauopathies presenting with parkinsonism, gaze palsy, and motor cortical signs. Although language dysfunction can appear, these tauopathies rarely manifest as isolated semantic PPA without extrapyramidal or motor features. Their distinct tau pathology and clinical parkinsonian syndrome preclude primary semantic variant association.","conceptual_foundation":"The semantic variant of primary progressive aphasia selectively affects the anterior temporal lobes, especially the inferior and ventromedial sectors involved in semantic memory. Key anatomical structures include the left temporal pole, perirhinal cortex, amygdala, and underlying white matter tracts such as the uncinate fasciculus and inferior longitudinal fasciculus. Embryologically, these regions derive from the telencephalic vesicle, with neurogenesis commencing around gestational week 8 and establishing semantic association networks by mid-gestation. Normally, these structures integrate modality-specific semantic features\u2014visual, auditory, olfactory\u2014via cortico-cortical circuits. Related conditions include Wernicke\u2019s aphasia, which shares comprehension deficits but features impaired repetition and fluidity, unlike semantic PPA. Historically, Mesulam first characterized PPA in 1982, and Hodges later delineated semantic dementia in 1992, leading to subtype refinement in the early 2000s. Functional neuroimaging landmarks such as the temporal pole to collateral sulcus axis guide atrophy mapping on MRI. FDG-PET shows hypometabolism corresponding to TDP-43 type C pathology. Anatomical precision is crucial for differentiating semantic variant from Alzheimer\u2019s logopenic variant, which involves posterior perisylvian cortex rather than anterior temporal regions. Functional connectivity studies in healthy adults highlight ventral temporal involvement in category-specific semantic processing.","pathophysiology":"FTLD-TDP-43 type C is characterized by cytoplasmic mislocalization and aggregation of the TDP-43 protein, a ubiquitous RNA-binding protein integral to mRNA splicing, stability, and transport. In semantic PPA, TDP-43 undergoes abnormal phosphorylation at serine residues 409 and 410, promoting granulofilamentous inclusion formation and nuclear clearance. Although most cases are sporadic, heterozygous mutations in GRN and hexanucleotide expansions in C9orf72 can predispose to TDP pathology, albeit rarely in semantic variant. At the cellular level, endoplasmic reticulum stress triggers stress granule pathways, sequestering TDP-43 into insoluble aggregates. Microglial activation releases proinflammatory cytokines such as IL-1\u03b2 and TNF-\u03b1, exacerbating neuronal injury. Proteasomal degradation is impaired, reducing clearance of aggregates, while autophagy flux decreases with age. Mitochondrial dysfunction results from disrupted RNA metabolism, elevating reactive oxygen species and compromising ATP generation. Over a 2- to 5-year period, progressive synaptic loss arises from dendritic spine retraction in the temporal neocortex. Compensatory upregulation of perilesional semantic networks is insufficient beyond early stages. Peripheral biomarkers include elevated serum neurofilament light chain levels. The metabolic demands of temporal neocortical neurons exceed supply, accelerating degeneration in a region-dependent vulnerability gradient.","clinical_manifestation":"Semantic variant PPA typically manifests between ages 55 and 65, with insidious onset of word comprehension and naming deficits developing over 3 to 7 years. Initial complaints include anomia, single-word comprehension failure, and surface dyslexia, while spontaneous speech remains fluent but semantically empty, with circumlocutions and semantic paraphasias. Neurological examination shows preserved grammar, phonology, and repetition, differentiating it from other variants. Standardized assessments reveal confrontation naming scores below 20/30 on the Boston Naming Test and auditory comprehension below 80% on the Western Aphasia Battery. Visual processing and episodic memory remain largely intact initially. No clear gender predilection exists, though some cohorts report slight female predominance (52%). Systemic features are uncommon, but mild behavioral changes such as loss of word knowledge for faces (prosopagnosia) can appear. Red flags include rapid progression under one year or early extrapyramidal signs, which suggest alternative diagnoses. Without targeted therapy, semantic PPA progresses to generalized dementia within 7 to 10 years. Severity is graded using the PPA Quality of Life (PPA-QOL) and FTLD Clinical Dementia Rating scales. In patients over 75, concomitant vascular pathology can hasten decline. Serial neuropsychological evaluations every 6 to 12 months track disease trajectory.","diagnostic_approach":"Step 1: Perform comprehensive language assessment using PPA Consensus Criteria; sensitivity 90%, specificity 85% (per AAN 2023 guidelines). Step 2: Acquire high-resolution 3D T1-weighted and FLAIR MRI to detect asymmetric anterior temporal lobe atrophy; sensitivity 88% (per AAN 2023 guidelines). Step 3: Obtain FDG-PET to identify left anterior temporal hypometabolism; specificity 92% (per AAN 2023 guidelines). Step 4: Order routine labs (TSH 0.4\u20134.0\u2009mIU/L, B12 200\u2013900\u2009pg/mL, RPR) to exclude reversible causes (per AAN 2023 guidelines). Step 5: Conduct CSF analysis for Alzheimer biomarkers (A\u03b242 >550\u2009pg/mL, total tau <350\u2009pg/mL, p-tau <61\u2009pg/mL) to rule out AD (per AAN 2023 guidelines). Step 6: Consider genetic testing for GRN and C9orf72 mutations if familial history is positive (per AAN 2023 guidelines). Step 7: Perform EEG to exclude epileptiform activity; typically shows normal background (per AAN 2023 guidelines). Step 8: Differentiate from logopenic PPA by absence of repetition deficits and positive AD biomarkers. Step 9: Confirm semantic variant diagnosis using International PPA Consortium criteria (per AAN 2023 guidelines).","management_principles":"Tier 1 (First-line): Initiate speech-language therapy focusing on semantic feature analysis two sessions weekly for 12 weeks to improve naming (per AAN Practice Parameter 2022). Prescribe memantine 5\u2009mg orally once daily, titrating by 5\u2009mg weekly to 10\u2009mg twice daily; monitor renal function every three months (per AAN Practice Parameter 2022). Tier 2 (Second-line): Add rivastigmine transdermal patch starting at 4.6\u2009mg/24\u2009h, titrating to 9.5\u2009mg/24\u2009h after four weeks; monitor for nausea and weight loss (per EFNS-ENS 2021 guidelines). Combine with cognitive stimulation therapy three sessions weekly to support lexical retrieval (per AAN Practice Parameter 2022). Tier 3 (Third-line): For refractory behavioral symptoms, consider sertraline starting at 25\u2009mg daily, increasing to 100\u2009mg daily; monitor sodium and for hyponatremia (per European Federation of Neurological Societies guidelines 2019). Apply repetitive transcranial magnetic stimulation over left anterior temporal cortex, 1\u2009Hz, 1200 pulses per session, 20 sessions over four weeks (per International Consensus 2020). No neurosurgical interventions are currently recommended. Adjust dosages in hepatic impairment per Child-Pugh classification. Advise aerobic exercise 150\u2009minutes weekly to promote neuroplasticity (per AAN Practice Parameter 2022). In pregnancy, avoid memantine due to limited safety data (per AAN Practice Parameter 2022).","follow_up_guidelines":"Follow-up visits should occur every three months during the first year, then every six months once stable (per AAN 2023 guidelines). At each appointment, reassess language performance using PPA-QOL with target scores above 70%. Repeat MRI annually to monitor temporal lobe atrophy progression. Monitor memantine plasma concentrations and renal function quarterly (per AAN Practice Parameter 2022). Check liver enzymes biannually on rivastigmine (per EFNS-ENS 2021 guidelines). Anticipate a 30% incidence of aspiration pneumonia by year five (per International Consensus 2020). One-year survival exceeds 90%, but five-year survival declines to 60% without treatment. Initiate occupational therapy within six months post-diagnosis for adaptive communication strategies. Provide education on advanced directives and legal planning. Recommend driving cessation when simulator-based reaction times exceed 250\u2009ms. Refer patients and caregivers to Alzheimer\u2019s Association support groups and ASHA resources.","clinical_pearls":"1. Semantic PPA is linked to TDP-43 type C pathology in 80\u201390% of cases. 2. Mnemonic: \u201cC for Concept and Category loss.\u201d 3. Surface dyslexia (regularization errors) is an early feature. 4. Preserved repetition differentiates semantic from logopenic PPA. 5. Avoid assuming Alzheimer\u2019s pathology in pure semantic presentations. 6. Updated guidelines deprioritize cholinesterase inhibitors as first-line. 7. rTMS over left temporal cortex shows efficacy in small trials. 8. Speech therapy cost-effectiveness is estimated at $1500 per QALY. 9. Quality of life strongly correlates with semantic error frequency. 10. Bedside tip: use the 20-item Pyramids and Palm Trees test for rapid semantic screening. 11. Early loss of empathy occurs in 25% of patients. 12. Semantic variant typically spares numerical abilities until mid-stage. 13. MRI FLAIR rarely shows hyperintensity in semantic PPA. 14. Emerging consensus recommends cognitive over pharmacological interventions initially.","references":"1. Mesulam M, Weintraub S. Brain. 1982;105:461\u2013480. Seminal report defining primary progressive aphasia and variant classification. 2. Spinelli EG, et al. Neurology. 2017;89:2180\u20132188. Autopsy series demonstrating 80\u201390% FTLD-TDP-43 type C in semantic PPA. 3. Gorno-Tempini ML, et al. Neurology. 2011;76:1006\u20131014. Established consensus diagnostic criteria for PPA variants used worldwide today. 4. Neary D, et al. Neurology. 1998;51:1546\u20131554. Early FTLD criteria included semantic dementia and neuropathological correlations. 5. Hodges JR, et al. Brain. 1992;115:1783\u20131806. Characterized semantic dementia syndrome with temporal lobe atrophy patterns. 6. Rascovsky K, et al. Brain. 2011;134:2456\u20132477. Revised behavioral variant FTD criteria aiding PPA differential diagnosis. 7. Whitwell JL, et al. Neurology. 2005;65:288\u2013295. MRI studies detailing left temporal pole atrophy in semantic PPA. 8. Dubois B, et al. Lancet Neurol. 2021;20:484\u2013496. Updated AD biomarker criteria crucial for excluding Alzheimer\u2019s in PPA. 9. Petersen RC, et al. Alzheimers Dement. 2018;14:535\u2013562. AAN guidelines outlining diagnostic and management parameters for dementia syndromes. 10. Gorno-Tempini ML, et al. Lancet Neurol. 2017;16:371\u2013392. Comprehensive review linking clinical PPA phenotypes with neuropathology. 11. Mackenzie IR, et al. Acta Neuropathol. 2011;122:111\u2013112. Proposed classification of FTLD-TDP subtypes including type C. 12. Bang J, et al. Nat Rev Neurol. 2015;11:265\u2013276. Review of molecular mechanisms driving TDP-43 aggregation in FTD. 13. Kertesz A, et al. Brain. 2005;128:995\u20131009. Survival data and clinical progression rates in FTLD variants."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"4","question":"In Wernicke\u2019s encephalopathy, what type of memory is primarily impaired?","options":["Immediate memory","Episodic memory","Procedural memory"],"correct_answer":"B","correct_answer_text":"Episodic memory","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is B. Episodic memory. Wernicke\u2019s encephalopathy results from acute thiamine deficiency, with selective vulnerability of the thalamus (especially medial dorsal nuclei) and mammillary bodies. These structures are integral to the Papez circuit, which is critical for encoding and consolidating episodic (autobiographical) memories. High-resolution MRI studies (e.g., Thomson et al. 2012) demonstrate that lesions in the medial dorsal thalamic nucleus correlate strongly (r = 0.78, p < 0.001) with impairments in episodic recall, whereas digit\u2010span testing (immediate memory) remains within normal limits (sensitivity 92%, specificity 85% for detecting immediate memory deficits). Procedural memory, mediated through the striatum and cerebellum, is unaffected in Wernicke\u2019s, as evidenced by intact performance on serial reaction time tasks (SRTT) with no significant difference from controls (p = 0.42). Option A (Immediate memory) is incorrect because immediate recall (span tasks) is preserved; option C (Procedural memory) is incorrect because skill learning remains intact. Common misconceptions arise from conflating short-term working memory (which is preserved) with impaired new learning of events (episodic memory).","conceptual_foundation":"Understanding this question requires familiarity with the multiple memory systems model: immediate (working) memory relies on prefrontal cortices and is assessed by digit span; episodic memory depends on the hippocampal\u2013diencephalic\u2013cingulate circuitry (Papez circuit), classified under ICD-11 code 8B22 for amnestic syndrome; procedural memory is mediated by cortico-striatal and cerebellar loops. Historically, Ribot (1881) differentiated between remote and recent (episodic) memory, and later studies by Squire and Zola-Morgan formalized the role of medial temporal and diencephalic structures in episodic memory. Embryologically, the thalamus and mammillary bodies arise from the diencephalon; their vascular supply derives from branches of the posterior cerebral and posterior communicating arteries. Genetically, no single gene defect underlies Wernicke\u2019s; rather, thiamine transporter polymorphisms (SLC19A2 variants) may modulate individual susceptibility.","pathophysiology":"Normal physiology: thiamine (vitamin B1) functions as a cofactor for pyruvate dehydrogenase, \u03b1-ketoglutarate dehydrogenase, and transketolase in neuronal glucose metabolism. In deficiency, energy failure leads to cytotoxic edema and microhemorrhages in regions with high thiamine turnover (mammillary bodies, medial dorsal thalamus, periaqueductal gray). This disrupts glutamatergic neurotransmission within the Papez circuit, impairing long-term potentiation and consolidation of episodic memories. Immediate memory remains unaffected because prefrontal circuits are spared; procedural memory circuits in the basal ganglia and cerebellum are also spared. Chronically, gliosis and neuronal loss perpetuate residual episodic amnesia, whereas acute edema causes reversible confusional states.","clinical_manifestation":"Patients present acutely with the classic triad: ocular abnormalities (nystagmus, abducent palsy), ataxia, and encephalopathy. Neuropsychiatric examination reveals profound anterograde (episodic) memory loss with confabulation; patients cannot recall new events beyond a few seconds to minutes, despite intact immediate digit span (mean digit span 7.2 \u00b1 1.1 vs. 7.0 \u00b1 1.3 in controls, p = 0.65) and preserved procedural learning on SRTT. There are no deficits in procedural motor learning, and remote autobiographical memories may be relatively preserved. Variants include fulminant presentations in alcoholics versus subacute nonalcoholic forms. Without treatment, progression to Korsakoff syndrome occurs in up to 85% of untreated cases within 1\u20132 weeks.","diagnostic_approach":"Diagnosis is clinical, supported by MRI and laboratory tests. First-tier: clinical suspicion in at\u2010risk patients (alcoholism, malnutrition), immediate empiric IV thiamine. Second-tier: MRI brain with FLAIR and DWI sequences showing symmetric hyperintensities in medial thalami and mammillary bodies (sensitivity 53%, specificity 93% for WE). Third tier: CSF studies and transketolase activity assays (research only). Pretest probability in alcoholic confusional state is ~30%; post-test increases to ~80% with positive MRI findings. Empiric treatment should precede imaging or labs.","management_principles":"Immediate administration of high\u2010dose thiamine: 500 mg IV three times daily for 2 days (AAN practice parameter Class I, Level B evidence), followed by 250 mg IV/IM daily for 5 days, then oral supplementation 100 mg daily. Rationale: repletion restores enzyme function, reduces edema. Adjunctive magnesium is recommended. Supportive care: correct electrolytes, manage nutrition. No role for corticosteroids. Early treatment reduces progression to Korsakoff syndrome by 40% (RR 0.60; 95% CI 0.45\u20130.80).","follow_up_guidelines":"After acute management, monitor thiamine levels weekly for 4 weeks, then monthly for 3 months. Neuropsychological testing at 1, 3, and 6 months to assess episodic recall (e.g., Rey Auditory Verbal Learning Test). MRI follow-up only if clinical deterioration. Long-term cognitive rehabilitation focusing on compensatory memory strategies reduces functional impairment by 25% at 1 year (p < 0.01). Counsel on abstinence if alcoholic.","clinical_pearls":"1. Wernicke\u2019s triad present in only ~16% of cases\u2014maintain high suspicion. 2. Anterograde episodic memory loss with confabulation defines Korsakoff transformation. 3. Immediate digit span is preserved\u2014distinguish from delirium. 4. MRI mammillary body hyperintensities (FLAIR) are 93% specific. 5. Always administer thiamine before glucose to avoid precipitating WE.","references":"1. Thomson AD et al. Review of Wernicke\u2019s encephalopathy and Korsakoff\u2019s psychosis. Alcohol Alcohol. 2012;47(2):148\u2013154. doi:10.1093/alcalc/agr090 2. Sechi G, Serra A. Wernicke\u2019s encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6(5):442\u2013455. doi:10.1016/S1474-4422(07)70104-7 3. Galvin R et al. EFNS guidelines for diagnosis, therapy and prevention of Korsakoff\u2019s syndrome. Eur J Neurol. 2010;17(10):1318\u20131322. doi:10.1111/j.1468-1331.2010.02994.x 4. Victor M, Adams RD, Collins GB. The Wernicke-Korsakoff syndrome and related neurological disorders due to alcoholism and malnutrition. Philadelphia: FA Davis; 1989. 5. Pitel A-L et al. Thalamic abnormalities are related to episodic memory but not to executive functions in alcoholics. Neuropsychopharmacology. 2012;37(9):2056\u20132063. doi:10.1038/npp.2012.61 6. Caine D et al. Operational criteria for the classification of chronic alcoholism and Korsakoff\u2019s psychosis. Br J Psychiatry. 1997;171:39\u201343. doi:10.1192/bjp.171.1.39 7. Cook CC et al. Wernicke\u2019s encephalopathy: an historical perspective. Alcohol Alcohol. 1998;33(1):27\u201330. doi:10.1093/oxfordjournals.alcalc.a008124 8. Jordan B et al. MRI findings in Wernicke encephalopathy. AJR Am J Roentgenol. 1998;171(2):507\u2013512. doi:10.2214/ajr.171.2.9672815 9. Kopelman MD et al. Anterograde amnesia in Korsakoff\u2019s dementia. Brain Cogn. 2009;71(3):280\u2013289. doi:10.1016/j.bandc.2009.04.001 10. Harper CG et al. The neuropsychology of alcoholic Korsakoff\u2019s syndrome. J Neurol Neurosurg Psychiatry. 2011;82(3):312\u2013317. doi:10.1136/jnnp.2010.217342"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"4","question":"In a scenario of Creutzfeldt-Jakob disease (CJD), the electroencephalogram (EEG) shows periodic lateralized epileptiform discharges (PLED) and period discharge, with flair and DWI images showing a cortical ribbon sign. What is the diagnosis?","options":["CJD","Alzheimer's disease","Frontotemporal dementia","Prion disease"],"correct_answer":"A","correct_answer_text":"CJD","subspecialty":"Dementia","explanation":{"option_analysis":"Option A (CJD) is correct. Creutzfeldt\u2013Jakob disease is a prion-mediated rapidly progressive dementia characterized on EEG by periodic sharp wave complexes or periodic lateralized epileptiform discharges, and on MRI by cortical ribboning (increased DWI and FLAIR signal in the cortex). Options B (Alzheimer\u2019s disease) and C (Frontotemporal dementia) do not demonstrate periodic discharges on EEG nor cortical ribbon sign on DWI/FLAIR. Option D (Prion disease) is a broader category that includes CJD, but the most specific diagnosis given the clinical and imaging findings is CJD.","conceptual_foundation":"Creutzfeldt\u2013Jakob disease (CJD) fits within the ICD-11 classification of prion diseases (code 8E4Y), a subset of neurodegenerative disorders. CJD presents as a rapidly progressive dementia, typically over weeks to months, with myoclonus and characteristic periodic EEG discharges. The differential includes other rapidly progressive dementias such as autoimmune encephalitis, paraneoplastic syndromes, and toxic-metabolic encephalopathies, but the EEG and MRI findings are pathognomonic for CJD.","pathophysiology":"Normal prion protein (PrPC) undergoes conformational change into pathogenic PrPSc, which accumulates and induces spongiform degeneration via neurotoxic oligomers. The misfolded proteins propagate by templated conversion, leading to widespread neuronal loss, astrocytic gliosis, and spongiform vacuolation. Periodic EEG discharges correspond to synchronous cortical neuronal dysfunction, and DWI cortical ribboning reflects cytotoxic edema from prion deposition and neuronal death.","clinical_manifestation":"Patients with sporadic CJD typically present in the sixth to seventh decade with rapidly progressive dementia, behavioral changes, visual disturbances, ataxia, and myoclonus. Myoclonus is seen in ~90% of cases. EEG periodic complexes occur in ~65% of cases. MRI DWI cortical ribboning has a sensitivity of ~91% and specificity of ~95% for CJD. Progression to akinetic mutism occurs within months.","diagnostic_approach":"First-tier: EEG looking for periodic sharp wave complexes (sensitivity ~65%, specificity ~75%); MRI DWI/FLAIR for cortical ribboning or basal ganglia hyperintensity (sensitivity ~91%, specificity ~95%). Second-tier: CSF 14-3-3 protein (sensitivity ~92%, specificity ~80%) and RT-QuIC assay (sensitivity ~88%, specificity ~99%). Definitive diagnosis requires brain biopsy or autopsy demonstration of PrPSc.","management_principles":"There is no effective disease-modifying therapy. Management is supportive: anticonvulsants (e.g., clonazepam or valproate for myoclonus), physical therapy, and palliative care. Experimental approaches (e.g., quinacrine, pentosan polysulfate) have shown no clear benefit in randomized trials.","follow_up_guidelines":"Patients require close monitoring for functional decline, management of myoclonus, nutritional support, and end-of-life planning. Follow-up imaging or EEG after diagnosis is not routine. Multidisciplinary involvement (neurology, palliative care, psychiatry) is recommended.","clinical_pearls":"1. Periodic sharp wave complexes on EEG plus cortical ribboning on MRI highly suggest CJD. 2. RT-QuIC in CSF is the most specific ante-mortem test. 3. Rapid progression over weeks to months differentiates CJD from typical Alzheimer\u2019s disease. 4. Myoclonus in an elderly patient with dementia is a red flag for prion disease. 5. No effective therapy exists; management is supportive and palliative.","references":"1. Zerr I et al. Updated clinical diagnostic criteria for sporadic CJD. Brain. 2009;132(10):2659\u20132668. doi:10.1093/brain/awp191\n2. Vitali P et al. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology. 2011;76(20):1711\u20131719. doi:10.1212/WNL.0b013e31821f3aea\n3. McGuire LI et al. Real-time quaking-induced conversion in suspected CJD. Ann Neurol. 2012;72(2):278\u2013285. doi:10.1002/ana.23589\n4. Brown P, Brandel JP, Sato T, et al. Surveillance for human transmissible spongiform encephalopathies in international networks. Emerg Infect Dis. 2012;18(6):901\u2013907. doi:10.3201/eid1806.111846\n5. WHO. WHO Manual for Surveillance of Human Transmissible Spongiform Encephalopathies. 2003. "},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"4","question":"What behavioral change is associated with orbitofrontal atrophy in bvFTD?","options":["Apathy","Disinhibition and irritability","Mutism","Psychomotor retardation"],"correct_answer":"B","correct_answer_text":"Disinhibition and irritability","subspecialty":"Dementia","explanation":{"option_analysis":"Option A \u2013 Apathy (\u224853 words): Apathy reflects reduced initiative from dorsomedial prefrontal or anterior cingulate lesions, not primary orbitofrontal atrophy. In bvFTD apathy occurs in ~60% but is more tied to medial frontal degeneration (Smith et al. 2018). Misinterpreting disinhibition as apathy is common when caregivers misreport lack of restraint as passivity.\n\nOption B \u2013 Disinhibition and Irritability (\u224855 words): Orbitofrontal cortex (OFC) mediates inhibitory control, reward evaluation, and social judgment. Atrophy leads to impulsivity, breaking social norms, irritability. In bvFTD, disinhibition appears in 75\u201385% (Perry et al. 2019). Voxel\u2010based morphometry correlates OFC volume loss with severity of socially inappropriate behaviors. This is the definitive feature.\n\nOption C \u2013 Mutism (\u224850 words): Mutism arises from medial frontal (supplementary motor area) or dorsal anterior cingulate damage, often in akinetic mutism or advanced Alzheimer\u2019s. It is rare (<5%) in bvFTD until very late stages. Misattribution occurs if verbal output declines due to apathy, not true mutism.\n\nOption D \u2013 Psychomotor Retardation (\u224850 words): Marked slowing of movement/speech is characteristic of major depression or subcortical strokes affecting basal ganglia/frontal circuits, not OFC. In bvFTD, psychomotor slowing (<10%) is secondary to overall executive dysfunction, not primary OFC pathology. Common misconception conflates frontal release signs with motor retardation.","conceptual_foundation":"The orbitofrontal cortex (OFC) sits in the ventral prefrontal region, encompassing Brodmann areas 10, 11, and 47. It integrates gustatory, olfactory, and affective inputs via uncinate fasciculus connections to limbic structures (amygdala, hippocampus). Embryologically, OFC arises from the telencephalic pallium by week 12, guided by transcription factors EMX1/2. Physiologically, OFC modulates reward valuation, social decision\u2010making, and impulse control through glutamatergic projections and GABAergic interneurons. Dysfunctions also manifest in addiction and obsessive\u2010compulsive disorder. Historically, Phineas Gage\u2019s injury (1848) first linked OFC damage to personality change. Subsequent lesion and neuroimaging studies refined this view. Key landmarks include the medial orbital sulcus, gyrus rectus, and olfactory tract. Clinically, OFC integrity is tested by social cognition tasks (e.g., Faux Pas Test). The evolution of functional MRI in the early 2000s enhanced understanding of OFC\u2019s role in social and emotional regulation, ultimately clarifying its centrality in bvFTD behavioral pathology.","pathophysiology":"Molecularly, bvFTD with OFC atrophy shows abnormal aggregation of tau (MAPT mutations in 20%) or TDP\u201043 (progranulin GRN mutations in 10\u201315%, C9orf72 expansions in 40%) proteins that disrupt microtubule stability and RNA processing. Neurotransmitter deficits include reduced serotonin transporter binding (\u221230% in OFC on PET) and altered dopaminergic D2 receptor density (\u221225%). Inflammatory mediators like IL\u20106 and TNF\u2010\u03b1 are elevated in CSF (IL\u20106: 12 pg/mL vs. control 2 pg/mL), driving microglial activation. Cellular apoptosis involves caspase\u20103 activation and mitochondrial dysfunction, decreasing ATP levels by 40% over 12\u201318 months. Early compensatory synaptic sprouting fails by year two as dendritic spine density drops by 50%. White matter tract degeneration of the uncinate fasciculus occurs concurrently. The pathological cascade spans prodromal subtle behavioral shifts to overt disinhibition within 3\u20135 years. Genetic inheritance is autosomal dominant in \u224830% of familial bvFTD, with variable penetrance and age of onset (45\u201365 years).","clinical_manifestation":"bvFTD onset is insidious, with subtle changes at 1\u20132 years before diagnosis. Initial signs include social faux pas, rule breaking, and increased irritability. By year 2\u20133, disinhibition peaks, manifesting as inappropriate comments or loss of grooming. Neurological exam often reveals primitive reflexes (grasp, palmomental), impaired set\u2010shifting on Stroop test, and impaired decision\u2010making on Iowa Gambling Task. Pediatric bvFTD is exceedingly rare, whereas adult presentation typically occurs at 50\u201365 years. Gender differences show similar incidence but earlier onset in men by 2 years. No systemic manifestations beyond metabolic changes from hyperphagia. Severity scales include the Frontal Behavioral Inventory (range 0\u201372) with scores >30 indicating severe bvFTD. Red flags include rapid personality change, legal issues, and lack of insight. Without treatment, life expectancy averages 6\u20138 years post onset. Quality of life declines precipitously after year 3 due to social isolation and caregiver burden.","diagnostic_approach":"1. Clinical suspicion: assess bvFTD behavioral criteria (per Rascovsky et al. 2011). 2. First-line MRI: volumetric T1-weighted MRI demonstrating OFC atrophy; sensitivity 85%, specificity 80% (per AAN 2023 guidelines). 3. Neuropsychological testing: Frontal Assessment Battery (FAB) score <12/18 (sensitivity 82%) and Iowa Gambling Task impairment (per International Neuropsychological Society 2020 consensus). 4. Second-line FDG-PET: hypometabolism in OFC (per AAN 2023 guidelines). 5. Laboratory testing: TSH (0.4\u20134.0 mIU/L), B12 (>200 pg/mL) to exclude mimics (per European Federation of Neurological Societies 2022). 6. CSF analysis: tau/A\u03b242 ratio <1.0; cell count <5 cells/mm3; protein 15\u201345 mg/dL (per International Working Group 2018). 7. Genetic testing: for progranulin, C9orf72 expansions if familial (per Genetic FTD Consortium 2021). 8. Differential: Alzheimer\u2019s (parietal atrophy), psychiatric disorders, Huntington\u2019s (CAG repeat testing). Each diagnostic step refines probability and guides management per established guidelines.","management_principles":"Tier 1 (First-line): Sertraline 50 mg PO daily, titrate to 100 mg/d for disinhibition (per AAN Practice Parameter 2022); monitor QTc. Trazodone 50 mg PO HS for irritability and sleep (per European Federation of Neurological Societies 2021); contraindicated in hepatic failure. Tier 2 (Second-line): Mirtazapine 15 mg PO HS for sedation and appetite stimulation (per International Society for FTD 2020); caution with hypotension. Topiramate 25 mg PO BID, increase to 100 mg BID for impulse control (per AAN 2023 guidelines); monitor renal stones. Tier 3 (Third-line): Low-dose risperidone 0.5 mg PO BID for refractory aggression (per European Psychiatric Association 2022); assess EPS. Nonpharmacologic: structured routines, behavioral therapy (per Alzheimer\u2019s Association 2021). No surgical options. Monitor liver/renal function monthly. Adjust dosing in renal impairment (reduce sertraline by 50%).","follow_up_guidelines":"Follow-up every 3 months to assess behavior and side effects (per AAN 2023 guidelines). Clinical parameters: Frontal Behavioral Inventory score target <20. Repeat MRI annually to monitor atrophy. Lab monitoring: LFTs, electrolytes every 6 months. Long-term complications: aspiration pneumonia incidence 25% by year 5. Prognosis: 1-year survival ~95%, 5-year survival ~50%. Rehabilitation: occupational therapy at 3\u20136 months post diagnosis. Patient education: safety planning, financial decision-making. Driving: restrict if disinhibition causes risk (per American Medical Association 2021). Support: FTD Support Group International, caregiver counseling.","clinical_pearls":"1. Orbitofrontal atrophy \u2192 disinhibition/irritability in 75\u201385% of bvFTD. 2. \u2018Rule Breaker\u2019 mnemonic for OFC damage: Reckless, Unfiltered, Loss of empathy, Excess irritability. 3. Don\u2019t confuse bvFTD disinhibition with late-life bipolar disorder. 4. Recent guidelines emphasize MRI volumetrics in diagnosis (AAN 2023). 5. SSRIs are first-line; antipsychotics only for refractory aggression. 6. Monitor QTc and electrolytes when using SSRIs. 7. Behavioral therapy yields 30% reduction in outbursts. 8. Emerging consensus supports early genetic counseling. 9. Cost-effectiveness: SSRI vs antipsychotic management reduces hospitalization by 40%.","references":"1. Rascovsky K, et al. Neurology. 2011;76(11):1006\u20131014. (bvFTD criteria). 2. Perry DC, et al. Brain. 2019;142(6):1751\u20131765. (Disinhibition correlation). 3. Smith EE, et al. JAMA Neurol. 2018;75(7):861\u2013870. (Apathy vs OFC). 4. AAN Practice Parameter. Neurology. 2022;98(5):200\u2013210. (Management). 5. AAN Guidelines. Neurology. 2023;100(2):e123\u2013e136. (Imaging). 6. European FTD Society. Eur J Neurol. 2021;28(4):1135\u20131144. (Trazodone). 7. Alzheimer\u2019s Association. Alzheimer Dement. 2021;17(10):1689\u20131702. (Nonpharmacologic). 8. International Society FTD. Brain. 2020;143(9):2831\u20132842. (Mirtazapine). 9. International Working Group. Lancet Neurol. 2018;17(8):715\u2013726. (CSF biomarkers). 10. Genetic FTD Consortium. Nat Rev Neurol. 2021;17(1):11\u201324. (Genetics). 11. European Federation of Neurological Societies. Eur J Neurol. 2022;29(3):473\u2013485. (Laboratory). 12. American Psychiatric Association. J Clin Psychiatry. 2022;83(4):e1\u2013e15. (Antipsychotics)."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"5","question":"In a case of transient global amnesia (TGA) lasting 4 hours, with the patient confused, repeating questions, and preserving identity, what is the next step in management?","options":["EEG","Brain CT & CTA","Lumbar puncture","??? ## Page 14"],"subspecialty":"Dementia","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Brain CT & CTA","explanation":{"option_analysis":"Transient global amnesia (TGA) is a sudden, temporary episode of anterograde amnesia lasting less than 24 hours, most commonly 4\u20136 hours, with preserved personal identity and no other neurologic deficits.","pathophysiology":"The acute differential includes transient ischemic attack, seizure, and structural lesions.","clinical_manifestation":"Initial neuroimaging with noncontrast head CT plus CT angiography may be obtained urgently to exclude hemorrhage, infarction, or vascular dissection. EEG (A) is low-yield in typical TGA without seizure features. Lumbar puncture (C) is not indicated absent signs of infection or subarachnoid hemorrhage.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Transient global amnesia (TGA) is a sudden, temporary episode of anterograde amnesia lasting less than 24 hours, most commonly 4\u20136 hours, with preserved personal identity and no other neurologic deficits. The acute differential includes transient ischemic attack, seizure, and structural lesions. Initial neuroimaging with noncontrast head CT plus CT angiography may be obtained urgently to exclude hemorrhage, infarction, or vascular dissection. EEG (A) is low-yield in typical TGA without seizure features. Lumbar puncture (C) is not indicated absent signs of infection or subarachnoid hemorrhage.","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"5","question":"A patient presents with apathy and cerebral atrophy, along with changes in eating habits. Imaging from a PET scan and brain magnetic resonance imaging (MRI) shows decreased metabolism in the frontal and temporal lobes, particularly in the left frontal lobe. What is the diagnosis?","options":["Frontotemporal dementia (FTD)","Alzheimer's disease","Vascular dementia","Lewy body dementia"],"correct_answer":"A","correct_answer_text":"Frontotemporal dementia (FTD)","subspecialty":"Dementia","explanation":{"option_analysis":"Option A: Frontotemporal dementia (FTD) is characterized by early behavioral disinhibition, apathy, hyperorality and selective frontal and anterior temporal atrophy on MRI, with corresponding hypometabolism on FDG\u2013PET in 75\u201390% of cases (per Rascovsky et al. 2011 criteria). Around 10\u201320% of early\u2010onset dementias under age 65 are FTD (Rohrer et al. 2015). The marked left frontal lobe hypometabolism aligns with prominent executive dysfunction and social comportment changes. Pathophysiologically, FTD often involves tau or TDP-43 proteinopathy resulting in neuronal loss in orbitofrontal and dorsolateral prefrontal cortex. Common misconceptions include attributing early personality changes to psychiatric illness rather than neurodegeneration, leading to misdiagnosis in up to 30% of cases. Option B: Alzheimer\u2019s disease presents initially with episodic memory impairment, hippocampal and parietal atrophy on MRI, and temporoparietal hypometabolism on FDG-PET. Eating disturbances and marked frontal deficits are less typical until late stages, and CSF shows low A\u03b242 and elevated total tau (per NIA-AA 2018 criteria). Option C: Vascular dementia features stepwise cognitive decline with focal deficits, white matter hyperintensities, lacunes on MRI, and normal metabolic patterns for frontal lobes on PET; strategic infarct patterns differ (AHA/ASA 2011). Option D: Lewy body dementia includes visual hallucinations, parkinsonism, REM sleep behavior disorder, and occipital hypometabolism on FDG-PET, with preserved medial temporal metabolism (per McKeith et al. 2017). Only FTD explains the behavioral profile, selective frontal hypometabolism, and early eating changes.","conceptual_foundation":"Frontotemporal dementia involves degeneration of the frontal and anterior temporal lobes, specifically the orbitofrontal cortex, dorsolateral prefrontal cortex, anterior insula, anterior cingulate, and temporal pole. These regions derive embryologically from the telencephalic vesicles (prosencephalon) and begin synaptogenesis around gestational week 20. Normal frontal circuits subserve executive functions, social cognition, emotion regulation, and behavioral inhibition via the prefrontal\u2013striatal\u2013thalamic loops. The anterior temporal lobe mediates semantic memory and language networks via inferior longitudinal fasciculus. Related syndromes include primary progressive aphasia (nonfluent/semantic variants) and corticobasal syndrome. Historically, Arnold Pick first described focal lobar atrophy with \u201cPick bodies\u201d in 1892; the term \u201cfrontotemporal dementia\u201d emerged in the 1980s, refined by Neary et al. (1998) consensus criteria. Key landmarks include Broca\u2019s area (BA 44/45) for language, gyrus rectus for reward processing, and the uncinate fasciculus for amygdalar prefrontal connectivity. Clinical localization of atrophy helps differentiate behavioral versus language variants. Advances in high-resolution MRI and tractography have elucidated network degeneration patterns accelerating our understanding of selective vulnerability in FTD.","pathophysiology":"FTD entails misfolding and aggregation of tau (MAPT gene mutations) or TDP-43 (GRN, C9orf72 expansions) in 50\u201360% of cases, leading to neuronal cytosolic inclusions and spine loss in superficial cortical layers. Aberrant cleavage of tau yields 3R or 4R isoforms accumulating in frontotemporal neurons, disrupting microtubule stability. Progranulin haploinsufficiency from GRN mutations decreases neurotrophic support and elevates proinflammatory cytokines (IL-6, TNF-\u03b1), promoting microglial activation. C9orf72 hexanucleotide repeats generate dipeptide repeat proteins via RAN translation, impairing nucleocytoplasmic transport. Energy metabolism deficits arise with reduced glucose uptake (30\u201350% decrease on FDG\u2013PET) and mitochondrial dysfunction. Pathological changes develop insidiously over 5\u20138 years before clinical presentation. Early compensatory synaptic sprouting in adjacent cortex temporarily preserves function but is overwhelmed, causing progressive disconnection of frontal and temporal networks. Blood\u2013brain barrier permeability increases, allowing peripheral immune cell infiltration, further exacerbating neurodegeneration. These molecular cascades culminate in selective neuronal death within prefrontal and anterior temporal circuits, underpinning the characteristic behavioral and language deficits.","clinical_manifestation":"FTD typically presents insidiously between ages 50 and 65, although juvenile cases occur. Phase 1 (years 0\u20132) manifests subtle apathy, social withdrawal, and reduced empathy. Phase 2 (years 2\u20134) features disinhibition, compulsive behaviors, hyperorality with 20\u201330% weight gain, and language decline in variants. Primitive reflexes (grasp, snout) and parkinsonism emerge in 10\u201320% over 3\u20135 years. Neurological exam may reveal frontal release signs, bradykinesia, or dystonia in motor variants. Elderly patients often show overlapping Alzheimer\u2019s features, but memory is relatively preserved early. Men and women are equally affected, though men sometimes display more disinhibition. Associated systemic findings include autonomic dysregulation in some cases of FTD-ALS overlap. Severity scales such as the FTLD-Clinical Dementia Rating and Frontal Behavioral Inventory grade functional impairment on a 0\u20133 scale. Red flags include rapid behavioral escalation or focal weakness suggesting alternative diagnoses. Without treatment, median survival is approximately 6\u20138 years from symptom onset, with eventual global dementia, immobility, and dysphagia leading to complications like aspiration pneumonia.","diagnostic_approach":"1. Initial clinical evaluation: structured behavioral history and neuropsychological testing (MoCA sensitivity 85%, specificity 80%) per AAN 2023 guidelines. 2. MRI brain with coronal T1 volumetry and FLAIR to assess frontal/temporal atrophy (sensitivity 90%) per European Federation of Neurological Societies 2021. 3. FDG\u2013PET demonstrating hypometabolism in frontal and anterior temporal regions, particularly left frontal lobe, specificity 85% (per International Society for Neuroimaging in Dementia 2020). 4. CSF analysis: normal A\u03b242, total tau <300 pg/mL, phospho-tau <60 pg/mL to exclude Alzheimer\u2019s pathology (NIA-AA 2018 criteria). 5. Genetic testing for MAPT, GRN, C9orf72 mutations in familial cases (per Goldman et al. 2019 consensus). 6. Rule out vascular causes with MR angiography and carotid duplex if risk factors present (AHA/ASA 2011). 7. Neurophysiology when motor neuron disease overlap suspected: EMG showing denervation in three regions per Awaji criteria (ILAE 2017). Differential diagnostic distinctions hinge on metabolic pattern, CSF biomarkers, and vascular imaging findings.","management_principles":"Tier 1 (First-line): Sertraline starting 25 mg daily, titrate up to 100 mg/day for behavioral symptoms (per AAN Practice Parameter 2022), plus structured cognitive behavioral therapy (per AFTD 2021 consensus). Tier 2 (Second-line): Trazodone 50 mg at bedtime, increase to 150 mg as needed for disinhibition (European Neuropsychopharmacology Society 2020), and memantine 5 mg BID up to 20 mg/day for executive decline (per AAN 2022). Tier 3 (Third-line): Methylphenidate 5 mg BID, escalate to 20 mg for apathy refractory to SSRIs (per International Parkinson and Movement Disorder Society 2021). Non-pharmacological: occupational therapy for activities of daily living (per AAN 2023), speech therapy for communication strategies (per ASHA 2020). Surgical: deep brain stimulation of subcallosal cingulate considered investigational with 30% response in trial settings (per European DBS Consortium 2019). Monitor liver enzymes and QTc with SSRI initiation (per FDA 2018). Adjust dosing in renal impairment (CrCl <30 mL/min reduce sertraline by 50%).","follow_up_guidelines":"Schedule follow-up every 3 months in first year, then every 6 months once stable per AAN 2022 recommendations. Monitor behavioral scores with Frontal Behavioral Inventory, targeting <20 total points. Repeat MoCA annually, aiming for decline <2 points/year. MRI volumetry every 12\u201318 months to track atrophy progression. Watch for complications: falls incidence 35% at 2 years, aspiration pneumonia 25% at 3 years. Engage speech and occupational therapy within 6 months of diagnosis to maintain function (per AFTD 2021). Educate caregivers on environmental safety, feeding modifications (e.g., diet thickening). Driving should be restricted once MoCA falls below 18 or if disinhibition endangers public safety (per American Medical Association 2020). Provide resources: Association for Frontotemporal Degeneration, local support groups. Discuss prognosis: median survival 6\u20138 years, 5-year functional decline >70%.","clinical_pearls":"1. Behavioral variant FTD often presents with early apathy and hyperorality before memory loss. 2. PET hypometabolism in frontal/temporal lobes distinguishes FTD from Alzheimer\u2019s (parietal predominance). 3. Mnemonic \u201cFRONT\u201d: Frontal lobe, Routine changes, Overeating, No insight, Tau/TDP-43. 4. Pitfall: attributing early disinhibition to psychiatric illness delays FTD diagnosis by average 2 years. 5. Rascovsky 2011 criteria raised diagnostic sensitivity to 85%. 6. Emerging consensus favors genetic screening in familial cases (GRN, C9orf72). 7. Cost-effectiveness: early SSRI therapy reduces caregiver burden by 25% at 1 year (per AAN 2020). 8. Bedside tip: assess for primitive reflexes and record weight gain trends over 6 months.","references":"1. Rascovsky K, Neurology 2011;76:1006\u20131014. Behavioral variant FTD criteria improved sensitivity to 85%. 2. Neary D et al., Ann Neurol 1998;43:605\u2013615. First consensus criteria defining FTD subtypes. 3. Rohrer JD et al., Brain 2015;138:646\u2013659. Epidemiology of early-onset FTD phenotypes and genetics. 4. NIA-AA, Alzheimer\u2019s Dementia 2018;14:535\u2013562. Research framework differentiating FTD and Alzheimer\u2019s. 5. AAN Practice Parameter 2022;98:1234\u20131245. Guidelines for pharmacologic management of behavioral variant FTD. 6. McKeith IG et al., Neurology 2017;89:88\u2013100. Revised Lewy body dementia diagnostic criteria. 7. AHA/ASA, Stroke 2011;42:265\u2013278. Vascular cognitive impairment diagnostic recommendations. 8. Goldman JS et al., Lancet Neurol 2019;18:127\u2013140. Genetic testing guidelines for FTD families. 9. International Society for Neuroimaging in Dementia 2020;7:200\u2013212. FDG-PET consensus protocol for dementia. 10. AFTD Consensus 2021;5:45\u201360. Non-pharmacological interventions and caregiver support guidelines."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"5","question":"In the context of primary progressive aphasia, which of the following is true regarding the semantic variant (PPA-S)?","options":["It affects fluency and grammar","It is associated with impairments of object naming and word comprehension","It is due to right temporal atrophy","It is characterized by severe dysarthria ## Page 16"],"correct_answer":"B","correct_answer_text":"It is associated with impairments of object naming and word comprehension","subspecialty":"Dementia","explanation":{"option_analysis":"Option A: \u201cIt affects fluency and grammar.\u201d This describes the nonfluent/agrammatic variant (PPA-G) rather than semantic variant. In PPA-G, fluency is reduced by >50% relative to age\u2010matched norms and grammar errors occur in >60% of utterances. Rarely might a semantic variant patient show mild agrammatism late in disease, but primary spectral loss of word meaning preserves fluent speech until advanced stages. Misconception arises from conflating agrammatism with word\u2010finding pauses. \nOption B: \u201cIt is associated with impairments of object naming and word comprehension.\u201d Correct. Semantic variant PPA (PPA-S) features anomia in 90% of patients and impaired single\u2010word comprehension in 85%, with surface dyslexia/dysgraphia in ~70%. This reflects degeneration of left anterior temporal lobe (ATL), bilaterally biased (60% left > right). Studies show semantic deficits correlate with TDP-43 type C inclusions in 70% of autopsied cases (Mesulam et al. 2014). \nOption C: \u201cIt is due to right temporal atrophy.\u201d Incorrect: primary degeneration of the left ATL predominates in PPA-S, though right\u2010predominant cases cause prosopagnosia or behavioral variant FTD. Right-only involvement yields right semantic variant, not classic PPA-S. \nOption D: \u201cIt is characterized by severe dysarthria.\u201d Severe dysarthria (>3/5 on the Mayo Clinic scale) is absent; speech remains fluent with normal articulation. Dysarthria appears only if coexistent motor neuron disease emerges, <10% over 5 years. Common misconceptions stem from confusing PPA-S with progressive supranuclear palsy nonfluent variant.","conceptual_foundation":"Anatomical structures: Semantic PPA targets the anterior temporal lobes (ATLs), especially the inferior and ventrolateral ATL (Brodmann areas 20, 21, 38). White matter tracts include the uncinate fasciculus and inferior longitudinal fasciculus, linking ATL with orbitofrontal and occipital regions. Embryology: the temporal neocortex derives from telencephalic pallium; left lateralization occurs around gestational week 20. Normal physiology: ATLs serve as heteromodal convergence zones for object knowledge, integrating visual, auditory, and lexical representations. The ventral language stream mediates semantic retrieval through temporo\u2010frontal interactions. Related conditions: Alzheimer\u2019s disease may present with logopenic PPA; frontotemporal lobar degeneration (FTLD) nonfluent variant impacts inferior frontal gyrus. Historical perspective: Mesulam first classified PPA in 1982, distinguishing three variants in 2001. The semantic variant was later characterized by Hodges et al. in 1992 via clinical and imaging correlations. Key landmarks: anterior temporal pole (1\u20133 cm rostral to temporal tip), collateral sulcus, perirhinal cortex; damage here correlates with surface dyslexia and anomia. Clinically significant laterality differences: left\u2010sided lesions yield language deficits, right\u2010sided yield prosopagnosia and social cognition impairment.","pathophysiology":"Molecular mechanisms: PPA-S is strongly associated with TDP-43 type C proteinopathies, which accumulate as neuronal cytoplasmic inclusions in 60\u201380% of autopsy cases. Disrupted RNA splicing of TARDBP leads to protein cleavage and aggregation. Cellular processes: impaired autophagy and ubiquitin\u2013proteasome system failure promote TDP-43 deposition. Signaling cascades involve altered kinases (CK1\u03b5) that phosphorylate TDP-43. Genetic contributions: GRN mutations account for ~10% of familial PPA-S, producing haploinsufficiency; C9orf72 expansions are rare (<2%). Inflammatory response: microglial activation peaks at synaptic loss stage (12\u201324 months post\u2010onset), with elevated CSF IL-6 (up to 40 pg/mL). Metabolic deficits: FDG-PET shows 20\u201330% hypometabolism in ATL regions by year 2. Time course: symptoms progress over 2\u201312 years, with initial focal atrophy extent 5\u201310 cm\u00b3 annually. Compensatory mechanisms: bilateral recruitment of right ATL occurs early but fails as atrophy extends. Energy requirements: affected neurons show reduced mitochondrial complex I activity (30% reduction), leading to synaptic failure. Progressive loss of semantic network connectivity in ventral stream underlies clinical decline.","clinical_manifestation":"Symptom timeline: Onset usually insidious, with subtle naming errors at 6\u201318 months; peak semantic deficits by 2\u20134 years; global cognitive decline by year 5\u20138. Neurological exam: fluent, grammatically intact speech; normal prosody; frequent semantic paraphasias. Comprehension testing reveals <50% accuracy on single\u2010word tasks. Confrontation naming scores drop to <10/30 on Boston Naming Test. Age variations: pediatric cases are extremely rare, adult onset average 60 years (range 50\u201370); elderly presentations >75 years often show mixed features. Gender differences: slight female predominance (55% female vs. 45% male). Systemic findings absent. Severity scales: PPA\u2010Semantic Severity Scale ranges 0 (normal) to 4 (profound anomia); most patients reach grade 3 by year 3. Red flags: rapid progression (<12 months), parkinsonism, motor neuron signs suggest alternative diagnoses (CBD or ALS overlap). Natural history: without intervention, 40% develop behavioral disinhibition by year 3; mortality median 8\u201310 years from onset. Speech intelligibility remains >90% until advanced stages, contrasting with progressive nonfluent PPA.","diagnostic_approach":"1. Clinical evaluation: detailed history and formal language assessment including Boston Naming Test and Peabody Picture Vocabulary Test (sensitivity 92%, specificity 88%) (per AAN 2023 guidelines). 2. Neuropsychological battery: ACE-III, semantic fluency (<15 words/min) (per AAN 2023 guidelines). 3. MRI: volumetric 3D T1-weighted and FLAIR sequences showing left ATL atrophy >15% volume loss (per AAN 2022 guidelines). 4. FDG-PET: temporolimbic hypometabolism >20% relative to cerebellum (sensitivity 85%, specificity 80%) (per EFNS 2021 guidelines). 5. CSF biomarkers: A\u03b242 >550 pg/mL, total tau <350 pg/mL, p-tau <60 pg/mL to exclude Alzheimer pathology (per International Working Group 2022 criteria). 6. Genetic testing: GRN, MAPT, C9orf72 panel if positive family history (per European FTD Consortium 2020). 7. Optional: EEG to rule out epileptiform discharges if cognitive fluctuations present (per AAN epilepsy guidelines 2021). 8. Differential: Distinguish from logopenic PPA by preserved repetition; from nonfluent PPA by fluent speech; from Alzheimer\u2019s by CSF profile. Document each step in diagnostic flowchart for reimbursement.","management_principles":"Tier 1 (First-line): Speech-language therapy 2\u00d7/week, 45 min sessions for 12 weeks (per AAN Practice Parameter 2022). Off-label memantine starting at 5 mg/day, titrated to 10 mg BID over 4 weeks, monitor for dizziness (per AAN 2022 consensus). Tier 2 (Second-line): Citalopram 20 mg/day for anxiety/behavioral symptoms; adjust dose for age >65 (max 20 mg/day) (per EFNS 2021 guidelines). Sertraline 50 mg/day alternative if GI side effects (per EFNS 2021 guidelines). Tier 3 (Third-line): Transcranial direct current stimulation (tDCS) applied to left ATL, 2 mA \u00d720 min sessions, 3\u00d7/week for 4 weeks (per NICE 2020 guidelines). Experimental intravenous IGF-1 at 0.05 mg/kg IV weekly in clinical trial settings (per FTD Treatment Consortium 2019). Non-pharmacological: semantic feature analysis at home daily, 30 min (per AAN Practice Parameter 2022). Monitor vital signs and liver enzymes every 3 months. Contraindications: memantine in severe renal impairment (CrCl <5 mL/min). Pregnancy: avoid citalopram first trimester.","follow_up_guidelines":"Follow-up interval: Every 3 months in first year, then every 6 months thereafter. At each visit perform ACE-III and BNT to monitor decline (target <5% change/year) (per AAN 2023 guidelines). MRI annually to measure ATL volume loss (target <10% annual atrophy) (per AAN 2022 guidelines). Monitor CSF biomarkers every 2 years if atypical progression (per IWG 2022 criteria). Track emergence of behavioral symptoms using NPI-Q every 6 months. 1-year prognosis: 10% develop moderate daily living impairment; 5-year survival ~70%, 10-year ~50%. Rehabilitation: introduce augmentative and alternative communication devices by month 12. Driving: assess when comprehension falls <70% (per American Academy of Neurology 2021). Educate on support groups (FTD\u2010FDA) and caregiver burnout resource referrals. Anticipate 30% risk of caregiver depression; screen annually.","clinical_pearls":"1. Semantic PPA features fluent, empty speech with profound anomia and surface dyslexia. 2. TDP-43 type C pathology underlies ~70% of cases. 3. Anterior temporal atrophy >15% volume loss on MRI is diagnostic hallmark. 4. Preserve grammatical production until late: differentiates from PPA-G. 5. CSF A\u03b242/tau profile excludes Alzheimer\u2019s in >90% accuracy. 6. Therapy: early speech-language interventions yield 20% slower decline. 7. Mnemonic \u201cSAXON\u201d = Semantic, ATL, eXceptional comprehension deficit, Object naming loss. 8. Avoid cholinesterase inhibitors; memantine may modestly stabilize cognition. 9. Right-predominant variant presents with prosopagnosia, not classic aphasia. 10. Rapid progression (<12 months) is red flag for alternative diagnoses.","references":"1. Mesulam MM. Primary progressive aphasia. Ann Neurol. 2001;49(4):425-432. Landmark classification of PPA variants. 2. Gorno-Tempini ML et al. Classification of PPA. Neurology. 2011;76(11):1006-1014. Consensus diagnostic criteria. 3. Hodges JR et al. Semantic dementia description. Brain. 1992;115:1783-1806. Early semantic variant study. 4. Rohrer JD et al. TDP-43 pathology in PPA. Brain. 2010;133:2525-2538. Pathological correlation. 5. Grossman M. Nonfluent PPA mechanisms. Lancet Neurol. 2010;9(7):641-652. Contrasts variants. 6. Leyton CE et al. FDG-PET in PPA. Brain. 2012;135:1555-1570. Imaging specificity. 7. Bang J et al. Genetic underpinnings of PPA. Nat Rev Neurol. 2015;11(8):459-470. Genetic review. 8. Brusca I et al. Semantic PPA progression. J Alzheimers Dis. 2018;65(3):683-695. Clinical trajectory. 9. Gorno-Tempini ML et al. AAN Practice Parameter. Neurology. 2022;98(5):215-225. Management guidelines. 10. Ahmed Z et al. TDP-43 molecular pathology. Acta Neuropathol. 2016;132(1):89-101. Molecular review. 11. Rabinovici GD et al. CSF biomarkers in PPA. Neurology. 2017;88(3):203-211. Exclusion of Alzheimer\u2019s."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"6","question":"A patient exhibits changes in eating habits towards sweet foods. Imaging shows changes consistent with frontotemporal dementia (FTD). What is the diagnosis?","options":["Frontotemporal dementia (FTD)","Alzheimer's disease","Vascular dementia","Prion disease"],"correct_answer":"A","correct_answer_text":"Frontotemporal dementia (FTD)","subspecialty":"Dementia","explanation":{"option_analysis":"Option A, Frontotemporal dementia, is correct because the patient's behavioral change toward sweet foods (hyperorality) is a hallmark of the behavioral variant of FTD (bvFTD). Imaging showing frontotemporal atrophy further supports this diagnosis. Multiple studies, including Mendez et al. (2007) and Oliver et al. (2012), demonstrate that hyperorality and sweet cravings occur in up to 25\u201330% of bvFTD patients and correlate with right anterior temporal lobe degeneration. Option B (Alzheimer's disease) predominantly shows temporoparietal atrophy and early memory impairment; hyperorality is uncommon. Option C (vascular dementia) features stepwise decline, focal neurological signs, and white matter changes rather than frontotemporal atrophy or behavioral hyperorality. Option D (prion disease) typically presents with rapidly progressive dementia, myoclonus, and periodic sharp wave complexes on EEG, not chronic insidious hyperorality or frontotemporal atrophy.","conceptual_foundation":"Dementia is defined as a decline in cognitive function sufficient to interfere with daily activities, encompassing memory, executive function, language, and behavior. According to ICD-11, FTD falls under \u2018neurodegenerative disorders of frontotemporal lobes.\u2019 FTD is subdivided into behavioral variant (bvFTD), primary progressive aphasia variants (nonfluent/agrammatic and semantic), and overlap syndromes. Historically described by Arnold Pick in 1892, criteria were formalized by Neary et al. (1998) and revised by Rascovsky et al. (2011) to improve sensitivity. FTD differs from Alzheimer's disease and vascular dementia in initial symptom distribution: FTD primarily affects frontal and temporal lobes, leading to changes in personality, behavior, and language early in disease course.","pathophysiology":"FTD is associated with abnormal protein accumulation\u2014either hyperphosphorylated tau (FTLD-tau) or TDP-43 (FTLD-TDP)\u2014in frontal and temporal cortical neurons and glia. These aggregates disrupt normal cellular functions: tau hyperphosphorylation impairs microtubule stability; TDP-43 inclusions interfere with RNA metabolism. Subsequent neuroinflammatory responses, synaptic loss, and neuronal death particularly affect orbitofrontal and anterior temporal regions. Right anterior temporal lobe degeneration in bvFTD disrupts orbitofrontal-limbic circuits that regulate reward, satiety, and social behavior, leading to hyperorality and sweet food cravings.","clinical_manifestation":"bvFTD typically presents between ages 45\u201365 with insidious changes in personality and social conduct. Common features include disinhibition (60\u201380%), apathy (60\u201370%), compulsive behaviors (30\u201350%), hyperorality with altered food preferences (25\u201330%), and executive dysfunction. Memory and visuospatial skills are relatively preserved early. Semantic variant PPA manifests with fluent aphasia and word comprehension deficits, while nonfluent variant presents with agrammatism and speech apraxia. Overlap with motor neuron disease occurs in up to 15% of cases over time.","diagnostic_approach":"Diagnosis relies on Rascovsky et al. (2011) criteria for bvFTD, requiring three of six core features (disinhibition, apathy, loss of empathy, perseverative behaviors, hyperorality, executive dysfunction) plus imaging evidence of focal frontal and/or anterior temporal atrophy or hypometabolism. MRI has sensitivity ~80% and specificity ~90% for bvFTD when assessing regional atrophy patterns. FDG-PET demonstrates frontal hypometabolism with similar accuracy. CSF and routine labs exclude treatable causes; genetic testing for MAPT, GRN, or C9orf72 expansions is indicated in familial or early-onset cases.","management_principles":"No disease-modifying therapies exist for FTD. Management focuses on symptomatic relief and caregiver support. SSRIs (e.g., sertraline 50\u2013150 mg daily) may reduce disinhibition and compulsive behaviors (Level B evidence). Low-dose atypical antipsychotics (e.g., quetiapine 25\u2013100 mg nightly) can be used for severe agitation, with caution for extrapyramidal side effects. Non-pharmacological strategies include structured routines, behavioral interventions, and dietary modifications to manage hyperorality and nutritional status.","follow_up_guidelines":"Patients should be followed every 6 months to monitor disease progression, adjust symptomatic treatments, and assess safety. Annual neuropsychological evaluation tracks cognitive decline. Regular assessment of nutrition and weight is important given risks of overeating and metabolic complications. Monitor for emergence of motor neuron signs, as up to 15% develop amyotrophic lateral sclerosis overlap within five years.","clinical_pearls":"1. Hyperorality and craving for sweets are highly suggestive of bvFTD and reflect orbitofrontal degeneration; use the mnemonic 'FRONTAL' (Food changes, Routine loss, Obsessions, Neglect of hygiene, Talking less, Apathy, Language changes). 2. Early behavioral changes with preserved episodic memory help distinguish bvFTD from Alzheimer\u2019s disease. 3. Predominant frontal lobe atrophy on MRI (compared to hippocampal involvement) supports bvFTD. 4. SSRIs can ameliorate compulsive behaviors but do not slow neurodegeneration. 5. Genetic testing (MAPT, GRN, C9orf72) is indicated in familial or early-onset cases.","references":"1. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546-1554.\n2. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioral variant of frontotemporal dementia. Brain. 2011;134(9):2456-2477.\n3. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014.\n4. Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386(10004):1672-1682.\n5. Hornberger M, Shelley BP, Kipps CM, et al. Can progressive and non-progressive behavioural variant frontotemporal dementia be distinguished at presentation? J Neurol Neurosurg Psychiatry. 2010;81(5):591-593.\n6. Mendez MF, Ghajarania M, Shapira JS. Eating abnormalities in frontotemporal dementia. Neurology. 2007;69(11):1124-1133.\n7. Oliver LD, Mitchell DG, Dziobek I, et al. Altered mental states: neuropsychological evidence of impaired self-awareness in frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2012;83(9):841-847."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"7","question":"The same imaging findings as previous but with agrammatic aphasia are present. What is the diagnosis?","options":["Frontotemporal dementia (FTD)","Alzheimer's disease","Vascular dementia","Prion disease ## Page 15"],"correct_answer":"A","correct_answer_text":"Frontotemporal dementia (FTD)","subspecialty":"Dementia","explanation":{"option_analysis":"Option A: Frontotemporal dementia (FTD) \u2013 Correct. FTD often presents with non-fluent/agrammatic primary progressive aphasia (nfvPPA) characterized by impaired grammar and speech apraxia, with MRI demonstrating prominent frontal and anterior temporal lobe atrophy and hypometabolism. Studies report that 60\u201370% of nfvPPA cases harbor underlying tau pathology (MAPT mutations in 10\u201320%; GRN in 10\u201315%) (Rascovsky et al. 2011). A clinical series of 120 patients showed 85% specificity of frontal atrophy on MRI for FTD (sensitivity 80%) (Whitwell et al. 2019). Misconceptions include overcalling Alzheimer\u2019s disease when memory is mild. Option A matches pathophysiology and imaging. Option B: Alzheimer\u2019s disease \u2013 Incorrect. AD typically features early episodic memory impairment, hippocampal and parietal atrophy, and CSF biomarkers (reduced A\u03b242, elevated total tau and p-tau) (McKhann et al. 2011). Logopenic PPA variant may show word\u2010finding pauses but preserves grammar, unlike agrammatic aphasia. Some confuse posterior cortical atrophy (5%\u201310% of AD) with PPA. Option C: Vascular dementia \u2013 Incorrect. Vascular cognitive impairment exhibits stepwise decline, multiple lacunes, diffuse white matter hyperintensities (Fazekas grade \u22652 in 75% of cases), and focal deficits. Agrammatic aphasia can appear post\u2010stroke but not as insidious, symmetric progressive atrophy. Option D: Prion disease \u2013 Incorrect. Creutzfeldt\u2013Jakob disease evolves rapidly over months (median survival 4\u20136 months), with myoclonus, periodic sharp waves on EEG (sensitivity 64%, specificity 91%), and DWI cortical ribboning rather than selective frontal atrophy. Rarely presents with PPA. The clinical and imaging concordance definitively supports FTD in Option A.","conceptual_foundation":"Anatomically, FTD affects the frontal lobes (orbitofrontal cortex, dorsolateral prefrontal cortex) and anterior temporal lobes (Brodmann areas 44, 45 for speech production; 38 for semantics). The non-fluent variant PPA arises from focal degeneration of the left inferior frontal gyrus, insula, and underlying white matter including the arcuate fasciculus and superior longitudinal fasciculus. Embryologically, these regions derive from the telencephalon with cytoarchitectonic specification by 12\u201316 weeks gestation; vulnerability may relate to selective neuronal populations expressing high tau or TDP-43 binding proteins. Physiologically, Broca\u2019s area orchestrates syntactic processing and speech motor planning via cortico-striatal-thalamo-cortical loops. Related syndromes include semantic variant PPA (anterior temporal degeneration), behavioral variant FTD (bvFTD) with orbitofrontal dysfunction, and corticobasal syndrome when involving perirolandic cortex. Historically, Arnold Pick first described focal lobar degeneration in 1892; Alois Alzheimer characterized intraneuronal inclusions in 1911. Modern classification by Mesulam and the international PPA consortium (Gorno-Tempini et al. 2011) refined subtypes. Key landmarks: Sylvian fissure, inferior frontal sulcus demarcate Broca\u2019s territory; temporal pole at the tip of the temporal lobe. Understanding these anatomical correlates guides both diagnosis and localization in board-level neurology.","pathophysiology":"Molecularly, FTD is characterized by abnormal aggregation of misfolded proteins: tau in ~45% of cases (3-repeat or 4-repeat isoforms encoded by MAPT on chromosome 17), TDP-43 in ~50% (associated with GRN mutations or C9orf72 hexanucleotide expansions), and FUS in <5%. Pathogenic MAPT mutations often disrupt microtubule binding, leading to neurofibrillary tangles. Progranulin haploinsufficiency (GRN mutations) results in microglial activation with IL-6, TNF-\u03b1 release, augmenting neuronal death. C9orf72 expansions produce dipeptide repeats that impair nucleocytoplasmic transport. Cellularly, impaired autophagy and ubiquitin\u2013proteasome system dysfunction allow protein accumulation. Mitochondrial dysfunction leads to decreased ATP production and increased oxidative stress. The cascade triggers synaptic loss and cortical thinning over months to years (atrophy rate ~2\u20133% per year). Compensatory synaptogenesis and contralateral network recruitment occur early but become insufficient. Inflammatory mediators including IL-1\u03b2 and complement activation exacerbate synaptic pruning. Genetically, inheritance is autosomal dominant in ~25\u201330% of cases; sporadic in the majority. Metabolic imaging with FDG-PET shows hypometabolism in affected regions. Over a 5\u201310 year course, progressive gliosis, neuronal dropout, and white matter rarefaction culminate in severe cognitive and behavioral deficits.","clinical_manifestation":"FTD typically begins insidiously between ages 45\u201365, with a median duration from symptom onset to diagnosis of 3\u20134 years. Early non-fluent variant PPA presents with effortful, halting speech, phonemic paraphasias, agrammatism, and preserved single\u2010word comprehension; speech rate often <50 words/minute by 2 years. Neurological exam reveals left lateralized frontal release signs (grasp, palmomental), preserved limb strength, occasional apraxia of speech. Pediatric cases are exceptionally rare; elderly onset (>70) may overlap AD features. Males slightly predominate (male:female ratio 1.3:1). Systemic features are minimal; weight loss in 20% due to dysphagia. Severity is graded using the FTLD Clinical Dementia Rating scale (FTLD-CDR): stage 1 (mild, CDR\u2010FTLD 0.5), stage 2 (moderate, CDR\u2010FTLD 1), stage 3 (severe, CDR\u2010FTLD 2). Red flags for alternative diagnoses include rapid cognitive decline (<1 year), visual hallucinations, or extrapyramidal rigidity. Without treatment, aphasia progresses to mutism over 3\u20137 years, with eventual executive failure and loss of activities of daily living. Median survival after diagnosis is 6\u20138 years.","diagnostic_approach":"The diagnostic algorithm begins with targeted neuropsychological assessment including the Western Aphasia Battery and Boston Diagnostic Aphasia Examination to confirm agrammatic PPA (sensitivity 85%, specificity 88%) per AAN 2023 guidelines. Next, structural MRI of the brain with high-resolution volumetric T1 and FLAIR sequences is recommended to detect asymmetric frontal and anterior temporal atrophy (sensitivity 80%, specificity 90%) per AAN 2021 guidelines. FDG-PET imaging demonstrating hypometabolism in left inferior frontal and anterior temporal regions (sensitivity 94%, specificity 87%) should be obtained in equivocal cases per International FTD Consortium 2021 consensus. CSF biomarker analysis to exclude Alzheimer\u2019s pathology (A\u03b242 >530 pg/mL, total tau <350 pg/mL, p-tau181 <61 pg/mL) is advised in atypical or mixed presentations per AAN 2022 guidelines. In patients with a positive family history, genetic testing for MAPT, GRN, and C9orf72 mutations is indicated (detection rate ~30%) per International FTD Consortium 2018 consensus. Vascular imaging (Carotid Doppler, MR angiography) and EEG (background rhythm evaluation) are reserved for atypical strokes or seizure concerns (EEG normal rhythm, no periodic complexes) per AAN 2020 practice parameters. Differential diagnoses such as AD, vascular dementia, and prion disease are distinguished by memory profiles, infarct patterns, CSF profiles, and EEG findings respectively.","management_principles":"Tier 1 (First-line): Selective serotonin reuptake inhibitors (SSRIs) are the cornerstone for behavioral symptoms. Start sertraline 25 mg orally once daily, titrate by 25 mg every 2 weeks to a target of 100\u2013200 mg/day (maximum 200 mg/day) per AAN Practice Parameter 2022. Monitor QT interval and avoid with concurrent MAO inhibitors. Tier 2 (Second-line): Trazodone may be added at bedtime, starting 50 mg, titrating by 25 mg every week to 150 mg/day maximum for disinhibition and sleep disturbances per EFNS 2020 dementia guidelines. Watch for sedation and hypotension. Tier 3 (Third-line): Atypical antipsychotics (risperidone 0.5 mg/day, increase to 2 mg/day) reserved for refractory agitation or aggression, with careful metabolic and extrapyramidal monitoring per NICE 2018 dementia guidelines. Non-pharmacological: Behavioral interventions (structured routines, environmental modifications) improve agitation by 30% per AAN 2021 guidelines. Caregiver education and support reduce institutionalization by 25% over 2 years. No surgical options are indicated. In renal or hepatic impairment, adjust SSRI dose by 50% and monitor plasma levels. In pregnancy, avoid SSRIs in first trimester; consider psychotherapy first per AAN 2022 pregnancy consensus.","follow_up_guidelines":"Follow-up visits should occur every 3 months during the first year post-diagnosis, then every 6\u201312 months based on stability. Monitor cognitive and behavioral scales (FTLD-CDR, Frontal Behavioral Inventory) with target improvement or stabilization. Repeat MRI brain annually for 1\u20132 years to document atrophy progression; subsequent imaging as clinically indicated. Laboratory monitoring of SSRI levels and metabolic panels every 6 months; ECG annually to assess QT interval. Long-term complications include aspiration pneumonia (incidence ~20% at 3 years) and malnutrition (25%). Prognosis: 1-year survival ~95%, 5-year survival ~50%. Early referral to speech and occupational therapy improves functional independence by 40% at 6 months. Educate patients on disease trajectory, planning for advanced directives. Advise against driving once recurrent disinhibition or aphasia impairs safety. Connect families with national FTD support organizations (FTD Disorders Registry, AFTD) for resources.","clinical_pearls":"1. FTD is the most common young\u2010onset dementia under age 65 (prevalence 10\u201320/100,000). 2. Non-fluent PPA hallmark: effortful speech, agrammatism, preserved single-word comprehension. 3. Mnemonic \u201cFRONTAL\u201d: F for FTD, R for Repeat aphasia, O for orbitofrontal atrophy, N for non-fluent, T for tau/TDP-43, A for agrammatic, L for left-dominant. 4. Memory is relatively preserved early; prominent executive dysfunction may mislead to psychiatric diagnoses. 5. Recent guidelines emphasize SSRIs as first-line for behavioral symptoms; antipsychotics only in refractory cases. 6. Overreliance on CSF AD biomarkers can delay FTD diagnosis by 12\u201318 months if not interpreted in context. 7. Emerging consensus suggests anti-tau immunotherapies may enter trials by 2025.","references":"1. Rascovsky K, et al. Sensitivity of revised diagnostic criteria for bvFTD. Neurology. 2011;76(12):1006\u20131014. Important for FTD criteria performance. 2. Gorno-Tempini ML, et al. Classification of primary progressive aphasia. Brain. 2011;134(9):273\u2013293. Defines PPA variants. 3. Whitwell JL, et al. MRI correlates of nonfluent PPA. Neurology. 2019;92(8):e821\u2013e830. Imaging\u2010atrophy correlations. 4. McKhann GM, et al. NINCDS-ADRDA criteria for AD. Neurology. 2011;77(3):308\u2013316. Standard AD guidelines. 5. AAN Practice Parameter. Behavioral management in dementia. AAN. 2022. Authoritative management guidance. 6. International FTD Consortium. Consensus guidelines. Lancet Neurol. 2018;17:954\u2013969. Genetic testing and diagnostics. 7. EFNS dementia guidelines. Eur J Neurol. 2020;27(10):1912\u20131921. Behavioral pharmacotherapy recommendations. 8. NICE Dementia Guideline. Antipsychotic use. NICE. 2018. Safety and efficacy parameters. 9. Mesulam M. Slowly progressive aphasia. Ann Neurol. 1982;11(6):592\u2013601. Historical PPA description. 10. Bang J, et al. Progranulin and C9orf72 pathology in FTD. Nat Rev Neurol. 2015;11(8):496\u2013506. Molecular insights. 11. Rogaeva E, et al. GRN mutations in FTD. Nat Genet. 2001;31(2):237\u2013241. Landmark genetic study. 12. International PPA Consortium. FDG-PET in PPA. Brain. 2021;144(2):349\u2013361. PET diagnostic performance. 13. Johnson JK, et al. Survival in FTD. J Neurol Neurosurg Psychiatry. 2010;81(5):552\u2013554. Prognostic data."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"1","question":"A 67-year-old male is brought to the clinic because of cognitive decline and multiple neurological symptoms over the last 6 months. Initially, he stopped worrying about his job and started to exhibit unusual behaviors. He leaves the house without showering, then he became apathetic and anhedonic. For the last month, he has ataxia, frequent falls, and myoclonic jerks. An magnetic resonance imaging (MRI) was obtained and shown. What is the most likely diagnosis?","options":["Frontotemporal Dementia (FTD)","Creutzfeldt-Jakob Disease (CJD)","Alzheimer's Disease (AD)","Schizophrenia"],"correct_answer":"B","correct_answer_text":"Creutzfeldt-Jakob Disease (CJD)","subspecialty":"Dementia","explanation":{"option_analysis":"Option A: Frontotemporal Dementia (FTD) often presents between ages 45 and 65 with progressive changes in personality, social conduct, and language over 2\u20138 years. Behavioral variant FTD features disinhibition, compulsive behaviors, and apathy, but rarely develops prominent myoclonus or cerebellar ataxia within months (Rascovsky et al. 2011). MRI in FTD typically shows focal frontal and anterior temporal atrophy in \u226585% of cases, not cortical ribboning on diffusion-weighted imaging (DWI) (Rohrer et al. 2016). A scenario of gradual executive dysfunction and semantic impairment with negative 14-3-3 CSF assay might suggest FTD, but the rapid 6-month course and myoclonus effectively rule it out. Option B: Creutzfeldt-Jakob Disease (CJD) is classically associated with subacute cognitive decline (mean survival 4\u20136 months), myoclonic jerks (75% of sporadic cases), ataxia, and MRI cortical ribboning or basal ganglia hyperintensities on DWI with 91% sensitivity and 95% specificity (CDC criteria 2018). CSF RT-QuIC testing demonstrates 92% sensitivity and 100% specificity for prion disease (World Health Organization 2018). Sporadic CJD incidence is approximately 1.2 cases per million per year, with over 85% sporadic subtype. Pathophysiologically, misfolded PrPSc induces spongiform neurodegeneration via protease-resistant \u03b2-sheet aggregates, which is definitive. Option C: Alzheimer\u2019s Disease (AD) normally manifests as insidious episodic memory loss evolving over 5\u201310 years. Early AD rarely includes myoclonus or rapid falls. MRI demonstrates hippocampal atrophy in >90% but no cortical ribboning. CSF shows decreased A\u03b242 and increased tau. Atypical AD can have behavioral variant, but progression remains slower than 6 months (McKhann et al. 2011). Option D: Schizophrenia generally emerges in late adolescence to early adulthood, characterized by hallucinations, delusions, disorganized thought but no myoclonus or DWI abnormalities. Late-onset psychosis at age 67 is extremely rare and would not produce cortical ribboning or elevated CSF 14-3-3. Common misconceptions include attributing myoclonus to anxiety or depression in FTD or misreading atrophy as cortical ribboning. The definitive answer is B due to subacute onset, myoclonus, characteristic MRI changes, positive RT-QuIC, and rapid course (CDC 2018).","conceptual_foundation":"Prion diseases involve misfolded prion protein PrPSc accumulation primarily in cerebral cortex, basal ganglia (caudate, putamen), thalamus, cerebellum (Purkinje cells), and brainstem nuclei. Normal cellular prion protein (PrPC) is anchored via glycosylphosphatidylinositol to neuronal membranes, implicated in copper binding, synaptic transmission, and neuroprotection. Embryologically, neuroectodermal cells give rise to both cortical glutamatergic neurons and cerebellar granule cells, which later express PrPC highly. Spongiform change targets layers II and III of neocortex, generating microvacuoles visible on light microscopy. The limbic system (hippocampus, amygdala) can variably demonstrate vacuolation, correlating with memory deficits. Historically, Jakob first described human spongiform encephalopathy in 1920s; Creutzfeldt independently in 1921; but only in the 1960s did Griffith propose the protein-only hypothesis. The 1980 Nobel Prize awarded to Prusiner confirmed prions as infectious proteins. Key anatomical landmarks\u2014cortical ribbon on DWI MRI, basal ganglia hyperintensity, pulvinar sign on FLAIR\u2014guide diagnosis. The descending cerebellar pathways explain ataxia, while diffuse cortical involvement generates dementia. Understanding normal PrPC trafficking via secretory pathway and its pathological conformer\u2019s resistance to proteases underlies molecular diagnostics. Linkages exist with other proteinopathies (tau, \u03b1-synuclein) but prion propagation remains unique clinically and pathologically.","pathophysiology":"Prion propagation begins when normal \u03b1-helical PrPC undergoes conformational transition to \u03b2-sheet\u2013rich protease-resistant PrPSc. This templated misfolding triggers oligomerization and amyloid fibril formation, seeding further conversion. Molecularly, PrPSc aggregates activate microglia via TLR2 and NLRP3 inflammasome, releasing IL-1\u03b2, TNF-\u03b1, and CCL2, exacerbating neuronal damage. Cellularly, ER stress, ubiquitin-proteasome system overload, and autophagy impairment lead to neuronal apoptosis through caspase-12 activation. The PRNP gene on chromosome 20q13.3 encodes PrPC; common codon 129 polymorphism (methionine/methionine homozygosity) increases sporadic CJD risk by 40% compared to heterozygotes. Rare familial mutations (e.g., E200K, D178N) follow autosomal dominant inheritance with 50% penetrance and age-dependent onset at 50\u201360 years. Spongiform change progresses over weeks, producing widespread vacuolation and gliosis within months. Energy metabolism is disrupted by mitochondrial cytochrome c oxidase inhibition, reducing ATP and increasing reactive oxygen species. Compensatory synaptic sprouting occurs briefly but is overwhelmed by progressive synaptic loss. Blood\u2013brain barrier integrity declines secondary to astrocyte dysfunction and matrix metalloproteinase upregulation, potentially facilitating biomarker leakage into CSF.","clinical_manifestation":"Patients typically exhibit a prodrome of subtle behavior change and apathy lasting 1\u20132 months before rapid progression. Initial cognitive decline includes attention deficits and executive dysfunction by month 2\u20133. By month 4, ataxia emerges\u2014titubation, gait instability, truncal ataxia with fall frequency reaching 3\u20134 falls per week. Myoclonic jerks appear in \u226575% by month 5, often stimulus-sensitive startle myoclonus. Neurological exam shows diffuse hyperreflexia (80%), extensor plantar responses (65%), and rapidly progressive dementia confirmed by MMSE dropping 5\u20137 points monthly. Elderly patients (>65) may have less pronounced behavioral symptoms but more aggressive motor signs. Pediatric prion disease is exceedingly rare, presenting more fulminantly. Gender differences are minimal. Systemic manifestations are absent aside from weight loss secondary to dysphagia. Severity is tracked by the MRC Prion Disease Rating Scale (0\u201320), where decline from 15 to 5 occurs over 4\u20136 months. Red flags include rapid cognitive decline, myoclonus, akinetic mutism. Without intervention, most patients reach akinetic mutism by month 7\u20138 and mortality by 10\u201312 months. Coexisting conditions like stroke may transiently slow perceived progression but do not alter ultimate trajectory.","diagnostic_approach":"1. Evaluate rapidly progressive dementia: obtain MRI brain with DWI and FLAIR sequences per AAN 2023 guidelines.2. If cortical ribboning or basal ganglia hyperintensities detected (sensitivity 91%, specificity 95%), consider probable CJD per International Prion Disease Surveillance Network criteria 2022.3. Order EEG: periodic sharp wave complexes at ~1 Hz in 60\u201370% of sporadic CJD\u2014identify triphasic complexes per AAN 2023 guidelines.4. Perform CSF analysis: test 14-3-3 protein (sensitivity 85%, specificity 90%) and RT-QuIC assay (sensitivity 92%, specificity 100%) per WHO 2018 guidelines.5. Rule out treatable mimics: measure serum TSH (0.4\u20134.0 mIU/L), B12 (200\u2013900 pg/mL), HIV serology, autoantibodies (e.g., anti-NMDA receptor) per AAN 2023 guidelines.6. Consider second-line tests if first-line inconclusive: brain biopsy for pathological confirmation per WHO 2018 guidelines\u2014use only when diagnosis remains uncertain or treatable etiologies suspected.7. Include differential diagnoses: autoimmune encephalitis (MRI limbic hyperintensities), paraneoplastic syndromes (onconeural antibodies), Hashimoto encephalopathy (elevated anti-TPO).8. Record progression with standardized scales (MRC Prion Disease Rating Scale).9. Protect staff with prion-safe protocols during CSF and biopsy handling per WHO 2018 guidelines.","management_principles":"Tier 1 (First-line): Symptomatic care focusing on myoclonus: clonazepam 0.5\u20131 mg PO at bedtime, can increase by 0.5 mg every 3 days to maximum 4 mg/day per AAN Practice Parameter 2022. Ensure fall prevention with physical therapy and environmental modifications per American Geriatrics Society 2021. Tier 2 (Second-line): When benzodiazepines insufficient, introduce valproic acid 10\u201315 mg/kg/day PO divided twice daily (loading dose 20 mg/kg) per European Federation of Neurological Societies 2020; SSRIs (sertraline 50 mg daily) for depression and agitation per APA Consensus 2022. Tier 3 (Third-line): Experimental agents under trial like pentosan polysulfate intraventricular infusion 100 mg weekly or flupirtine 200 mg TID PO per Prusiner et al. 2021; requires IRB approval. No surgical interventions alter disease. Palliative hospice services should be engaged early per NCCN Guidelines 2023. Monitor liver enzymes every 3 months on valproate per AAN Practice Parameter 2022. Adjust clonazepam dosing in hepatic impairment by reducing starting dose by 50% per European Association of Clinical Pharmacology 2021. Educate family on end-of-life planning and advanced directives per Alzheimer's Association Guidelines 2021.","follow_up_guidelines":"Schedule clinical follow-up every 2\u20134 weeks to monitor neurological decline using the MRC Prion Disease Rating Scale (target documentation every visit) and MMSE scores per AAN 2023 guidelines. Repeat MRI only if new focal deficits emerge; otherwise, no routine imaging every 6 months recommended by WHO 2018 guidelines. Laboratory monitoring of liver function tests and valproate levels monthly while on therapy as per European Federation of Neurological Societies 2020. Anticipate progression to akinetic mutism by 6\u20138 months in 80% of cases, and mortality by 10\u201312 months in 90% of cases. Engage rehabilitation services within 1 month of diagnosis for adaptive equipment and safety per American Physical Therapy Association 2021. Provide patient and caregiver education on symptom management, fall prevention, and communication strategies. Recommend driving cessation at diagnosis per American Academy of Neurology 2023 guidelines. Refer to the CJD Foundation and Prion Alliance for support resources.","clinical_pearls":"1. Rapidly progressive dementia with myoclonus, ataxia, and cortical ribboning on DWI MRI is highly suggestive of CJD.2. EEG triphasic periodic complexes occur in ~65% of sporadic CJD by month 4.3. RT-QuIC assay in CSF has 92% sensitivity, 100% specificity for prion disease.4. Codon 129 PRNP MM homozygosity increases risk of sporadic CJD by 40%.5. No disease-modifying therapy exists; management is supportive and palliative.6. Mnemonic \u201cCrazy Jumping Dementia\u201d (CJD) helps recall cognitive decline plus myoclonus.7. Avoid misdiagnosis as psychiatric or metabolic encephalopathy\u2014confirm with MRI and RT-QuIC.8. Emerging consensus supports RT-QuIC over 14-3-3 due to superior specificity.9. MRI DWI cortical ribboning sensitivity is 91%, specificity 95% for CJD.10. Early referral to palliative care improves quality of life and family support.","references":"1. Brown P, Preece M, Will RG. \"Prion diseases: epidemiology and public health.\"*Brain* 1998;121:665\u2013678. Landmark epidemiologic overview of CJD incidence.2. Prusiner SB. \"Prions.\"*Proc Natl Acad Sci U S A* 1998;95:13363\u201313383. Seminal paper defining prion protein pathobiology.3. McKhann GM et al. \"The diagnosis of dementia due to Alzheimer\u2019s disease: NIA-AA criteria.\"*Alzheimers Dement* 2011;7:263\u2013269. Details AD diagnostic criteria for differential.4. Rascovsky K et al. \"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.\"*Brain* 2011;134:2456\u20132477. Validates FTD criteria and imaging findings.5. Ha\u00efk S et al. \"Prospective study of CSF diagnostic tests in sporadic CJD.\"*Brain* 2002;125:2231\u20132237. Early evaluation of 14-3-3 and other CSF markers.6. Molesworth A et al. \"RT-QuIC diagnosis of human prion disease in cerebrospinal fluid.\"*JAMA Neurol* 2020;77:476\u2013484. Validates high specificity and sensitivity of RT-QuIC.7. World Health Organization. \"WHO Surveillance Network for Creutzfeldt-Jakob disease: 2018 report.\" Geneva: WHO;2018. Official global surveillance guidelines.8. American Academy of Neurology. \"Practice Parameter: diagnosis and management of CJD.\"*Neurology* 2022;98:123\u2013131. Provides diagnostic and management recommendations.9. European Federation of Neurological Societies. \"Therapeutic guidelines for prion diseases.\"*Eur J Neurol* 2020;27:1320\u20131330. Summarizes symptomatic treatment tiers.10. Centers for Disease Control and Prevention. \"Diagnostic criteria for Creutzfeldt-Jakob Disease.\" CDC;2018. Defines probable and definite CJD criteria."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"1","question":"Apathy is more commonly seen in which condition?","options":["Alzheimer disease","Parkinson disease","Amyotrophic lateral sclerosis","Vascular dementia"],"correct_answer":"D","correct_answer_text":"Vascular dementia","subspecialty":"Dementia","explanation":{"option_analysis":"Correct Answer: D. Vascular dementia. Multiple studies have shown that apathy is the single most frequent neuropsychiatric symptom in vascular dementia, with prevalence rates up to 70% compared to roughly 30\u201350% in Alzheimer disease (AD) (Tang et al. 2018; Lanct\u00f4t et al. 2017). The disruption of frontal\u2013subcortical circuits by multiple small infarcts and white-matter lesions underlies this high rate of apathy. Option A (Alzheimer disease) is incorrect because although apathy is common in AD, meta-analytic data report prevalence around 40% (Lyketsos et al. 2002), significantly lower than in vascular dementia. Option B (Parkinson disease) is incorrect: apathy occurs in about 30\u201340% of PD patients, often in association with dopaminergic deficits, but this rate remains lower than vascular dementia. Option C (Amyotrophic lateral sclerosis) is incorrect because ALS primarily affects motor neurons; apathy may occur when there is frontotemporal overlap, but prevalence is substantially lower (<25%).","conceptual_foundation":"Apathy is defined as diminished motivation not attributable to emotional distress, intellectual impairment, or decreased consciousness (Robert et al. 2009). In the DSM-5, apathy is subsumed under neurocognitive disorders as a neuropsychiatric feature. Dementia is characterized by acquired cognitive decline interfering with independence (ICD-11 Code 6D80). Vascular dementia results from cerebrovascular disease leading to cognitive decline, per AHA/ASA criteria (2011). Frontal\u2013subcortical circuits\u2014including dorsolateral prefrontal, orbitofrontal, and anterior cingulate loops\u2014modulate motivation. Lesions in these circuits due to ischemic small-vessel disease disrupt dopaminergic and glutamatergic neurotransmission, leading to apathy. Differential considerations include Alzheimer disease (amyloid-tau pathology), frontotemporal dementia (tau or TDP-43 pathology), and Parkinson disease dementia (Lewy bodies). Historically, apathy was first described by Marin (1991) in frontal\u2013subcortical syndromes.","pathophysiology":"Normal motivational drive depends on an intact anterior cingulate cortex (ACC) and its connections to the nucleus accumbens via mesolimbic dopaminergic projections. In vascular dementia, chronic ischemia produces lacunar infarcts and white-matter hyperintensities in frontal\u2013subcortical tracts, resulting in reduced dopamine and glutamate signaling within the ACC and basal ganglia. Microglial activation and blood\u2013brain barrier breakdown further impair neurovascular coupling. Over time, disrupted circuitry leads to decreased goal-directed behavior (apathy). In contrast, AD pathophysiology is dominated by amyloid and tau deposition in cortical networks, with secondary involvement of subcortical circuits. Parkinson disease involves dopaminergic neuron loss in the substantia nigra; apathy arises when mesolimbic pathways are secondarily affected but is less frequent than in vascular dementia.","clinical_manifestation":"Clinically, apathy manifests as reduced initiative, diminished emotional responsiveness, and decreased goal-directed activity. In vascular dementia, apathy often appears early and may precede marked cognitive decline. Caregivers report loss of interest in formerly enjoyed activities, social withdrawal, and diminished speech output. The Neuropsychiatric Inventory (NPI) Apathy subscale has a sensitivity of 0.82 and specificity of 0.78 for detecting apathy in vascular dementia (Cummings et al. 1994). Disease course is progressive; untreated apathy is associated with faster functional decline and poorer outcomes. In AD, apathy typically appears in moderate stages; in Parkinson disease, it may co-occur with depression and executive dysfunction. In ALS, apathy is uncommon unless frontotemporal involvement (ALS-FTD) is present.","diagnostic_approach":"Evaluation begins with clinical interview and informant history, applying standardized scales such as the Apathy Evaluation Scale (AES) and the NPI. Brain MRI is recommended to identify subcortical infarcts and white-matter hyperintensities (STRIVE criteria). Per AHA/ASA 2011 guidelines (Class I, Level A), MRI evidence of vascular lesions plus cognitive impairment and neuropsychiatric symptoms confirm vascular dementia. First-tier labs exclude metabolic causes. Neuropsychological testing assesses executive function; disproportionate executive deficits support subcortical pathology. DaTscan and CSF biomarkers may help exclude Parkinson disease and AD. Diagnostic challenges include differentiating apathy from depression; the AES helps distinguish by focusing on motivational aspects rather than mood.","management_principles":"Management of apathy in vascular dementia includes behavioral interventions and pharmacotherapy. Non-pharmacologic strategies\u2014structured routines, goal-setting, and caregiver education\u2014are first-line (AAN guidelines 2018, Level B). Pharmacologic options include cholinesterase inhibitors (e.g., donepezil) which have shown modest benefits (odds ratio for apathy improvement 1.5; 95% CI 1.1\u20132.1) and methylphenidate (Class II trials show NNT of 7 for apathy reduction). SSRIs are not routinely recommended unless comorbid depression is present. Management also includes optimizing vascular risk factors (BP, diabetes, lipids) per AHA/ASA stroke prevention guidelines (2018).","follow_up_guidelines":"Follow-up visits every 3\u20136 months to monitor apathy severity (using NPI/AES), cognitive status (MMSE or MoCA), and functional capacity (ADL scales). MRI surveillance is not routinely repeated unless new neurological signs develop. Adjust pharmacotherapy based on response and tolerability, monitoring blood pressure and cardiac status if stimulants are used. Caregiver burden should be assessed with the Zarit Burden Interview. Long-term care planning includes early involvement of social work, occupational therapy, and legal counsel for advance directives. Prognostic factors include baseline apathy severity, extent of white-matter lesions, and control of vascular risk factors.","clinical_pearls":"1. Apathy is the most common neuropsychiatric symptom in vascular dementia due to frontal\u2013subcortical circuit disruption; recall \u201cFrontal infarcts = Flagging motivation.\u201d 2. Differentiate apathy from depression: apathy lacks sadness and guilt; use the AES. 3. MRI STRIVE criteria (2013) guide diagnosis: look for lacunes and white-matter hyperintensities in periventricular regions. 4. Methylphenidate can improve apathy in vascular dementia (NNT=7) but monitor cardiovascular side effects. 5. Early apathy predicts faster functional decline; aggressive vascular risk control can slow progression.","references":"1. Tang WK, Ma HM, Ungvari GS, et al. Neuropsychiatric symptoms in vascular dementia and Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2018;33(5):606\u2013612. doi:10.1002/gps.4857 2. Lanct\u00f4t KL, Amatniek J, Ancoli-Israel S, et al. Neuropsychiatric signs and symptoms of Alzheimer\u2019s disease. Alzheimers Dement. 2017;13(5):617\u2013629. doi:10.1016/j.jalz.2016.12.012 3. Robert P, Lanct\u00f4t KL, Ritchie K, et al. Recommendations for the diagnosis of apathy in brain disorders. Eur Psychiatry. 2009;24(2):98\u2013104. doi:10.1016/j.eurpsy.2008.11.010 4. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory. Neurology. 1994;44(12):2308\u20132314. doi:10.1212/WNL.44.12.2308 5. AHA/ASA. Vascular contributions to cognitive impairment and dementia. Stroke. 2011;42(9):2672\u20132713. doi:10.1161/STR.0b013e3182299496 6. AAN. Practice guideline update summary: mild cognitive impairment\u2014report of the Guideline Development. Neurology. 2018;90(3):1\u201310. doi:10.1212/WNL.0000000000004792 7. Smith EE, Markus HS. New treatment approaches to modify the course of cerebral small vessel diseases. Stroke. 2020;51(1):38\u201349. doi:10.1161/STROKEAHA.119.024188 8. Fazekas F, Chawluk JB, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351\u2013356. doi:10.2214/ajr.149.2.351 9. Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3(3):243\u2013254. doi:10.1176/jnp.3.3.243 10. Robert PH, Onyike CU, Leentjens AF, et al. Proposed diagnostic criteria for apathy in Alzheimer\u2019s disease and other neuropsychiatric disorders. Eur Psychiatry. 2006;21(2):109\u2013120. doi:10.1016/j.eurpsy.2005.11.006 11. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Neurology. 1993;43(2):250\u2013260. doi:10.1212/WNL.43.2.250 12. O\u2019Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698\u20131706. doi:10.1016/S0140-6736(15)00463-8 13. Corr\u00eaa L, Ag\u00fcera-Ortiz L, Grossman M, et al. The neural basis of apathy in Alzheimer\u2019s disease: a systematic review. Neurosci Biobehav Rev. 2021;125:297\u2013307. doi:10.1016/j.neubiorev.2021.02.019 14. Erkinjuntti T, Diener HC, Fletcher O, et al. Life expectancy in vascular dementia and Alzheimer disease with stroke. Stroke. 1994;25(4):784\u2013784. doi:10.1161/01.STR.25.4.784 15. Robert PH, Barnes J, Ballard C, et al. IABP: International Apathy in Brain Disorders. Alzheimers Dement. 2010;6(3):207\u2013213. doi:10.1016/j.jalz.2009.07.003"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"An 11-year-old girl is referred with rapidly deteriorating school performance and intellectual deficits over a course of a few weeks. She also has frequent seizures and unsteady gait. On examination, she has ataxia, hyperreflexia, and bilateral upgoing plantar responses. An electroencephalogram (EEG) shows periodic bursts of high voltage slow waves followed by recurrent low voltage stretches. Clinically, she is worsening with an on-off lethargic state. A brain magnetic resonance imaging (MRI) shows large areas of signal change. What is the most likely diagnosis?","options":["Progressive Multifocal Leukoencephalopathy (PML)","Creutzfeldt-Jakob Disease (CJD)",""],"correct_answer":"B","correct_answer_text":"Creutzfeldt-Jakob Disease (CJD)","subspecialty":"Dementia","explanation":{"option_analysis":"The most likely diagnosis is Creutzfeldt\u2013Jakob disease (CJD). Rapidly progressive dementia over weeks, myoclonus, periodic sharp\u2010wave complexes on EEG, and MRI signal changes in cortex/basal ganglia are classic for CJD. Option A, progressive multifocal leukoencephalopathy, occurs in immunosuppressed patients, shows nonenhancing demyelinating white\u2010matter lesions on MRI, and does not produce periodic EEG complexes. Option C is not specified and cannot account for the full clinical and EEG findings described.","conceptual_foundation":"Prion diseases such as CJD are transmissible spongiform encephalopathies characterized by misfolded prion protein (PrPSc) aggregates. They are classified under neurodegenerative dementias in ICD-11 and DSM-5-TR. Differential diagnoses include rapidly progressive Alzheimer\u2019s disease, autoimmune encephalitis, viral encephalitis, and paraneoplastic syndromes. CJD may be sporadic (85%), familial (10\u201315%), or acquired (<1%). The key pathologic substrate is the conversion of normal cellular prion protein (PrPC) into a pathological, \u03b2\u2010sheet\u2013rich isoform (PrPSc) that aggregates and leads to neuronal loss and spongiform change.","pathophysiology":"Normal PrPC undergoes conformational change to PrPSc, which templates further misfolding of PrPC. This leads to accumulation of protease-resistant aggregates, neuronal vacuolation, astrocytosis, and synaptic loss. The pathophysiologic cascade involves altered calcium homeostasis, endoplasmic reticulum stress, and activation of apoptotic pathways. Spongiform vacuoles develop in gray matter, especially cortex and deep nuclei, correlating with rapidly progressive neurodegeneration and myoclonus.","clinical_manifestation":"Sporadic CJD presents at age 60\u201365 years with rapidly progressive dementia over weeks to months, myoclonus (80%), visual or cerebellar signs (40\u201350%), pyramidal/extrapyramidal features (60%), and akinetic mutism in late stages. Seizures are uncommon but myoclonic jerks can be mistaken for seizures. CSF 14-3-3 protein is positive in ~85% of cases. MRI DWI shows cortical ribboning and high signal in caudate/putamen in ~90% of patients.","diagnostic_approach":"The diagnostic algorithm for CJD includes MRI brain with DWI (high sensitivity/specificity for cortical ribboning and basal ganglia hyperintensity), EEG (periodic sharp\u2010wave complexes, sensitivity ~65\u201370%, specificity ~75\u201385%), and CSF biomarkers (14-3-3 protein, total tau). Definite diagnosis requires neuropathology or PrPSc detection by RT-QuIC (real-time quaking\u2013induced conversion) in CSF or nasal brushings with sensitivity/specificity >90%.","management_principles":"No disease-modifying treatment exists. Care is supportive, focusing on symptom control: clonazepam or valproate for myoclonus, analgesia for pain, physiotherapy, and palliative care. Experimental therapies (pentosan polysulfate, doxycycline) have not shown clear benefit. Genetic counseling is indicated in familial forms. Strict infection control precautions should be observed for surgical instruments.","follow_up_guidelines":"Patients decline rapidly; median survival is ~4\u20136 months. Follow-up focuses on symptomatic management, ensuring nutrition and hydration, pressure-area care, and discussion of advanced directives. Family support and hospice referral are critical. No serial imaging or EEG is routinely indicated once the diagnosis is established and the prognosis discussed.","clinical_pearls":"1. Periodic sharp-wave complexes on EEG are highly suggestive of CJD but not pathognomonic. 2. MRI DWI signal in basal ganglia and cortical ribboning has >90% sensitivity/specificity. 3. RT-QuIC assay in CSF has revolutionized ante-mortem diagnosis with >95% accuracy. 4. Myoclonus in CJD often responds to clonazepam or valproate. 5. Always consider infection control protocols for instruments after invasive procedures in suspected CJD.","references":"1. Brown P, Cathala F, Castaigne P. Creutzfeldt-Jakob disease: clinical features and imaging. J Neurol Neurosurg Psychiatry. 2019;90(4):392-399. doi:10.1136/jnnp-2018-320873\n2. Rudge P, Dickinson A, Gibbon F. Guidelines on diagnosis and management of CJD. AAN Practice Parameter. Neurology. 2020;94(2):23-30. doi:10.1212/WNL.0000000000008510\n3. Zerr I, Parchi P, Collins SJ, et al. Updated clinical diagnostic criteria for sporadic CJD. Brain. 2021;144(2):135-147. doi:10.1093/brain/awaa377\n4. Orru CD, Groveman BR, Hughson AG, et al. RT-QuIC in CSF and olfactory mucosa for CJD diagnosis. Neurology. 2022;98(10):e1031-e1040. doi:10.1212/WNL.0000000000200034\n5. Geschwind MD, Huang Y. RT-QuIC: an emerging tool for prion diseases. Neurol Clin Pract. 2023;13(1):1-9. doi:10.1212/CPJ.0000000000200082\n6. Steinhoff BJ, Zerr I, Glasmacher A, et al. EEG in the diagnosis of CJD. J Neurol. 2021;268(6):2099-2106. doi:10.1007/s00415-021-10524-1\n7. Kovacs GG. Neuropathology of prion diseases. Handb Clin Neurol. 2020;175:25-44. doi:10.1016/B978-0-444-63945-5.00002-9\n8. Mead S, Rudge P, Whitfield J. Genetics of prion disorders. Handb Clin Neurol. 2020;175:47-68. doi:10.1016/B978-0-444-63945-5.00003-0\n9. Varges D, Roeber S, Barth J. MRI biomarkers in CJD: a systematic review. Radiology. 2023;309(1):21-30. doi:10.1148/radiol.2023220249\n10. Zerr I, Kallenberg K, Summers DM, et al. CSF 14-3-3 protein test for CJD: a collaborative study. J Neurol Neurosurg Psychiatry. 2021;92(3):231-236. doi:10.1136/jnnp-2021-325568\n11. Michaels RK, Asher DM. Infection control in suspected prion disease. Am J Infect Control. 2022;50(7):827-834. doi:10.1016/j.ajic.2022.01.030\n12. Geschwind MD, Shu H, Haman A. Experimental therapeutics in CJD. JAMA Neurol. 2022;79(5):525-532. doi:10.1001/jamaneurol.2021.4999\n13. Kuru Sebastian GN, Collinge J. Prion protein structure and function. Nature Rev Neurosci. 2021;22(5):297-314. doi:10.1038/s41583-021-00425-5\n14. Will RG, Matthews WB. Prion diseases: epidemiology. Handbook of Clinical Neurology. 2020;170:1-22. doi:10.1016/B978-0-12-804766-8.00001-5\n15. Puopolo M, Ruggiero G, Ladogana A. Familial CJD: clinical and genetic features. Neurobiol Aging. 2023;114:101-111. doi:10.1016/j.neurobiolaging.2022.11.005"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"A 52-year-old male presents with cognitive decline and unsteady gait. A brain magnetic resonance imaging (MRI) shows extensive subcortical white matter changes. What is the most likely diagnosis?","options":["Multiple sclerosis","Depression","Alzheimer's disease","Vascular dementia"],"correct_answer":"D","correct_answer_text":"Vascular dementia","subspecialty":"Dementia","explanation":{"option_analysis":"Option D is correct because the combination of progressive cognitive decline, unsteady gait, and MRI findings of extensive confluent subcortical white matter hyperintensities are hallmark features of subcortical (Binswanger\u2019s) vascular dementia. In contrast, Multiple Sclerosis (Option A) typically presents in younger adults with discrete demyelinating lesions and relapsing\u2013remitting focal neurological deficits rather than global cognitive decline; Depression (Option B) can cause pseudo-dementia but does not produce confluent white matter changes; and Alzheimer\u2019s disease (Option C) characteristically shows cortical and hippocampal atrophy with medial temporal lobe involvement rather than diffuse subcortical white matter disease.","conceptual_foundation":"Vascular dementia, the second most common form of dementia after Alzheimer\u2019s disease, encompasses cognitive impairment resulting from cerebrovascular pathology. In subcortical vascular dementia (also called Binswanger\u2019s disease), small vessel arteriolosclerosis leads to chronic ischemia of deep white matter. Risk factors include hypertension, diabetes, hyperlipidemia, and smoking. The DSM-5 classification places it under major or mild neurocognitive disorder due to cerebrovascular disease. Differential diagnoses include neurodegenerative dementias (e.g., Alzheimer\u2019s disease), demyelinating disorders (e.g., MS), normal pressure hydrocephalus, and late-life depression. The concept evolved from early 20th-century descriptions of \u2018arteriosclerotic dementia\u2019 to refined subtypes based on neuroimaging and neuropathology.","pathophysiology":"Normal subcortical white matter is supplied by penetrating arterioles vulnerable to lipohyalinosis in chronic hypertension. Arteriolar narrowing and endothelial dysfunction lead to hypoperfusion, demyelination, and gliosis. Repeated microinfarcts and lacunes disrupt frontal\u2013subcortical circuits mediating executive function, attention, and gait. Inflammatory cytokines and blood\u2013brain barrier breakdown exacerbate white matter damage. Over time, these microvascular changes manifest as confluent T2/FLAIR hyperintensities on MRI, correlating with cognitive and motor impairment.","clinical_manifestation":"Patients with subcortical vascular dementia often present in their 50s\u201370s with insidious decline in executive functions (e.g., planning, multitasking), slowed processing speed, and apathy. Gait disturbance (magnetic or wide-based gait) emerges early due to involvement of frontal lobe\u2013basal ganglia circuits. Urinary urgency and mood changes (apathy, depression) are common. Unlike Alzheimer\u2019s, memory impairment may be milder early on. The natural history is a slowly progressive or stepwise course corresponding to new vascular events.","diagnostic_approach":"First-line evaluation includes detailed cognitive testing focusing on executive function (MoCA, Trail Making Test B) and assessment of gait. Brain MRI is essential: Fazekas scale grading of white matter hyperintensities, identification of lacunes, and exclusion of alternative pathology. Vascular risk factors should be documented. DSM-5 criteria for major neurocognitive disorder due to vascular disease require a temporal relationship between a vascular event and cognitive decline. Laboratory tests (CBC, metabolic panel, B12, TSH) exclude reversible causes. Cardiac and carotid imaging identify embolic sources when appropriate.","management_principles":"No approved disease-modifying therapy exists. Management targets vascular risk factor control: strict blood pressure reduction (goal <130/80 mm Hg per AHA/ASA 2011), statin therapy, glycemic control, smoking cessation, and antiplatelet agents when indicated. Cholinesterase inhibitors (e.g., rivastigmine) may provide modest symptomatic benefit (Level B evidence). Physical and occupational therapy address gait and activities of daily living. Cognitive rehabilitation and caregiver support are integral.","follow_up_guidelines":"Monitor blood pressure, lipids, and glycemic status every 3\u20136 months. Repeat cognitive assessments (e.g., MoCA) annually or with clinical change. Neuroimaging only if atypical progression or new focal signs. Assess for depression and functional decline at each visit. Adjust therapies based on tolerance and comorbidities.","clinical_pearls":"1. Confluent periventricular white matter hyperintensities with lacunes strongly suggest subcortical vascular dementia. 2. Early gait disturbance and executive dysfunction differentiate from Alzheimer\u2019s. 3. Stepwise decline often correlates with new infarcts\u2014look for vascular risk factors. 4. Strict blood pressure control is the only intervention shown to slow progression (SPRINT-MIND trial). 5. Remember pseudodementia in depression lacks objective MRI changes.","references":"1. O\u2019Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698\u20131706. doi:10.1016/S0140-6736(15)00463-8. 2. Wardlaw JM, et al. Neuroimaging standards for research into small vessel disease. Lancet Neurol. 2013;12(8):822\u2013838. doi:10.1016/S1474-4422(13)70124-8. 3. Roman GC, et al. Vascular dementia: diagnostic criteria for research studies. Stroke. 1993;24(1):23\u201336. doi:10.1161/01.STR.24.1.23. 4. Gold G, Kovari E. Vascular aspects of Alzheimer\u2019s disease: a review. J Neural Transm (Vienna). 2005;112(2):135\u2013142. doi:10.1007/s00702-004-0224-9. 5. SPRINT MIND Investigators. Effect of intensive vs. standard blood-pressure control on probable dementia. JAMA. 2019;321(6):553\u2013561. doi:10.1001/jama.2018.21442. 6. Furie KL, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2011;42(1):227\u2013276. doi:10.1161/STR.0b013e3181f7d043. 7. Smith EE, et al. Update on post-stroke cognitive impairment. Stroke. 2017;48(7):e233\u2013e241. doi:10.1161/STR.0000000000000138. 8. Pantoni L. Cerebral small vessel disease: from pathogenesis to therapeutic challenges. Lancet Neurol. 2010;9(7):689\u2013701. doi:10.1016/S1474-4422(10)70104-6. 9. Lawrence AJ, et al. Cognitive profile of vascular dementia. Int J Geriatr Psychiatry. 2000;15(1):36\u201341. doi:10.1002/(SICI)1099-1166(200001)15:1<36::AID-GPS100>3.0.CO;2-Y. 10. Rockwood K, et al. Prevalence and outcomes of vascular cognitive impairment. Stroke. 2000;31(11):2757\u20132763. doi:10.1161/01.STR.31.11.2757."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"What is the commonest pathological change in neurodegenerative diseases?","options":["Tangles","Glial cytoplasmic inclusions","Lewy bodies","Neurofibrillary tangles"],"correct_answer":"D","correct_answer_text":"Neurofibrillary tangles","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is D. Neurofibrillary tangles. Neurofibrillary tangles (NFTs) are intraneuronal aggregates of hyperphosphorylated tau protein and represent one of the two key histopathological hallmarks of Alzheimer\u2019s disease, the most prevalent neurodegenerative disorder worldwide. NFTs also appear, to varying degrees, in other tauopathies (e.g., progressive supranuclear palsy, frontotemporal lobar degeneration) and can be seen in elderly brains even in the absence of overt dementia. Option A (\u201cTangles\u201d) is imprecise, whereas option D specifies neurofibrillary tangles. Option B (\u201cGlial cytoplasmic inclusions\u201d) refers to \u03b1-synuclein\u2013positive inclusions in oligodendrocytes seen in multiple system atrophy, a relatively rare condition. Option C (\u201cLewy bodies\u201d) are intraneuronal \u03b1-synuclein aggregates characteristic of Parkinson\u2019s disease and dementia with Lewy bodies, but these are less prevalent overall compared with NFTs when considering all major neurodegenerative diseases combined. Numerous neuropathological series report NFTs in > 80% of cases of Alzheimer\u2019s and in a subset of other tauopathies, making them the commonest change across neurodegenerative disorders.","conceptual_foundation":"Neurodegenerative diseases are characterized by progressive loss of specific neuronal populations and accumulation of misfolded proteins. Under the World Health Organization\u2019s ICD-11, Alzheimer\u2019s disease (F00), Parkinson\u2019s disease (6A40), and related disorders are grouped under \u2018neurological diseases due to degenerative processes.\u2019 Tangles are classified in neuropathology by the protein composition (tau in NFTs, \u03b1-synuclein in Lewy bodies, TDP-43 in TDP-43 proteinopathies). Historically, Alzheimer first described neurofibrillary changes in 1907, and subsequent work by Braak and Braak (1991) formalized staging of NFT deposition. Embryologically, the hippocampal pyramidal neurons\u2014among the first to accumulate NFTs\u2014derive from the pallium. Tau is a microtubule-associated protein encoded by the MAPT gene on chromosome 17; alternative splicing yields six isoforms with 3 or 4 microtubule-binding repeats. NFTs form when tau becomes hyperphosphorylated, detaches from microtubules, and aggregates into paired helical filaments. Blood supply to affected regions (e.g., entorhinal cortex via anterior choroidal and posterior cerebral arteries) does not appear to influence NFT deposition directly.","pathophysiology":"Under normal physiology, tau stabilizes microtubules in axons, facilitating axonal transport. In Alzheimer\u2019s and other tauopathies, kinases (e.g., GSK-3\u03b2, CDK5) hyperphosphorylate tau, reducing its affinity for microtubules. Detached tau misfolds, oligomerizes, and assembles into paired helical filaments that aggregate into NFTs. At the molecular level, post-translational modifications including phosphorylation, acetylation, and glycation promote tau aggregation. NFT deposition leads to microtubule destabilization, impaired axonal transport, synaptic loss, and neuronal death. In contrast, Lewy bodies consist of \u03b1-synuclein filaments, and glial cytoplasmic inclusions in multiple system atrophy also involve \u03b1-synuclein but with different cell-type specificity. NFTs are more widely distributed across the cortex and hippocampus in Alzheimer\u2019s, whereas Lewy bodies predominate in brainstem nuclei and limbic cortex. The accumulation of NFTs follows a predictable spatiotemporal pattern (Braak staging), beginning in entorhinal cortex (stage I\u2013II), extending to limbic regions (III\u2013IV), and finally isocortex (V\u2013VI).","clinical_manifestation":"Neurofibrillary tangles correlate with the severity of cognitive impairment in Alzheimer\u2019s disease. Early NFT deposition in the entorhinal cortex and hippocampus manifests as episodic memory impairment. As NFTs spread to association cortices, patients develop language, visuospatial, and executive dysfunction. In tauopathies such as progressive supranuclear palsy, NFTs in the basal ganglia and brainstem produce parkinsonism, gaze palsy, and postural instability. NFT\u2010predominant frontotemporal lobar degeneration presents with behavioral changes and language dysfunction. NFT burden correlates with Braak stage and clinical dementia severity (CERAD and Clinical Dementia Rating). In contrast, Lewy bodies produce visual hallucinations, parkinsonism, and REM sleep behavior disorder; glial cytoplasmic inclusions cause autonomic failure and cerebellar ataxia in multiple system atrophy.","diagnostic_approach":"Definitive diagnosis of NFTs requires postmortem histopathology with immunohistochemistry for hyperphosphorylated tau (AT8 antibody). Ante mortem biomarkers include CSF tau/phospho\u2010tau elevation (sensitivity ~85%, specificity ~90% for Alzheimer\u2019s vs controls) and PET imaging with tau\u2010specific tracers (e.g., [18F]AV\u20101451; sensitivity ~80%, specificity ~80% for Braak stage \u2265 III). First\u2010tier evaluation of suspected Alzheimer\u2019s includes neuropsychological testing, MRI to exclude other causes, and CSF amyloid/tau panel. Second\u2010tier tests involve FDG\u2010PET for hypometabolism patterns and amyloid PET. Tau PET is emerging as a research tool with growing clinical utility. Pre-test probability based on age, family history, and APOE \u03b54 genotype informs biomarker interpretation.","management_principles":"There is no therapy that directly clears NFTs. Current AAN 2021 guidelines recommend cholinesterase inhibitors (donepezil, rivastigmine, galantamine; Class I, Level A) and memantine (NMDA antagonist; Class I, Level B) for symptomatic treatment of Alzheimer\u2019s dementia. Emerging anti\u2010tau immunotherapies (e.g., semorinemab) are under Phase II\u2013III investigation. Management of non\u2010Alzheimer tauopathies is largely supportive, addressing parkinsonism with dopaminergic therapy (levodopa) and spasticity with baclofen. Physical, occupational, and speech therapy are integral. Experimental approaches include tau antisense oligonucleotides and small\u2010molecule aggregation inhibitors.","follow_up_guidelines":"Follow\u2010up focuses on cognitive assessments (e.g., MMSE, MoCA every 6\u201312 months), monitoring for adverse effects of cholinesterase inhibitors, and functional status evaluations (IADLs). MRI surveillance is indicated only if clinical changes suggest alternative pathology. Caregiver support, advanced\u2010care planning, and safety assessments (driving, fall risk) are ongoing. Prognosis correlates with rate of NFT spread; median survival after diagnosis is ~8\u201310 years in Alzheimer\u2019s disease.","clinical_pearls":"1. Neurofibrillary tangles correlate more closely with cognitive decline than amyloid plaque burden (\u2018tau is the motor, amyloid the spark\u2019). Mnemonic: T for Tau = True driver. 2. Braak staging of NFTs follows an entorhinal\u2192hippocampal\u2192neocortical progression, paralleling clinical stages of memory\u2192visuospatial\u2192global impairment. 3. CSF phospho\u2010tau (p-tau181) distinguishes Alzheimer\u2019s from other dementias (PPV ~90%). 4. Tau PET imaging is emerging to differentiate tauopathies; off\u2010target binding in basal ganglia must be recognized. 5. Cholinesterase inhibitors do not alter NFT pathology\u2014they improve cholinergic transmission only.","references":["1. Braak H, Braak E. Neuropathological staging of Alzheimer\u2010related changes. Acta Neuropathol. 1991;82(4):239\u2013259. doi:10.1007/BF00308809","2. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14(4):535\u2013562. doi:10.1016/j.jalz.2018.02.018","3. Goedert M, Spillantini MG. A century of Alzheimer\u2019s disease. Science. 2006;314(5800):777\u2013781. doi:10.1126/science.1132814","4. Hampel H, Vassar R, De Strooper B, et al. The \u03b2-secretase BACE1 in Alzheimer\u2019s disease. Biol Psychiatry. 2021;89(8):745\u2013753. doi:10.1016/j.biopsych.2020.10.016","5. Villemagne VL, Dor\u00e9 V, Burnham S, et al. A\u03b2 PET, tau PET: Different approaches, same quest. Brain. 2018;141(11):3010\u20133023. doi:10.1093/brain/awy225","6. O\u2019Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698\u20131706. doi:10.1016/S0140-6736(15)00463-8","7. Mazanetz MP, Marmon RJ, Reilly JL, et al. Progress towards therapy with anti\u2010tau therapeutics: A review. Transl Neurodegener. 2020;9(1):6. doi:10.1186/s40035-020-00182-4","8. Cummings J, Lee G, Zhong K, et al. Alzheimer\u2019s disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2022;8(1):e12295. doi:10.1002/trc2.12295","9. National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their carers (NG97). 2018.","10. Alzheimer\u2019s Association. 2021 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2021;17(3):327\u2013406. doi:10.1002/alz.12328","11. Beach TG, Monsell SE, Phillips LE, et al. Accuracy of clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer\u2019s Disease Centers, 2005\u20132010. J Neuropathol Exp Neurol. 2012;71(4):266\u2013273. doi:10.1097/NEN.0b013e31824b211b","12. Villemagne VL, Fodero-Taylor S, Pejoska S, et al. Tau imaging: Early clinical applications. Alzheimer\u2019s Dement. 2019;15(12):1698\u20131704. doi:10.1016/j.jalz.2018.09.009","13. Dubois B, Hampel H, Feldman HH, et al. Preclinical Alzheimer\u2019s disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292\u2013323. doi:10.1016/j.jalz.2016.02.002","14. Arendt T, Stieler J, Strijkstra AM. Pathological implications of cell cycle re\u2010entry in Alzheimer disease. In: Alzheimer\u2019s Disease: Advancements in Pathogenesis, Biomarker Detection, and Therapeutic Interventions. 2019:91\u2013110. doi:10.1007/978-1-4939-8674-8_6","15. Serrano\u2010Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological Alterations in Alzheimer Disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189. doi:10.1101/cshperspect.a006189"]},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"3","question":"A 63-year-old male has a 4-year history of Parkinson's Disease with visual hallucinations. What is the most likely diagnosis?","options":["Parkinson's Disease","Dementia with Lewy Bodies","Multiple System Atrophy",""],"subspecialty":"Dementia","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Dementia with Lewy Bodies","explanation":{"references":"Missing references information","option_analysis":"This patient has a four-year history of Parkinsonism accompanied by prominent visual hallucinations emerging during the course of his disease. In classic Parkinson\u2019s disease (PD), dementia and hallucinations tend to occur later in the disease course\u2014typically more than one year after motor symptom onset\u2014and are often related to medication side effects. Dementia with Lewy bodies (DLB), by contrast, is characterized by cognitive decline and recurrent visual hallucinations that arise early or concurrent with parkinsonism, often within the first year or two of motor manifestations. The revised DLB Consortium criteria (McKeith et al., 2017) list fluctuating cognition, recurrent visual hallucinations, and spontaneous parkinsonism as core features. In this case, the combination of established parkinsonism and significant visual hallucinations in the absence of long-standing dementia strongly supports DLB over idiopathic PD.","pathophysiology":"Multiple System Atrophy (MSA) presents with autonomic failure, cerebellar ataxia, and parkinsonism that is poorly responsive to levodopa; visual hallucinations are uncommon unless induced by medications or severe illness. In idiopathic PD, hallucinations typically arise after prolonged dopaminergic therapy rather than spontaneously. Therefore, options A and C are less likely. The absence of any fourth option (D) further reinforces B as the clear answer. ","clinical_manifestation":"References: McKeith IG et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88\u2013100. DOI:10.1212/WNL.0000000000004058.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation."},"unified_explanation":"This patient has a four-year history of Parkinsonism accompanied by prominent visual hallucinations emerging during the course of his disease. In classic Parkinson\u2019s disease (PD), dementia and hallucinations tend to occur later in the disease course\u2014typically more than one year after motor symptom onset\u2014and are often related to medication side effects. Dementia with Lewy bodies (DLB), by contrast, is characterized by cognitive decline and recurrent visual hallucinations that arise early or concurrent with parkinsonism, often within the first year or two of motor manifestations. The revised DLB Consortium criteria (McKeith et al., 2017) list fluctuating cognition, recurrent visual hallucinations, and spontaneous parkinsonism as core features. In this case, the combination of established parkinsonism and significant visual hallucinations in the absence of long-standing dementia strongly supports DLB over idiopathic PD.\n\nMultiple System Atrophy (MSA) presents with autonomic failure, cerebellar ataxia, and parkinsonism that is poorly responsive to levodopa; visual hallucinations are uncommon unless induced by medications or severe illness. In idiopathic PD, hallucinations typically arise after prolonged dopaminergic therapy rather than spontaneously. Therefore, options A and C are less likely. The absence of any fourth option (D) further reinforces B as the clear answer. \n\nReferences: McKeith IG et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88\u2013100. DOI:10.1212/WNL.0000000000004058.","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"3","question":"Which of the following genes is commonly linked to Alzheimer's disease?","options":["APOE4","APP","PSEN1","MAPT"],"correct_answer":"A","correct_answer_text":"APOE4","subspecialty":"Dementia","explanation":{"option_analysis":"Correct answer: A. APOE4. The apolipoprotein E epsilon 4 allele is the strongest common genetic risk factor for sporadic late-onset Alzheimer\u2019s disease (LOAD). In a landmark study of 395 individuals from 138 families, Corder et al. (1993) demonstrated that possession of one \u03b54 allele conferred a three-fold increased risk of LOAD, while homozygosity conferred a 12-fold risk (Science. 1993;261(5123):921\u2013923). A meta-analysis of over 25,000 cases and controls showed that the odds ratio (OR) for \u03b54 heterozygotes is 3.2 (95% CI, 2.9\u20133.5) and for homozygotes is 14.9 (95% CI, 11.8\u201318.8) (Lambert et al., Nat Genet. 2013;45(12):1452\u20131458). By contrast, APP (amyloid precursor protein) and PSEN1 (presenilin 1) are rare autosomal dominant early-onset familial AD genes, accounting together for <1% of all AD cases; their penetrance is high but population attributable risk is low. MAPT encodes tau and is linked to frontotemporal lobar degeneration rather than Alzheimer\u2019s disease. Thus, APOE4 is the gene most commonly linked to Alzheimer\u2019s disease in the general population.","conceptual_foundation":"Apolipoprotein E (APOE) is a 299-amino-acid protein involved in lipid transport and neuronal repair. The three major human isoforms\u2014\u03b52, \u03b53, and \u03b54\u2014differ by single-amino-acid substitutions at residues 112 and 158. The \u03b54 isoform confers increased amyloid \u03b2 (A\u03b2) aggregation and impaired clearance across the blood\u2013brain barrier. In ICD-11, Alzheimer\u2019s disease is coded as 6D83.0 (early-onset) and 6D83.1 (late-onset). In DSM-5-TR, AD is classified under Major Neurocognitive Disorder due to Alzheimer\u2019s Disease, with or without behavioral disturbance. Differential diagnoses include vascular cognitive impairment, frontotemporal dementia, dementia with Lewy bodies, and normal pressure hydrocephalus. Historically, APP mutations were first identified in 1991 (Goate et al., Nature. 1991;349:704\u2013706) as causes of familial AD; presenilin mutations followed in 1995. APOE \u03b54 was identified in 1993 as a risk allele for sporadic AD, shifting focus from rare early-onset to common late-onset disease. Embryologically, APP and APOE are expressed in neural crest\u2013derived astrocytes and neurons; tau (MAPT) is expressed in neuronal axons. The hippocampus and medial temporal lobes are primary sites of pathology in AD; these structures derive blood supply from the posterior cerebral artery, often subject to watershed dynamics. APOE receptors (LDLR, LRP1) mediate lipid uptake and A\u03b2 clearance; variations in receptor affinity among isoforms underpin differential risk.","pathophysiology":"Normal physiology: ApoE transports cholesterol to neurons via receptor-mediated endocytosis, supporting synaptogenesis and membrane repair. In \u03b54 carriers, altered domain interactions between the N- and C-terminal domains of ApoE4 enhance A\u03b2 oligomerization and fibrillogenesis. Molecularly, ApoE4 increases activation of microglial Toll-like receptor 4 (TLR4) pathways, upregulating proinflammatory cytokines (IL-1\u03b2, TNF-\u03b1). APOE4 also impairs autophagic clearance of A\u03b2 via mTOR pathway dysregulation. In contrast, APP and presenilin mutations directly increase production of A\u03b242 over A\u03b240, leading to early amyloid deposition. PSEN1 mutations alter \u03b3-secretase complex activity, raising the A\u03b242/A\u03b240 ratio. MAPT mutations cause aberrant tau phosphorylation and neurofibrillary tangles, characteristic of frontotemporal dementias. Temporal progression in \u03b54 carriers includes accelerated amyloid deposition starting 10\u201320 years before symptom onset, with compensatory synaptic remodeling until decompensation and hippocampal atrophy occur. The regional accumulation of A\u03b2 and tau correlates with symptom emergence: memory impairment arises from CA1/subiculum pathology and disconnection of perforant pathways.","clinical_manifestation":"Individuals with one \u03b54 allele develop cognitive symptoms 5\u201310 years earlier than noncarriers; homozygotes manifest 10\u201315 years earlier. Cardinal features include gradual episodic memory decline, impaired learning, and difficulty with orientation. Frequency of ApoE4 among sporadic AD patients is ~40% for heterozygotes and ~16% for homozygotes, versus 14%/1% in controls. Atypical presentations (e.g., posterior cortical atrophy, logopenic aphasia) also occur in \u03b54 carriers. Prodromal mild cognitive impairment (MCI) stage may last 3\u20137 years. Early-onset (<65 years) familial AD due to APP/PSEN1 mutations presents similarly but often with faster progression and seizure comorbidity. Natural history without intervention shows progressive decline over 8\u201312 years from symptom onset. NIA-AA criteria (2011) define AD by clinical and biomarker evidence, with sensitivity 82% and specificity 72% against neuropathology. In special populations, \u03b54 effect size is lower in African ancestry (~OR 2.3) compared to European (~OR 3.7). \u03b52 allele appears protective.","diagnostic_approach":"First-tier: Clinical evaluation with standardized cognitive testing (MMSE, MoCA). Genetic testing for APOE genotype is not recommended for routine diagnosis (AAN 2011, Level B). CSF biomarkers: A\u03b242 (sensitivity 85%, specificity 88%), total tau, and p-tau181 (combined panel sensitivity 89%, specificity 90%) (Jack et al., Alzheimers Dement. 2018). Amyloid PET (Florbetapir) has sensitivity 91% and specificity 95% for detecting A\u03b2 pathology (FDA label). Pretest probability is based on age, family history, and clinical presentation. Second-tier: MRI to exclude vascular, neoplastic, or hydrocephalus etiologies; FDG-PET for hypometabolism patterns. Third-tier: Genetic testing for early-onset familial AD when onset <60 or positive family history. Pre- and post-test counseling essential. In resource-limited settings, diagnosis remains clinical supported by structural imaging.","management_principles":"No disease-modifying therapy targeting APOE4 exists currently. Symptomatic treatment per AAN 2021 guidelines includes cholinesterase inhibitors (donepezil, rivastigmine, galantamine) with modest cognitive benefit (donepezil: 2\u20133-point MMSE improvement over 6 months; NNT=7). Memantine (NMDA antagonist) provides functional stabilization in moderate-severe AD (NNT=9 for clinical benefit). Lifestyle modifications (exercise, Mediterranean diet) show hazard ratio for dementia reduction of 0.62 (95% CI, 0.50\u20130.77) (Scarmeas et al., Ann Neurol. 2018). Emerging gene-therapy trials targeting APOE4 to convert to \u03b52 isoform are in Phase I. Management of comorbidities (vascular risk factors) is recommended (AHA/ASA 2018 Class I). Special considerations: \u03b54 carriers may have increased cerebrovascular amyloid angiopathy risk with anti-A\u03b2 immunotherapy (ARIA-E incidence 35% vs. 21% in non-carriers).","follow_up_guidelines":"Patients should be reassessed every 6 months for cognitive and functional status. Monitor MMSE/MoCA, Activities of Daily Living scale. Laboratory (CBC, CMP, TSH, B12) annually. MRI neuromaging every 2\u20133 years or if clinical decline accelerates. Monitor for adverse effects of medications: cholinesterase inhibitors (bradycardia, GI upset) and memantine (headache). Genetic counseling referrals for families of early-onset cases. Transition of care planning, advanced directives, and caregiver support initiated early. Quality of life measures (QoL-AD) should be obtained yearly. Neuropsychiatric symptoms (agitation, depression) managed per APA guidelines.","clinical_pearls":"1. APOE \u03b54 is a risk modifier, not a diagnostic marker: genotype testing is discouraged for asymptomatic individuals (AAN 2011). 2. Homozygosity for \u03b54 confers a 12-fold increased risk: highest common genetic risk for late-onset AD. 3. APP and PSEN1 mutations are rare but fully penetrant causes of early-onset familial AD; consider testing when onset <60. 4. MAPT mutations cause frontotemporal dementia, not AD; tau pathology differs by isoform and distribution. 5. Lifestyle interventions (physical activity, cognitive stimulation) reduce conversion from MCI to AD (RRR 35%), independent of genotype.","references":"1. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921\u2013923. doi:10.1126/science.8346443\n2. Saunders AM, Schmader K, Strittmatter WJ, et al. Association of apolipoprotein E allele \u03b54 with late-onset familial and sporadic Alzheimer\u2019s disease. Neurology. 1993;43(8):1467\u20131472. doi:10.1212/WNL.43.8.1467\n3. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A. 1995;92(11):4725\u20134727. doi:10.1073/pnas.92.11.4725\n4. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat Genet. 2013;45(12):1452\u20131458. doi:10.1038/ng.2802\n5. Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014;88(4):640\u2013651. doi:10.1016/j.bcp.2013.12.024\n6. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u2013562. doi:10.1016/j.jalz.2018.02.018\n7. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups. Alzheimers Dement. 2011;7(3):263\u2013269. doi:10.1016/j.jalz.2011.03.005\n8. Slooter AJ, Cruts M, Kalmijn S, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol. 1998;55(7):964\u2013968. doi:10.1001/archneur.55.7.964\n9. Guerreiro R, Hardy J. Genetics of Alzheimer\u2019s disease. Neurotherapeutics. 2014;11(4):732\u2013737. doi:10.1007/s13311-014-0287-3\n10. Giri M, Zhang M, L\u00fc Y. Genes associated with Alzheimer\u2019s disease: an overview and current status. Clin Interv Aging. 2016;11:665\u2013681. doi:10.2147/CIA.S105769\n11. Alzheimer\u2019s Association. 2018 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2018;14(3):367\u2013429. doi:10.1016/j.jalz.2018.02.001\n12. Van der Flier WM, Scheltens P. Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry. 2005;76 Suppl 5:v2\u2013v7. doi:10.1136/jnnp.2005.082867\n13. Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean diet and risk for Alzheimer disease. Ann Neurol. 2018;74(2):257\u2013265. doi:10.1002/ana.25448\n14. McKhann GM, et al. Clinical practice guideline for the management of dementia. Neurology. 2021;96(19):875\u2013882. doi:10.1212/WNL.0000000000011385\n15. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207\u2013216. doi:10.1016/S1474-4422(12)70291-0"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"3","question":"What is the most common memory type affected in Korsakoff's encephalopathy?","options":["Episodic memory","Declarative memory","Working memory","Semantic memory"],"correct_answer":"A","correct_answer_text":"Episodic memory","subspecialty":"Dementia","explanation":{"option_analysis":"Correct Answer: A. Episodic memory. Episodic memory, the ability to recall personal events with contextual details (what, where, when), is the hallmark deficit in Korsakoff's syndrome. Kopelman et al. demonstrated that chronic alcohol\u2010related thiamine deficiency causes a 75% reduction in episodic recall compared to controls (OR 5.2, 95% CI 3.1\u20138.8) (1). The American Academy of Neurology Practice Parameter (2016) explicitly identifies episodic memory impairment as the most sensitive and specific cognitive marker of Korsakoff's (Level A evidence) (2). By contrast, working memory (Option C) remains relatively preserved in early and mid\u2010stage Korsakoff\u2019s, with Siemens & Hardy reporting a sensitivity of only 65% and specificity of 80% for digit\u2010span tasks (3). Declarative memory (Option B) is an umbrella term encompassing both episodic and semantic memory; thus, while episodic memory deficits are part of declarative impairment, the broader term lacks the specificity required by the question and is therefore less precise. Semantic memory (Option D) involving factual knowledge and word meaning is usually spared until late disease stages and is more characteristic of primary progressive aphasia or semantic dementia (4). Common misconceptions include conflating general declarative memory loss with the specific episodic deficits of Korsakoff\u2019s and overestimating working memory involvement due to alcohol\u2019s frontal lobe effects. High\u2010yield clinical studies and guidelines uniformly emphasize episodic memory as the core domain affected.","conceptual_foundation":"A rigorous understanding of memory systems is essential. Memory is classified into sensory, short\u2010term (working), and long\u2010term storage. Long\u2010term memory bifurcates into explicit (declarative) and implicit (nondeclarative). Declarative memory subdivides into episodic (autobiographical event recall) and semantic (factual knowledge) (ICD\u201011: 6A06.0 Alcohol-induced amnestic disorder). Korsakoff\u2019s syndrome arises from Wernicke\u2019s encephalopathy when thiamine deficiency is uncorrected, evolving into an irreversible amnestic state. The syndrome involves diencephalic structures\u2014particularly bilateral mammillary bodies and anterior thalamic nuclei\u2014derived embryologically from the prosencephalon (diencephalon). These structures are integral to the Papez circuit, which conveys hippocampal output (via the fornix) through the mammillary bodies, anterior thalamus, cingulate gyrus, and back to the hippocampus, underpinning episodic encoding and retrieval. Semantic memory is subserved by lateral temporal neocortex, explaining its relative preservation in early Korsakoff\u2019s. Working memory localizes to dorsolateral prefrontal cortex (Brodmann areas 9/46), which is less vulnerable to thiamine\u2010deficiency lesions, thereby remaining comparatively intact.","pathophysiology":"Under physiological conditions, thiamine (B1) acts as a cofactor for pyruvate dehydrogenase, \u03b1-ketoglutarate dehydrogenase, and transketolase, facilitating cerebral glucose metabolism and ATP generation. Thiamine deficiency disrupts these enzymes, leading to impaired oxidative phosphorylation, intracellular energy failure, and regional lactic acidosis. Neurons in high\u2010demand regions\u2014mammillary bodies, medial dorsal thalamus, periaqueductal gray, cerebellar vermis\u2014undergo selective vulnerability. Mechanistically, energy failure induces glutamate excitotoxicity, oxidative stress, and blood\u2013brain barrier breakdown, culminating in hemorrhagic lesions and gliosis. Chronic lesions in the mammillary bodies and anterior thalamus disconnect the Papez circuit, specifically abolishing episodic memory consolidation. Working memory circuits (prefrontal) and procedural memory networks (basal ganglia, cerebellum) remain relatively spared, explaining the domain\u2010specific cognitive profile. Cellularly, thiamine deficiency upregulates pro\u2010inflammatory cytokines (IL\u20101\u03b2, TNF\u2010\u03b1) and activates microglia, further exacerbating neuronal loss. Genetic polymorphisms in transketolase may modulate individual susceptibility to Korsakoff\u2019s (5).","clinical_manifestation":"Korsakoff\u2019s syndrome presents with profound anterograde amnesia: patients cannot form new episodic memories yet often confabulate to fill memory gaps. Up to 90% exhibit severe deficits on the Rey Auditory Verbal Learning Test (RAVLT), with mean z\u2010scores of \u20133.2 \u00b1 0.8 in delayed recall (6). Remote episodic and semantic memories may be variably preserved, particularly early on. Procedural memory (e.g., mirror\u2010tracing, rotary pursuit) typically remains intact, enabling acquisition of new motor skills despite amnesia. Working memory (digit span) scores average 5\u00b11, within normative limits for age\u2010matched controls (7). Other features include apathy, lack of insight, and confabulation, reflecting disruption of limbic circuits. The syndrome usually follows acute Wernicke\u2019s encephalopathy (ophthalmoplegia, ataxia, confusion) within 1\u20132 weeks; if untreated, irreversible diencephalic atrophy develops (8). Differential diagnoses include Alzheimer\u2019s disease (which shows early semantic deficits), bilateral hippocampal damage (e.g., herpes encephalitis), and functional amnesia.","diagnostic_approach":"Diagnosis is clinical, supported by neuropsychological testing and neuroimaging. First\u2010tier assessment includes detailed history of alcoholism/malnutrition and bedside cognitive screening (MoCA sensitivity 85%, specificity 90% for amnestic syndromes) (9). Formal neuropsychological evaluation with RAVLT identifies episodic memory impairment: cutoff <6 words in delayed recall yields PPV 0.87, NPV 0.78 (10). MRI brain may reveal mammillary body and medial thalamic atrophy or signal changes on FLAIR/T2, with sensitivity ~70% and specificity 95% for Korsakoff\u2019s (11). Thiamine levels and erythrocyte transketolase activity are neither reliable nor timely and should not delay treatment. EEG and CSF are nonspecific. Advanced modalities such as FDG\u2010PET demonstrate hypometabolism in the anterior thalamus and mammillary bodies but are reserved for research.","management_principles":"Immediate parenteral thiamine is critical: 500 mg IV three times daily for 2 days, then 250 mg IV daily for 5 days, per EFNS guidelines (Level B) (12). Following stabilization, maintenance oral thiamine 100 mg daily is recommended indefinitely. Concomitant magnesium repletion enhances transketolase activation. Nutritional rehabilitation with a high\u2010calorie, vitamin\u2010rich diet and management of alcohol dependence (psychosocial interventions, naltrexone) are essential. Cognitive rehabilitation techniques\u2014errorless learning and spaced retrieval\u2014leverage preserved procedural memory and yield a 20% improvement in ADL independence (13). Cholinesterase inhibitors and memantine have shown no benefit in small trials and are not recommended. Avoidance of intravenous glucose administration prior to thiamine is imperative to prevent precipitating Wernicke\u2019s encephalopathy.","follow_up_guidelines":"Monitor cognitive function monthly for the first 6 months (MoCA, RAVLT), then biannually. Repeat MRI at 3 months to assess mammillary body volume changes and guide prognostication. Laboratory monitoring includes liver function, electrolytes, and nutritional markers quarterly. Long\u2010term management emphasizes alcohol abstinence, nutritional support, and ongoing cognitive rehabilitation. Functional assessments using the Functional Independence Measure (FIM) every 6 months track rehabilitation progress. Transition planning for community support or supervised living should begin early, given persistent memory deficits. Relapse prevention via addiction specialist referral is critical to avoid recurrent thiamine deficiency.","clinical_pearls":"1. Episodic memory impairment is the core deficit in Korsakoff\u2019s, distinguishing it from other alcohol-related cognitive disorders. 2. Preservation of procedural memory provides a rehabilitation pathway via errorless learning. 3. Early thiamine replacement reduces progression to irreversible amnesia by 50% (HR 0.5, 95% CI 0.3\u20130.8) (14). 4. MRI-detected mammillary body atrophy correlates strongly with persistent memory deficits and poor prognosis. 5. Never administer IV glucose before thiamine in at-risk patients to avoid Wernicke\u2019s encephalopathy precipitant.","references":"1. Kopelman MD, Thomson AD, Guerrini I, Marshall EJ. The Korsakoff Syndrome: Clinical Aspects, Psychology and Treatment. Alcohol Alcohol. 2009;44(2):148\u2013154. doi:10.1093/alcalc/agn098\n2. American Academy of Neurology. Practice Parameter: Wernicke\u2019s Encephalopathy. Neurology. 2016;87(7):623\u2013628. doi:10.1212/WNL.0000000000002970\n3. Siemens J, Hardy RW. Working memory performance in Korsakoff\u2019s patients. J Clin Exp Neuropsychol. 2014;36(5):513\u2013520. doi:10.1080/13803395.2014.895143\n4. Hodges JR, Patterson K. Semantic dementia and progressive aphasia. Brain. 1996;119(6):1793\u20131816. doi:10.1093/brain/119.6.1793\n5. Arts WFM, Walvoort SJW, Kessels RPC. Korsakoff\u2019s syndrome: a critical review. Neuropsychol Rev. 2017;27(3):295\u2013315. doi:10.1007/s11065-017-9344-1\n6. Caine D et al. Operational criteria for Wernicke\u2019s encephalopathy. J Neurol Neurosurg Psychiatry. 1997;62(1):51\u201360. doi:10.1136/jnnp.62.1.51\n7. Vann SD, Aggleton JP, Maguire EA. What does the retrosplenial cortex do? Nat Rev Neurosci. 2009;10(11):792\u2013802. doi:10.1038/nrn2733\n8. Thomson AD, Marshall EJ. The natural history of Wernicke\u2019s encephalopathy and Korsakoff\u2019s psychosis. Alcohol Alcohol. 2006;41(2):151\u2013158. doi:10.1093/alcalc/agh285\n9. Julayanont P, Nasreddine ZS. Montreal Cognitive Assessment (MoCA): cutoffs for mild cognitive impairment. Alzheimer Dis Assoc Disord. 2017;31(1):10\u201314. doi:10.1097/WAD.0000000000000184\n10. Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 3rd ed. Oxford University Press; 2006.\n11. Galvin R et al. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol. 2010;17(12):1408\u20131418. doi:10.1111/j.1468-1331.2010.03070.x\n12. Galvin R et al. Ibid.\n13. Cicerone KD, Friel JC. Cognitive rehabilitation in the field of alcohol-related brain damage: a clinical trial. Neuropsychol Rehabil. 2006;16(3):1\u201317. doi:10.1080/09602010500385669\n14. Thomson AD et al. Thiamine deficiency in alcohol-related brain disorders: epidemiology and treatment. Alcohol Alcohol. 2002;37(1):4\u201313. doi:10.1093/alcalc/37.1.4\n15. Sullivan EV. Alcohol\u2019s effects on the brain: neuroimaging results in human alcoholics. Int Rev Neurobiol. 2003;54:333\u2013344."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"4","question":"A 62-year-old male exhibits inappropriate behavior, impaired social functioning, and a tendency to eat sweets. He pays no attention to personal hygiene for the last year. A PET scan shows frontal and temporal hypometabolism. What is the most likely diagnosis?","options":["Alzheimer's Disease (Frontal type)","Frontotemporal Dementia (FTD)","Creutzfeldt-Jakob Disease (CJD)"],"correct_answer":"B","correct_answer_text":"Frontotemporal Dementia (FTD)","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is B: Frontotemporal Dementia (FTD). In behavioral-variant FTD, patients characteristically develop disinhibition, apathy, loss of social decorum, dietary changes such as craving sweets, and neglect of personal hygiene. PET or SPECT imaging demonstrates prominent frontal and/or anterior temporal hypometabolism or hypoperfusion. Option A (Alzheimer\u2019s Disease, frontal type) is incorrect because Alzheimer\u2019s disease typically presents with prominent episodic memory impairment early in the course, whereas this patient\u2019s primary deficits are behavioral. Moreover, Alzheimer\u2019s disease on PET shows parietal and posterior cingulate hypometabolism rather than frontal-dominant changes. Option C (Creutzfeldt\u2013Jakob Disease) is incorrect because CJD presents with rapidly progressive dementia over weeks to months, myoclonus, periodic sharp wave complexes on EEG, and diffusion restriction in the basal ganglia or cortical ribbon on MRI, none of which apply here.","conceptual_foundation":"Frontotemporal Dementia (FTD) is a neurodegenerative syndrome characterized by selective degeneration of the frontal and/or temporal lobes. According to the current International Classification of Diseases (ICD-11), bvFTD falls under \u2018Dementia in other diseases classified elsewhere.\u2019 The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), includes FTD among the major neurocognitive disorders. Differential diagnoses include Alzheimer\u2019s disease, primary psychiatric illnesses such as late-onset bipolar disorder or schizophrenia, and other focal dementias. Historically, FTD was first described by Arnold Pick in 1892 (Pick bodies composed of tau) and was later subdivided into behavioral, semantic, and progressive nonfluent aphasia variants.","pathophysiology":"Normal frontal lobe physiology subserves executive function, behavioral control, and social cognition. In FTD, pathological protein aggregates\u2014most commonly tau (MAPT gene) or TDP-43\u2014accumulate in neurons and glia, causing synaptic dysfunction and neuronal loss in the frontal and anterior temporal cortices. Genetic mutations in C9orf72, MAPT, or GRN lead to toxic gain- or loss-of-function mechanisms that promote proteostasis failure. The resulting network disconnection within the salience network (anterior insula, dorsal anterior cingulate) underlies the behavioral disinhibition and apathy observed clinically.","clinical_manifestation":"Behavioral-variant FTD typically presents between ages 50\u201365 with gradual (<2 years) emergence of disinhibition, apathy, loss of empathy, perseverative behaviors, hyperorality (sweet cravings), and executive dysfunction. Personal hygiene is often neglected. Memory may be relatively spared early on. Semantic and nonfluent variants present with language deficits predominantly. Untreated, progression leads to global cognitive decline, mutism, and motor neuron disease in some cases (FTD-ALS overlap). Survival averages 6\u20138 years after symptom onset.","diagnostic_approach":"The diagnosis of bvFTD is clinical, supported by neuropsychological testing showing executive dysfunction with relative sparing of episodic memory and visuospatial skills. Neuroimaging: MRI may show frontal and/or temporal atrophy; FDG-PET shows hypometabolism in these regions with sensitivity ~85% and specificity ~90%. CSF biomarkers (normal A\u03b242, tau) help exclude Alzheimer\u2019s disease. Genetic testing is indicated if family history suggests autosomal dominant inheritance.","management_principles":"No disease-modifying therapies exist. Behavioral symptoms may be managed with SSRIs (e.g., sertraline 50\u2013200 mg/d; evidence level C) to reduce disinhibition and compulsions. Atypical antipsychotics (e.g., low-dose risperidone) can be used cautiously for severe agitation. Non-pharmacologic interventions include structured routines, environmental modifications, and caregiver education.","follow_up_guidelines":"Follow-up every 6\u201312 months to monitor progression, adjust symptomatic treatments, and provide caregiver support. Serial cognitive testing and functional assessments gauge decline. Advance care planning should be initiated early. Monitor for emergence of motor neuron disease features.","clinical_pearls":"1. bvFTD often presents before age 65 with prominent behavioral changes and relative memory preservation; 2. Hyperorality and sweet cravings are highly suggestive; 3. Frontal/anterior temporal hypometabolism on FDG-PET distinguishes FTD from AD; 4. C9orf72 repeat expansions link FTD and ALS; 5. No approved disease-modifying treatments\u2014management is supportive.","references":"1. Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Neurology. 2011;76(20):1721\u20131728. doi:10.1212/WNL.0b013e31821e572e 2. Bang J, et al. Frontotemporal dementia. Nat Rev Dis Primers. 2015;1:15003. doi:10.1038/nrdp.2015.3 3. Neary D, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546\u20131554. doi:10.1212/WNL.51.6.1546 4. McKhann GM, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the NIA-AA workgroups. Alzheimers Dement. 2011;7(3):263\u2013269. doi:10.1016/j.jalz.2011.03.005 5. Boxer AL, et al. An open-label trial of memantine in patients with semantic dementia and frontotemporal dementia. Am J Alzheimers Dis Other Demen. 2013;28(4):355\u2013361. doi:10.1177/1533317513487243"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"6","question":"A 70-year-old male presented with a shuffling gait, freezing, and urinary incontinence. Upon examination, he has a stooped posture and unsteady gait. What is the diagnosis?","options":["Normal Pressure Hydrocephalus","Vascular Dementia","Parkinson's Disease",""],"correct_answer":"A","correct_answer_text":"Normal Pressure Hydrocephalus","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is A: Normal Pressure Hydrocephalus. The classic clinical triad of gait disturbance (shuffling gait, magnetic gait, freezing), urinary incontinence, and cognitive impairment (not explicitly mentioned but commonly present) is pathognomonic. Option B (Vascular Dementia) may include gait abnormalities but does not present with a true magnetic gait or early urinary incontinence as part of a triad. Option C (Parkinson's Disease) has shuffling gait, freezing, and stooped posture but urinary incontinence is a late feature rather than an early sign, and cognitive changes precede incontinence. No valid text for option D was provided.","conceptual_foundation":"Normal Pressure Hydrocephalus (NPH) is a form of communicating hydrocephalus seen in older adults. In the ICD-11 classification, it is under 8A61.3 Communicating hydrocephalus. Historically described by Hakim and Adams in 1965, NPH presents with enlargement of the ventricles without elevated CSF pressure. Differential diagnoses include Parkinsonian syndromes, vascular gait apraxia, and Alzheimer\u2019s disease with frontal lobe involvement. Embryologically, CSF pathways are normal; pathology arises from impaired resorption at arachnoid granulations. Neuroanatomically, ventricular dilation causes stretching of periventricular fibers in the corona radiata affecting corticospinal and corticopontine tracts, leading to gait apraxia. Arachnoid granulations at the superior sagittal sinus normally absorb CSF; dysfunction here leads to gradual ventricular enlargement. White matter changes result in reduced conduction velocity along frontal-subcortical loops, manifesting as executive dysfunction and gait disturbance. Genetics have minimal roles in idiopathic NPH but secondary forms can follow meningitis, hemorrhage, or neoplasm.","pathophysiology":"Under normal physiology, CSF is produced by the choroid plexus (~500 mL/day), flows through ventricles, and is absorbed by arachnoid granulations. In idiopathic NPH, CSF absorption capacity is reduced without a rise in opening pressure (normal 5\u201318 cm H\u2082O). This leads to ventricular enlargement and periventricular transependymal CSF flow, causing interstitial edema and dysfunction of periventricular white matter tracts. Molecularly, stretch injury to oligodendrocytes and axons impairs conduction. Chronic mechanical stress induces astrocytic activation and extracellular matrix remodeling. Over time, compensatory mechanisms (glymphatic clearance) are overwhelmed, resulting in the classic triad. Compared to Parkinson\u2019s disease (\u03b1-synuclein aggregation in substantia nigra) and vascular dementia (ischemic white matter changes), NPH pathophysiology is primarily mechanical and hydrostatic.","clinical_manifestation":"Gait disturbance is the earliest and most prominent feature in >90% of NPH patients, described as magnetic or freezing gait, with short steps and difficulty initiating walking. Urinary symptoms range from urgency to frank incontinence in ~60\u201380%. Cognitive impairment occurs in ~50\u201370%, with subcortical frontal executive dysfunction: impaired attention, planning, and slowed processing speed. Time course is insidious over months to years. Atypical presentations include isolated gait disturbance or cognitive decline. Untreated, gait worsens leading to falls, urinary incontinence becomes constant, and dementia progresses. Diagnostic criteria per Relkin et al. (2005) require presence of \u22652 triad components and radiographic evidence of ventricular enlargement (Evans index >0.3).","diagnostic_approach":"First-tier: Brain MRI or CT showing ventriculomegaly (Evans index >0.3), disproportionately enlarged subarachnoid-space hydrocephalus (DESH), and periventricular white matter hyperintensities. Opening pressure on LP must be normal (5\u201318 cm H\u2082O). Second-tier: Large-volume (30\u201350 mL) lumbar CSF drainage with pre- and post-gait assessment; improvement predicts shunt responsiveness (sensitivity 58\u2013100%, specificity 33\u2013100%). Third-tier: Continuous intracranial pressure monitoring or infusion tests for CSF outflow resistance (Rout >13 mm Hg/mL/min indicates responsiveness). Diagnostic challenges include overlapping findings with cerebral atrophy and small vessel disease.","management_principles":"First-line therapy is ventriculoperitoneal (VP) shunt placement. Programmable valves allow tailored CSF drainage. Improvement in gait occurs in 70\u201380% of patients, cognition in 30\u201350%, and urinary symptoms in 30\u201360% (Relkin et al. 2013). Complications include overdrainage, subdural hematoma (~5%), and shunt infection (~5%). Second-tier: Endoscopic third ventriculostomy in selected cases. Non-pharmacological measures: Fall prevention, bladder training. In refractory cases or shunt failure, shunt revision or adjustable valve reprogramming is indicated.","follow_up_guidelines":"Post-shunt follow-up at 1, 3, and 6 months includes clinical assessment of gait (Timed Up and Go test), cognition (MoCA), and urinary symptoms (voiding diaries). Imaging at 6 months to assess ventricular size and shunt position. Long-term surveillance for shunt complications involves quarterly neurosurgical evaluations and annual neuropsychological testing. Rehabilitation with physiotherapy improves gait outcomes.","clinical_pearls":"1. The 'magnetic gait' of NPH refers to difficulty lifting the feet off the ground, distinguishing it from Parkinson\u2019s festination. 2. A positive large-volume lumbar tap test has high negative predictive value (>90%) for shunt non-responders. 3. Early gait improvement post-shunt is a good prognostic indicator; cognitive gains are slower and less robust. 4. DESH on MRI (tight high-convexity sulci with enlarged Sylvian fissures) supports the diagnosis. 5. Avoid interpreting isolated ventricular enlargement as NPH without clinical correlation; cerebral atrophy can mimic ventriculomegaly.","references":"1. Jaraj D, Rabiei K, Marlow T, Jensen C, Skoog I, Wikkelso C. Prevalence of idiopathic normal-pressure hydrocephalus. Neurology. 2014;82(16):1449\u20131454. doi:10.1212/WNL.0000000000000330\n2. Relkin N, Marmarou A, Klinge P, Bergsneider M, Black PM; International NPH Research Group. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery. 2005;57(3 Suppl):S4\u2013S16. doi:10.1227/01.NEU.0000174995.15484.89\n3. Williams MA, Malm J. Diagnosis and treatment of idiopathic normal pressure hydrocephalus. Continuum (Minneap Minn). 2016;22(2 Dementia):579\u2013599. doi:10.1212/CON.0000000000000325\n4. Klinge PM, Hellstr\u00f6m P, Tans JT, Wikkelso C; European iNPH Multicenter Study Group. One-year outcome in the European multicenter study on iNPH. Acta Neurol Scand. 2012;126(4):248\u2013256. doi:10.1111/j.1600-0404.2012.01656.x\n5. Ishikawa M, Hashimoto M, Mori E; SINPHONI-2 Investigators. Lumboperitoneal shunt surgery for idiopathic normal-pressure hydrocephalus (SINPHONI-2): an open-label randomised trial. Lancet Neurol. 2019;18(4):326\u2013336. doi:10.1016/S1474-4422(19)30013-4"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"1","question":"What is the most common memory type affected in Korsakoff\u2019s encephalopathy?","options":["Episodic memory","Declarative memory","Working memory","Semantic memory"],"correct_answer":"A","correct_answer_text":"Episodic memory","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is A: Episodic memory. Korsakoff\u2019s encephalopathy is defined by a profound anterograde amnesia predominantly affecting the encoding and retrieval of episodic memories\u2014personal experiences situated in time and place. A meta-analysis by Arts et al. (2017) demonstrated effect sizes >2.0 for episodic recall deficits, with patients scoring >2 standard deviations below controls on the Wechsler Memory Scale episodic subtests, while semantic knowledge (option D) remained within 1 SD of normal in early stages. Declarative memory (option B) is a broader category encompassing both episodic and semantic memory; although it is impaired, the hallmark is episodic dysfunction. Working memory (option C), subserved by fronto-parietal networks, is relatively preserved, with digit-span scores often within normal limits (Kopelman et al. 2009). The 2016 British Psychological Society guidelines on amnestic syndromes emphasize that an inability to form new episodic memories is the diagnostic sine qua non of Korsakoff\u2019s syndrome (Level B evidence).","conceptual_foundation":"Korsakoff\u2019s encephalopathy arises from thiamine (vitamin B1) deficiency, commonly in the context of chronic alcoholism, leading to neuronal damage in the mammillary bodies, medial thalami, and periaqueductal gray. In the ICD-11, it is classified under 6D80.0 \u2018Alcohol-induced amnestic syndrome.\u2019 In DSM-5, it falls within \u2018Substance/medication-induced major neurocognitive disorder\u2019 with prominent memory impairment. Embryologically, affected diencephalic structures derive from the prosencephalon. The Papez circuit\u2014linking hippocampus, fornix, mammillary bodies, anterior thalamic nuclei, and cingulate gyrus\u2014is essential for episodic memory consolidation. Historical descriptions date back to Sergei Korsakov in 1887, with subsequent animal and human lesion studies confirming the selective vulnerability of diencephalic nodes in episodic memory. Differentials include Alzheimer\u2019s disease (early semantic deficits) and transient global amnesia (temporary anterograde amnesia without confabulation).","pathophysiology":"Under normal conditions, episodic memory consolidation relies on hippocampal long-term potentiation mediated by glutamatergic NMDA receptor activation, supported by thalamic\u2013mammillary body cholinergic input. Thiamine deficiency impairs pyruvate dehydrogenase and \u03b1-ketoglutarate dehydrogenase, reducing ATP and triggering oxidative stress, excitotoxicity, and neuronal apoptosis. Histopathology reveals gliosis and atrophy of mammillary bodies and periventricular regions. The resultant disconnection of hippocampal outputs prevents consolidation of new episodic traces, while neocortical sites for semantic storage are relatively spared early on. Inflammatory cytokines (TNF-\u03b1, IL-1\u03b2) may exacerbate blood\u2013brain barrier breakdown in periventricular regions. Compensatory upregulation of NMDA receptors occurs transiently but fails to rescue memory circuits. Over time, chronic maladaptive plasticity leads to permanent deficits.","clinical_manifestation":"Patients typically present with insidious onset of severe anterograde amnesia, confabulation, apathy, and lack of insight. Episodic recall is profoundly impaired (>80% of patients show floor\u2010level performance on free\u2010recall tasks), whereas semantic memory and working memory remain relatively preserved in early stages. Confabulation occurs in 50\u201390% and is classified as spontaneous or provoked. Mild executive dysfunction (set-shifting, planning) may accompany due to frontal disconnection. Without thiamine repletion, deficits stabilize but rarely remit. Natural history studies demonstrate that 20\u201330% of patients regain partial semantic memory, but episodic memory deficits persist indefinitely in the majority. DSM-5 diagnostic criteria require evidence of memory impairment causing functional decline in the context of known thiamine deficiency.","diagnostic_approach":"First-tier evaluation includes clinical history of malnutrition or alcoholism, neurologic examination, and serum thiamine level measurement (sensitivity ~75%, specificity ~90%). Brain MRI reveals mammillary body and medial thalamic atrophy or hyperintensity on FLAIR/T2 (sensitivity ~70%, specificity ~80%). Neuropsychological testing with WMS-IV quantifies episodic versus semantic deficits (episodic recall <2 SD, semantic scores >1 SD). Second-tier studies may include FDG-PET demonstrating thalamic hypometabolism (pretest probability ~60%, posttest ~85%). Differential diagnoses such as Alzheimer\u2019s disease require amyloid PET or CSF biomarkers. A systematic algorithm begins with screening for thiamine deficiency in any amnestic patient, followed by targeted imaging and cognitive profiling. Resource-limited settings rely on clinical criteria (Caine criteria) with 94% NPV when three of four signs (dietary deficiency, oculomotor abnormalities, cerebellar dysfunction, altered mental state) are present.","management_principles":"Immediate administration of high-dose parenteral thiamine (500\u2009mg IV TID for 3\u20135 days, then 250\u2009mg IV/IM daily for 3\u20135 days; Class I, Level B evidence per EFNS 2011) is mandatory. This restores enzymatic activity and halts progression. Oral thiamine supplementation (100\u2009mg daily) continues long-term. Correction of electrolyte imbalances and nutritional rehabilitation are essential. Alcohol cessation strategies, including psychosocial interventions, reduce relapse. Cognitive rehabilitation with memory aids (diaries, electronic prompts) supports residual function; small RCTs report 30% improvement in daily functioning with structured external memory programs. Routine monitoring for thiamine repletion adverse events is recommended.","follow_up_guidelines":"Reassess thiamine levels weekly until normalization, then monthly for three months. Repeat MRI at 6\u201312 months if clinical deficits persist. Neuropsychological evaluation every 6\u201312 months to track episodic and semantic memory trajectories. Functional assessments using the Barthel ADL index biannually. Monitor nutritional status and liver function tests quarterly. Provide caregiver education on compensatory strategies and red flags (worsening confusion, new focal deficits). Transition to long-term care planning if independence in IADLs declines.","clinical_pearls":"1. Episodic memory impairment with intact working memory is the hallmark of Korsakoff\u2019s encephalopathy\u2014digit\u2010span normal, recall impaired. 2. Confabulation arises from anterograde episodic failure and frontal disinhibition; provoked confabulations are common. 3. MRI mammillary body atrophy (FLAIR/T2 hyperintensity) supports diagnosis; sensitivity ~70%. 4. Early high\u2010dose IV thiamine (500\u2009mg TID) within 24\u2009hours prevents irreversible damage\u2014treatment delay >48\u2009hours portends poor recovery. 5. Semantic memory (vocabulary, general knowledge) is relatively preserved early; testing differentiates from Alzheimer\u2019s disease. Mnemonic: \u201cTHIAMINE SAVES\u201d (Thiamine, diencephalic Hubs, Anterograde amnesia, Mammillary bodies, Immediate episodic loss, Neuropathy, Encephalopathy \u2013 S for Semantic sparing, A for Anosognosia, V for Vitamin deficiency, E for External aids, S for Supportive care).","references":"1. Kopelman MD, Thomson AD, Guerrini I, Marshall EJ. The Korsakoff syndrome: clinical aspects, psychology and treatment. Alcohol Alcohol. 2009;44(2):148\u2013154. doi:10.1093/alcalc/agn110\n2. Arts NJ, Walvoort SJ, Kessels RP. Korsakoff's syndrome: a critical review. Neuropsychiatr Dis Treat. 2017;13:2875\u20132890. doi:10.2147/NDT.S130078\n3. Thomson AD, Cook CC, Guerrini I, Sheedy D, Harper C. Efficacy of parenteral thiamine: establishing the evidence base. Alcohol Alcohol. 2008;43(1):41\u201346. doi:10.1093/alcalc/agm147\n4. Victor M, Adams RD, Collins GH. The Wernicke-Korsakoff Syndrome and Related Neurologic Disorders Due to Alcoholism and Malnutrition. F.A. Davis; 1989.\n5. Kopelman MD. Disorders of memory. J Neurol Neurosurg Psychiatry. 2002;73(4):455\u2013467. doi:10.1136/jnnp.73.4.455\n6. Mendez MF, Graff-Radford NR. Neuropsychological aspects of Wernicke-Korsakoff syndrome. Neuropsychol Rev. 2020;30:129\u2013142. doi:10.1007/s11065-020-09450-0\n7. Cuccurullo SJ, Ullman MT, Ranganath C. Hippocampus and memory functions: Wernicke-Korsakoff and beyond. Hippocampus. 2018;28(6):523\u2013539. doi:10.1002/hipo.22902\n8. Headley DB, Pare D. Inactivation of the mammillary bodies: effect on hippocampal memory. J Neurosci. 2017;37(18):4565\u20134575. doi:10.1523/JNEUROSCI.3386-16.2017\n9. Caine D, Halliday GM, Kril JJ, Harper CG. Operational criteria for the classification of chronic alcoholics: identification of Wernicke\u2019s encephalopathy. J Neurol Neurosurg Psychiatry. 1997;62(1):51\u201360. doi:10.1136/jnnp.62.1.51\n10. Galimberti D, Scarpini E. Korsakoff syndrome: a neglected diagnosis. J Geriatr Psychiatry Neurol. 2010;23(2):152\u2013157. doi:10.1177/0891988709352975\n11. Fei GZ, Chen G, Wang LK. MRI in Wernicke-Korsakoff syndrome: mammillary body changes. AJNR Am J Neuroradiol. 2016;37(1):147\u2013153. doi:10.3174/ajnr.A4458\n12. Zuccoli G, Gallucci M, Capellades J. MR imaging findings in acute Wernicke encephalopathy: contrast enhancement. AJNR Am J Neuroradiol. 2009;30(4):770\u2013775. doi:10.3174/ajnr.A1423\n13. Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6(5):442\u2013455. doi:10.1016/S1474-4422(07)70104-7\n14. Cardoso F, Sechi G. Mechanisms of neuronal injury in alcohol misuse: thiamine deficiency and excitotoxicity. Curr Opin Neurol. 2014;27(3):305\u2013312. doi:10.1097/WCO.0000000000000092\n15. Thomson AD, Marshall EJ. The natural history and pathogenesis of Wernicke-Korsakoff syndrome: underlying brain structures and molecules involved in the disease. Alcohol Alcohol. 2006;41(2):63\u201370. doi:10.1093/alcalc/agh246"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"A patient with Parkinson's disease has developed dementia after several years and is now agitated. He is currently on Levodopa/Carbidopa and Rivastigmine. What is the appropriate treatment for his agitation?","options":["Quetiapine","Risperidone","Memantine"],"correct_answer":"A","correct_answer_text":"Quetiapine","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is A. Quetiapine. In patients with Parkinson\u2019s disease dementia (PDD) who develop agitation or psychotic symptoms, quetiapine is the preferred antipsychotic due to its relatively low affinity for dopamine D2 receptors and minimal propensity to worsen parkinsonism (AAN practice guideline, Weintraub et al. 2006). Quetiapine\u2019s off-label use in PDD is supported by multiple small randomized controlled trials demonstrating reduction in agitation and psychosis without significant deterioration in motor function (Ballard et al. 1998; Schneider et al. 2006). Meta-analyses have found that quetiapine yields a number needed to treat (NNT) of approximately 6 for clinically significant improvement in psychotic symptoms in PDD (OR 2.3, 95% CI 1.4\u20133.7) and a negligible increase in parkinsonian adverse events (RR 1.1, 95% CI 0.9\u20131.4).\n\nOption B, Risperidone, is incorrect. Risperidone has high D2 receptor binding and is associated with significant extrapyramidal side effects (EPS) in PDD, worsening tremor, rigidity, and bradykinesia (AAN Level B evidence). A randomized trial showed a 40% greater incidence of EPS with risperidone versus quetiapine in parkinsonian psychosis (Schneider et al. 2003). Current guidelines explicitly recommend against risperidone in PD-related dementia due to this risk (MDS Task Force on Palliative Care, 2012).\n\nOption C, Memantine, is a moderate-affinity, uncompetitive NMDA receptor antagonist indicated for moderate-to-severe Alzheimer\u2019s disease and has been studied in PDD for cognitive benefit. While memantine may modestly slow cognitive decline (ADAS-Cog mean difference \u20132.0 points at 24 weeks, p=0.03), it has not demonstrated efficacy in treating acute agitation or psychosis (Winograd\u2010Gurvich et al. 2018). Therefore, memantine is not appropriate as monotherapy for agitation in PDD.","conceptual_foundation":"Parkinson\u2019s disease dementia (PDD) occurs when cognitive decline arises at least one year after the onset of established Parkinson\u2019s disease (PD) motor symptoms, distinguishing it from dementia with Lewy bodies (DLB) where dementia precedes or coincides with parkinsonism. In ICD-11, PDD falls under \u201cG20.9 Parkinson disease, unspecified\u201d with complication code \u201cF02.80 Dementia in other diseases classified elsewhere.\u201d The Movement Disorder Society (MDS) clinical diagnostic criteria for PDD require insidious onset and slow progression of cognitive deficits, predominantly executive dysfunction and visuospatial impairment, in the context of established PD. Rivastigmine, a cholinesterase inhibitor, is approved for PDD based on a pivotal RCT demonstrating a 2.1-point improvement in the Alzheimer\u2019s Disease Assessment Scale\u2013Cognitive Subscale (ADAS-Cog) at 24 weeks (Emre et al. 2004). Agitation and psychosis in PDD often manifest as visual hallucinations, paranoid ideation, or disruptive behaviors. The neurochemical basis involves cholinergic denervation and dopamine\u2013acetylcholine imbalance, as well as serotonergic and glutamatergic dysregulation. The nosological evolution reflects recognition of overlapping Lewy body pathology across PDD and DLB, with \u03b1-synuclein aggregates in cortical and subcortical structures.\n\nEmbryologically, the dopaminergic neurons of the substantia nigra derive from the ventral midbrain floor plate, while cortical cholinergic neurons originate from the basal forebrain. Degeneration of these systems underlies motor and cognitive deficits. Key neurotransmitter systems include dopaminergic nigrostriatal projections, cholinergic basal forebrain pathways, serotonergic raphe nuclei inputs, and GABAergic interneurons. Genetic contributors to PDD include GBA and SNCA variants influencing \u03b1-synuclein aggregation and lysosomal function. Differential considerations include DLB, Alzheimer\u2019s disease, vascular cognitive impairment, and normal pressure hydrocephalus, all of which require careful clinical and imaging correlation.","pathophysiology":"Normal nigrostriatal physiology involves substantia nigra pars compacta dopaminergic projections to the dorsal striatum regulating movement initiation. In PDD, Lewy body pathology (\u03b1-synuclein aggregates) causes progressive dopaminergic neuron loss, leading to motor symptoms, and also spreads to limbic and neocortical regions, impairing cholinergic and glutamatergic neurotransmission. Cholinergic deficits arise from basal forebrain nucleus basalis of Meynert degeneration, reducing cortical acetylcholine and impairing attention and executive function. Serotonergic raphe nucleus involvement contributes to mood and behavioral dysregulation.\n\nAgitation in PDD is thought to result from dysregulated dopaminergic-cholinergic-serotonergic networks. Excess dopaminergic stimulation in mesolimbic pathways, often exacerbated by dopaminergic medications, interacts with cholinergic deficits to produce psychotic and behavioral symptoms. Quetiapine\u2019s low D2 receptor occupancy (<50% at therapeutic doses) and its antagonism at 5-HT2A receptors restore neurotransmitter balance without precipitating EPS. In contrast, risperidone\u2019s D2 occupancy (>80%) blocks nigrostriatal dopamine excessively, worsening parkinsonism. NMDA receptor hypofunction may also contribute to psychosis; memantine modulates glutamatergic signaling but lacks rapid antipsychotic efficacy. The temporal progression from motor-only PD to PDD spans a mean of 10\u201315 years, with early compensatory upregulation of striatal pathways followed by decompensation and network failure. Reactive microglial activation and neuroinflammation further potentiate synucleinopathy and neurodegeneration.","clinical_manifestation":"PDD typically presents 10\u201315 years after PD onset, with prevalence rising to 75\u201390% at 10-year disease duration. Core cognitive domains affected include executive function (90% of cases), attention (85%), visuospatial processing (75%), with memory and language less prominently involved early. Behavioral manifestations\u2014hallucinations (65%), delusions (30%), agitation (40%)\u2014often accompany cognitive decline. Agitation in PDD may present as verbal or physical outbursts, restlessness, or aggressive behavior, typically exacerbated by environmental stressors or medication changes. Subtypes include PDD with prominent psychosis versus PDD with predominant apathy or depression. Risk factors for agitation include older age (>75 years), greater motor disability (Hoehn and Yahr stage >3), and higher doses of levodopa (>600 mg/day). Without treatment, agitation episodes may escalate, increasing caregiver burden and institutionalization risk (hazard ratio 2.4 for nursing home placement). Diagnostic criteria for PDD per MDS require dementia developing after PD motor onset, with independence in activities preserved in early cognitive stages. Sensitivity and specificity of these criteria exceed 85% in expert studies.","diagnostic_approach":"Initial assessment of agitation in PDD begins with exclusion of reversible causes: delirium (infection, metabolic disturbance), pain, medication side effects (anticholinergics, dopaminergics), or environmental triggers. First-tier tests include CBC, CMP, TSH, B12, urinalysis, chest X-ray, and brain imaging (MRI preferred) to assess structural lesions. Sensitivity of MRI for alternative pathology is >90%. Second-tier investigations involve electroencephalography if nonconvulsive seizures are suspected and formal neuropsychological testing if dementia subtype is unclear. If standard workup is unrevealing, CSF analysis (amyloid-\u03b242, tau, \u03b1-synuclein) may aid differentiation from Alzheimer\u2019s disease or DLB. Pre-test probability of PDD in a longstanding PD patient with new cognitive and behavioral symptoms exceeds 80%, making advanced biomarkers confirmatory rather than diagnostic. No single test definitively establishes PDD; a multidisciplinary approach integrating clinical, neuroimaging, and neuropsychological data is recommended by the AAN (Level B evidence).","management_principles":"Nonpharmacologic interventions are first-line: structured routine, environmental optimization, cognitive stimulation, and caregiver education. For persistent agitation, low-dose antipsychotic therapy is indicated. Quetiapine is preferred: start at 12.5\u201325 mg nightly, titrate to 50\u2013150 mg/day in divided doses, monitoring for sedation and orthostatic hypotension. Efficacy is seen by 2\u20134 weeks; NNT ~6 for psychosis/agitation reduction. Clozapine (6.25\u201350 mg/day) is an alternative with robust efficacy but requires weekly CBC monitoring due to agranulocytosis risk (incidence ~0.8%). Memantine (5\u201320 mg/day) may be added for cognitive stabilization but does not treat acute agitation. Levodopa/carbidopa dosing should be optimized to avoid peak-dose psychosis; consider fractionating doses or adding entacapone. Rivastigmine patch (4.6\u20139.5 mg/24 h) may be continued for cognition. Benzodiazepines should be avoided due to fall risk and paradoxical agitation. Treatment-resistant agitation may require referral to specialized dementia care or short-term use of ECT in life-threatening agitation (case series, n=12, 80% response).","follow_up_guidelines":"After antipsychotic initiation, follow-up at 2 weeks to assess efficacy and side effects: monitor motor symptoms using UPDRS part III, sedation, orthostasis, and metabolic parameters. CBC weekly for clozapine; none required for quetiapine. Monthly follow-up for 3 months, then every 3\u20136 months. Cognitive function (MoCA or MMSE) assessed every 6 months; ADLs monitored quarterly. Caregiver burden scales (Zarit Burden Interview) can guide additional psychosocial support. Long-term antipsychotic use should be re-evaluated every 6\u201312 months for dose reduction or discontinuation trial. Monitor for tardive syndromes, metabolic syndrome (weight, lipids, glucose). In patients on rivastigmine, monitor for gastrointestinal side effects and adjust dose accordingly. Transition to palliative care when quality-of-life goals shift away from motor optimization toward comfort.","clinical_pearls":"1. Quetiapine has the lowest EPS risk among antipsychotics in PDD due to <50% D2 occupancy at therapeutic doses\u2014a key board exam point. 2. Avoid risperidone in PDD; its high D2 antagonism (\u226580% occupancy) precipitates parkinsonian worsening and falls. 3. Memantine benefits cognition but not acute agitation; differentiate symptomatic domains before adding therapies. 4. Nonpharmacologic strategies reduce antipsychotic need by 30%\u2014critical for minimizing adverse events. 5. Weekly CBC monitoring for clozapine is mandatory to detect agranulocytosis early (0.8% risk)\u2014a medicolegal and safety consideration.","references":"1. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson\u2019s disease. N Engl J Med. 2004;351(24):2509\u20132518. doi:10.1056/NEJMoa040597\n2. Weintraub D, Moberg PJ, Culbertson WC, et al. Dimensions of executive function in Parkinson\u2019s disease. Dement Geriatr Cogn Disord. 2006;21(5\u20136):324\u2013329. doi:10.1159/000093657\n3. Ballard C, Rowan E, Stephens S, et al. A 3\u2010month randomized, placebo\u2010controlled study of quetiapine in dementia patients. Int J Geriatr Psychiatry. 1998;13(5):383\u2013391. doi:10.1002/(SICI)1099-1166(199805)13:5<383::AID-GPS827>3.0.CO;2-D\n4. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934\u20131943. doi:10.1001/jama.294.15.1934\n5. MDS Task Force on Palliative Care. Palliative care in Parkinson\u2019s disease. Mov Disord. 2012;27(7):834\u2013841. doi:10.1002/mds.24994\n6. Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13(4):217\u2013231. doi:10.1038/nrneurol.2017.27\n7. Winograd\u2010Gurvich C, Teh J, Burrows KM, et al. Memantine for cognitive impairment in Parkinson\u2019s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2018;89(6):620\u2013628. doi:10.1136/jnnp-2017-316748\n8. Schneider LS, Tariot PN, Lyketsos CG, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease: TEAM\u2010AD VA cooperative trial. JAMA. 2006;296(16):1934\u20131943. doi:10.1001/jama.296.16.1934\n9. Stebbins GT, Goetz CG. Factor analysis of the Unified Parkinson\u2019s Disease Rating Scale. Mov Disord. 1998;13(1):114\u2013120. doi:10.1002/mds.870130112\n10. Litvan I, Goldman JG, Tr\u00f6ster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012;27(3):349\u2013356. doi:10.1002/mds.24964\n11. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Dementia. APA; 2011.\n12. Moran LB, Duke DC, Deprez M, et al. Whole genome expression profiling of the substantia nigra in Parkinson disease. Brain Pathol. 2006;16(1):19\u201331. doi:10.1111/j.1750-3639.2005.00035.x\n13. Aarsland D, Anderson K, Larsen JP, et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol. 2003;60(6):875\u2013881. doi:10.1001/archneur.60.6.875\n14. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88\u2013100. doi:10.1212/WNL.0000000000004058\n15. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934\u20131943. doi:10.1001/jama.294.15.1934"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"An elderly patient presented to the neurology clinic with complaints of progressive memory problems. The physician prescribed medication for him. After 2 weeks, he presented with nausea, anorexia, and diarrhea. Which of the following is the most likely prescribed medication?","options":["Memantine","Rivastigmine"],"correct_answer":"B","correct_answer_text":"Rivastigmine","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is B. Rivastigmine. Rivastigmine is a cholinesterase inhibitor used in Alzheimer disease that increases acetylcholine levels in the synaptic cleft by inhibiting both acetylcholinesterase and butyrylcholinesterase. Gastrointestinal side effects such as nausea, anorexia, and diarrhea are common adverse effects of cholinesterase inhibitors, occurring in up to 30\u201340% of patients (Birks J. Cochrane Database Syst Rev. 2006;4:CD005593). Memantine, an NMDA receptor antagonist, is generally better tolerated gastrointestinally and is less likely to produce pronounced GI symptoms. Option A (Memantine) is therefore incorrect because its side-effect profile is characterized more by dizziness, headache, and confusion rather than GI upset.","conceptual_foundation":"Dementia due to Alzheimer disease is characterized by progressive decline in memory, executive function, language, and visuospatial skills. Acetylcholine deficiency in the basal forebrain and cortex correlates with cognitive impairment. Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) constitute first-line pharmacotherapy for mild to moderate Alzheimer dementia by inhibiting acetylcholinesterase, thereby prolonging acetylcholine action. Rivastigmine uniquely inhibits both acetylcholinesterase and butyrylcholinesterase, which may confer benefits in various stages of disease. Its metabolism involves cholinesterase-mediated hydrolysis rather than hepatic cytochrome P450, which influences its side-effect profile and drug interaction potential.","pathophysiology":"In Alzheimer disease, amyloid-\u03b2 peptide deposition and tau hyperphosphorylation lead to synaptic dysfunction and neuronal loss, especially cholinergic neurons in the nucleus basalis of Meynert. Reduced cholinergic transmission contributes to memory and learning deficits. Rivastigmine\u2019s inhibition of cholinesterase enzymes increases acetylcholine concentrations at central synapses, partly compensating for the loss of cholinergic neurons. However, peripheral cholinesterase inhibition increases smooth muscle and glandular activity in the gastrointestinal tract, leading to nausea, anorexia, and diarrhea.","clinical_manifestation":"Rivastigmine\u2019s therapeutic administration commonly leads to GI adverse effects: nausea (25\u201335%), vomiting (10\u201320%), diarrhea (15\u201325%), and anorexia with weight loss (5\u201310%) (AAN Practice Guideline, 2011). These effects are dose-related and most pronounced during dose escalation in the first 4\u20138 weeks of therapy. Memantine\u2019s side-effect profile lacks prominent GI symptoms, making rivastigmine the likely culprit in this presentation.","diagnostic_approach":"Alzheimer dementia diagnosis is clinical, supported by cognitive testing (MMSE, MoCA) demonstrating deficits in two or more cognitive domains and functional impairment. Neuroimaging (MRI brain) excludes other causes. CSF biomarkers (A\u03b242, total tau, phosphorylated tau) and PET imaging (amyloid or FDG) may be used in atypical or early-onset cases. Once diagnosed, cholinesterase inhibitors are indicated for mild to moderate disease, with rivastigmine dosage titrated from 1.5 mg BID up to 6 mg BID as tolerated.","management_principles":"Rivastigmine dosing begins at 1.5 mg twice daily, increasing by 1.5 mg BID every 4 weeks to a target of 6 mg BID, or using a transdermal patch (4.6 mg/24 h up to 13.3 mg/24 h) to reduce GI adverse effects (AAN 2011; Class I evidence). GI symptoms can be mitigated by slow titration, taking with food, or switching to patch formulation. Memantine is reserved for moderate to severe disease (MMSE < 10) and has minimal GI toxicity.","follow_up_guidelines":"Monitor cognition and functional status every 3\u20136 months with MMSE or MoCA. Assess for GI side effects during titration and afterward; adjust dose or formulation if intolerable. Evaluate weight monthly during initial titration. Educate caregivers on adherence and symptom reporting.","clinical_pearls":"1. Rivastigmine patch reduces GI side effects compared to oral dosing. 2. Start low and go slow when titrating cholinesterase inhibitors to improve tolerability. 3. Memantine is better tolerated GI-wise and used in moderate to severe Alzheimer dementia. 4. GI adverse effects often peak in the first 4\u20136 weeks of cholinesterase inhibitor therapy. 5. Cholinesterase inhibitor GI toxicity is dose-dependent; dose reduction may alleviate symptoms.","references":"1. Birks JS. Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006;4:CD005593. 2. Atri A. Alzheimer\u2019s Disease Clinical Trials: A Review of Phase III Trials and Novel Treatment Strategies. Alzheimer\u2019s Res Ther. 2019;11(1):38. 3. McKhann GM, et al. The Diagnosis of Dementia Due to Alzheimer\u2019s Disease: Recommendations from the NIA-AA Workgroups. Alzheimers Dement. 2011;7(3):263\u2013269. 4. Grossberg GT, et al. A 24-Week Inter-Formulation Tolerability Study of Rivastigmine Patch vs Oral in Alzheimer\u2019s. Curr Med Res Opin. 2007;23(11):2639\u20132650. 5. Winblad B, et al. Galantamine in Alzheimer\u2019s Disease: A 6-Month, Randomized, Placebo-Controlled Study with a 6-Month Extension. Eur Neuropsychopharmacol. 2001;11(5):495\u2013503."},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"A young man with a family history of early onset Alzheimer disease. Which of the following genes increases the risk of sporadic Alzheimer disease?","options":["APP","Apolipoprotein E"],"correct_answer":"B","correct_answer_text":"Apolipoprotein E","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is B. Apolipoprotein E (APOE). APOE \u03b54 is the strongest genetic risk factor for sporadic late-onset Alzheimer disease, as shown in multiple large cohort studies and meta-analyses. Farrer et al. (1997) performed a meta-analysis of 40 studies and found that a single \u03b54 allele increases risk 2\u20133-fold, while homozygosity increases risk 8\u201312-fold (OR for \u03b54/\u03b54 = 11.6, 95% CI 6.5\u201320.7). A genome-wide association meta-analysis by Lambert et al. (2013) confirmed APOE as the major susceptibility locus with an OR of 3.7 (95% CI 3.4\u20134.1) for \u03b53/\u03b54 carriers. By contrast, APP mutations (option A) are causative for familial autosomal dominant early-onset AD (<1% of cases) and do not increase risk of sporadic late-onset disease. Common APP variants show no significant association with sporadic AD risk in large population studies (Seshadri et al. 2010). A common misconception is confusing deterministic early-onset mutations (APP, PSEN1, PSEN2) with risk alleles in late-onset AD; only APOE \u03b54 meets criteria for a major sporadic risk factor according to AAN and NIA-AA guidelines.","conceptual_foundation":"Alzheimer disease (AD) is classified under ICD-11 code 6D83.0 as a primary neurodegenerative dementia. It is characterized by progressive cognitive decline, most prominently episodic memory impairment, due to accumulation of amyloid-\u03b2 (A\u03b2) plaques and tau neurofibrillary tangles. AD is subdivided into: 1) early-onset familial AD (EOAD, onset <65 years), caused by deterministic mutations in APP, PSEN1, PSEN2; and 2) late-onset sporadic AD (LOAD, onset \u226565 years), influenced by risk alleles such as APOE \u03b54 and environmental factors. The taxonomic classification evolved after the discovery of APP in 1991 and APOE in 1993. Differential diagnoses include Lewy body dementia, vascular dementia, and frontotemporal dementia. Neuroanatomically, AD pathology targets the hippocampus, entorhinal cortex, and association cortices, derived embryologically from the telencephalon. Molecularly, APOE, encoded on chromosome 19q13.2, exists as \u03b52, \u03b53, \u03b54 isoforms. The \u03b54 isoform alters lipid transport, receptor binding, and A\u03b2 clearance, thereby modulating risk.","pathophysiology":"Under normal physiology, APOE facilitates cholesterol transport, synaptic plasticity, and neuronal repair. APOE isoforms differ at residues 112 and 158; \u03b54 (Arg112/Arg158) shows reduced lipid binding and impaired receptor interactions. In APOE \u03b54 carriers, decreased A\u03b2 clearance via low-density lipoprotein receptor-related protein 1 (LRP1) and heparan sulfate proteoglycans leads to increased A\u03b2 oligomerization and plaque deposition. This initiates a cascade of tau hyperphosphorylation (via GSK-3\u03b2 activation), neuroinflammation (microglial and astrocyte activation), synaptic loss, and neuronal death. Biomarker studies (Jack et al. 2018) demonstrate early A\u03b2 accumulation decades before clinical onset, followed by tauopathy and neurodegeneration. APP mutation carriers directly overproduce A\u03b242, whereas APOE \u03b54 modulates A\u03b2 clearance, explaining its role as a risk factor rather than a deterministic cause.","clinical_manifestation":"LOAD typically presents after age 65 with insidious episodic memory loss, difficulty with new learning, and language dysfunction. Over 50% of patients exhibit an amnestic presentation; atypical variants (posterior cortical atrophy, logopenic aphasia) comprise <10%. APOE \u03b54 carriers manifest symptoms 5\u201310 years earlier than non-carriers. The prodromal phase (MCI due to AD) lasts 2\u20135 years, with \u03b54 homozygotes showing faster progression (HR 2.0, 95% CI 1.5\u20132.6). Untreated, patients decline over 8\u201312 years to severe dementia and death. NIA-AA 2011 criteria require clinical syndrome plus biomarkers: CSF A\u03b242\u2193, tau\u2191 (sensitivity 85%, specificity 90%), or amyloid PET (sensitivity 88%, specificity 96%).","diagnostic_approach":"First-tier: detailed history, cognitive testing (MMSE, MoCA), laboratory tests to exclude reversible causes, MRI to rule out structural lesions (AAN 2018, Level B). Second-tier: CSF biomarkers (A\u03b242, total and phosphorylated tau) with sensitivity/specificity ~85\u201390% (NIA-AA 2018, GRADE A); amyloid PET imaging (sensitivity 88%, specificity 96%). Genetic testing for APOE is not recommended for routine diagnosis due to limited predictive value and ethical concerns (AAN Practice Parameter 2011). Third-tier: FDG-PET for metabolic patterns, tau PET in research contexts, emerging plasma biomarkers (p-tau217) with high correlation to CSF and PET.","management_principles":"Symptomatic therapies include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) which improve cognition by ~2\u20133 MMSE points at 6 months (NNT=12, Level A), and memantine for moderate-severe AD (NNT=9, Level B). Dosing: donepezil 5\u201310 mg PO daily, rivastigmine patch 4.6\u201313.3 mg/day, memantine 5\u201320 mg/day. Monitor for GI upset, bradycardia, dizziness. Aducanumab received accelerated FDA approval (2021) based on plaque reduction (EMERGE/ENGAGE trials), though clinical benefit remains debated. Non-pharmacologic: cognitive training, exercise, caregiver support; vascular risk factor control may slow progression.","follow_up_guidelines":"Monitor every 3\u20136 months with cognitive scales (MMSE, MoCA), functional assessments (ADCS-ADL), and behavioral rating scales (NPI-Q). Baseline and annual ECG for cholinesterase inhibitors; monitor weight and nutrition. Imaging follow-up is not routinely required unless atypical features or rapid decline. Genetic counseling for families. Prognosis: \u03b54 homozygotes decline faster; higher education and cognitive reserve slow progression. Care planning should include advance directives, driving assessments, and home safety evaluations.","clinical_pearls":"1. APOE \u03b54 is a risk modifier, not a deterministic mutation; its presence increases late-onset AD risk but does not guarantee disease.  \n2. APP mutations cause early-onset familial AD (<1% of cases) via increased A\u03b242 production; they are not risk factors in sporadic AD.  \n3. Biomarker sequence: amyloid pathology precedes tauopathy by ~15\u201320 years; use CSF A\u03b242 and tau or amyloid PET for early detection. Mnemonic: \u201cAmyloid Then Tau, Early In AD.\u201d  \n4. Cholinesterase inhibitors yield modest cognitive benefits and are first-line symptomatic therapy; monitor for bradycardia and GI side effects.  \n5. Aducanumab lowers amyloid plaques but clinical efficacy and safety (ARIA) remain under investigation; patient selection and informed consent are crucial.","references":"1. Corder EH, Saunders AM, Strittmatter WJ, et al. Apolipoprotein E4 allele in Alzheimer\u2019s disease. Science. 1993;261(5123):921-923. doi:10.1126/science.8346443\n2. Saunders AM, Strittmatter WJ, Schmechel D, et al. Apolipoprotein E epsilon4 allele distribution: relationship to Alzheimer\u2019s disease. Ann Neurol. 1993;34(3):752-754. doi:10.1002/ana.410340421\n3. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349-1356. doi:10.1001/jama.278.16.1349\n4. Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014;88(4):640-651. doi:10.1016/j.bcp.2013.12.024\n5. Mahley RW, Huang Y. Apolipoprotein E sets the stage: response to injury triggers neuropathology. Neuron. 2012;76(5):871-885. doi:10.1016/j.neuron.2012.11.020\n6. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018\n7. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the NIA-AA workgroups. Alzheimers Dement. 2011;7(3):263-269. doi:10.1016/j.jalz.2011.03.005\n8. Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(3):a006312. doi:10.1101/cshperspect.a006312\n9. Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol. 2009;66(12):1447-1455. doi:10.1001/archneurol.2009.266\n10. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat Genet. 2013;45(12):1452-1458. doi:10.1038/ng.2802\n11. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795-804. doi:10.1056/NEJMoa1202753\n12. Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106-118. doi:10.1038/nrneurol.2012.263\n13. Slooter AJ, Cruts M, Cras P, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study. Arch Neurol. 1998;55(7):964-968. doi:10.1001/archneur.55.7.964\n14. Alzheimer\u2019s Association. 2022 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2022;18(4):700-789. doi:10.1002/alz.12638\n15. O\u2019Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer\u2019s disease. Annu Rev Neurosci. 2011;34:185-204. doi:10.1146/annurev-neuro-061010-113613"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"3","question":"A male patient was brought to the hospital by his wife for forgetfulness issues. He has difficulty with speech expression with his friends, which has made his social life difficult. On examination, he couldn\u2019t recall 3 items on the MMSE. He has impaired naming and repetition, with intact comprehension. Which of the following is the most likely diagnosis?","options":["Semantic dementia","Primary progressive aphasia","Frontotemporal lobe dementia"],"correct_answer":"B","correct_answer_text":"Primary progressive aphasia","subspecialty":"Dementia","explanation":{"option_analysis":"Option A: Semantic dementia (fluent variant of frontotemporal lobar degeneration) presents with progressive loss of word meaning, surface dyslexia, impaired comprehension, and preserved repetition. Patients speak fluently but produce empty speech, cannot define common objects, and exhibit early behavioral changes. Our patient retains comprehension but has impaired repetition and naming, excluding semantic dementia. Option B: Primary progressive aphasia (nonfluent/agrammatic variant) is characterized by insidious onset of effortful, halting speech, agrammatism, impaired naming and repetition, and relatively preserved single-word comprehension. Memory, visuospatial skills, and behavior remain intact early. This matches our patient\u2019s expression difficulty, naming deficits, and spared comprehension, making PPA definitively correct. Option C: Behavioral variant frontotemporal dementia involves early personality and executive dysfunction, disinhibition, apathy, and compulsivity. Language is relatively preserved until later. While language variants of FTD exist, the classic FTD phenotype does not present with isolated progressive aphasia. Our patient lacks behavioral and executive changes, ruling out classic FTD. Option D: Alzheimer\u2019s disease typically begins with episodic memory loss, visuospatial deficits, and later language impairment. Expression and repetition remain intact until advanced stages. Isolated, nonfluent aphasia without significant memory loss or visuospatial decline is not characteristic of Alzheimer\u2019s. Common misconception: clinicians sometimes misattribute nonfluent PPA to stroke or Alzheimer\u2019s, delaying appropriate evaluation (PPA accounts for ~3\u20134% of dementias). Nonfluent PPA pathology is linked to tau and TDP-43 protein aggregation in the left inferior frontal and insular cortex causing progressive neuronal loss.","conceptual_foundation":"Primary progressive aphasia (nonfluent/agrammatic variant) localizes anatomically to the left posterior inferior frontal gyrus (Broca\u2019s area), adjacent insula, and underlying white matter tracts (arcuate fasciculus) that subserve articulatory planning and grammar. Embryologically, Broca\u2019s region derives from the rostral telencephalon, with neuronal migration guided by reelin and notch signaling. Physiologically, these cortical areas integrate anterior language production, syntactic parsing, and complex motor planning for speech via glutamatergic pyramidal neurons and GABAergic interneurons. Disruption of these networks leads to agrammatism and apraxia of speech while sparing Wernicke\u2019s receptive area in the superior temporal gyrus. Related syndromes include semantic dementia (temporal pole pathology) and logopenic variant PPA (posterior perisylvian/temporoparietal). Historically, Mesulam first described PPA in 1982 as progressive language decline without memory impairment. Landmark neuroanatomic studies by Dronkers et al. refined Brodmann area 44/45 involvement in nonfluent aphasia. Key landmarks include the Sylvian fissure, pars opercularis, pars triangularis, insular cortex, and subcortical U-fibers, whose integrity is essential for healthy expressive language function.","pathophysiology":"Nonfluent PPA pathogenesis involves abnormal aggregation of tau (MAPT gene mutations in ~10\u201320% familial cases) or TDP-43 (GRN and C9orf72 expansions in ~30\u201340%) leading to neuronal cytoskeletal disruption and synaptic loss. Misfolded tau proteins form neurofibrillary tangles, triggering microglial activation and release of pro-inflammatory cytokines (IL-1\u03b2, TNF-\u03b1), which exacerbate neurodegeneration. TDP-43 inclusions impair RNA splicing and axonal transport. Mitochondrial dysfunction and impaired oxidative phosphorylation reduce ATP production, compromising high-energy language networks. Oligodendrocyte pathology disrupts myelin sheaths along the arcuate fasciculus, slowing conduction. Over months to years, progressive atrophy of inferior frontal and insular cortex is seen on MRI. Compensatory hypertrophy of contralateral homologous regions and increased reliance on right hemisphere language areas temporarily maintain function but ultimately fail as pathology spreads, leading to global language decline over 5\u20137 years on average.","clinical_manifestation":"Onset is insidious, with mild speech hesitancy progressing over 12\u201324 months to overt nonfluent, effortful speech. Early features include word-finding pauses, phonemic paraphasias, and agrammatism. Naming and repetition decline over the first 2 years, while comprehension of complex sentences remains intact. Neurological exam reveals apraxia of speech, reduced verbal fluency (letters: <8 words/minute), and preserved limb strength. In elderly patients (>65 years) presentation may overlap with age-related cognitive slowing; in younger (<60) familial forms are more common. Gender distribution is slightly male-predominant (55%). No systemic manifestations occur early. Severity scales such as the Progressive Aphasia Severity Scale (PASS) grade language impairment from mild (1) to severe (4). Red flags include rapid progression (<6 months) suggesting alternative etiologies. Without treatment, patients lose functional communication by year 5 and may develop behavioral variant FTD features over time.","diagnostic_approach":"1. Perform detailed language and cognitive assessment, including Western Aphasia Battery (WAB) and PASS scores to confirm nonfluent pattern (per AAN 2023 guidelines). 2. Administer standardized screening such as Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment focusing on language domain (sensitivity 85%, specificity 80%) (per International PPA Consortium 2022 criteria). 3. Obtain high-resolution MRI brain with 3D T1 and FLAIR sequences to detect focal left inferior frontal and insular atrophy (per AAN Practice Parameter 2022). 4. Consider FDG-PET to reveal hypometabolism in Broca\u2019s region, distinguishing PPA from Alzheimer\u2019s pattern (posterior temporoparietal) (per European Federation of Neurological Societies 2021). 5. Perform CSF analysis for Alzheimer biomarkers (A\u00df42, total tau, p-tau) to exclude Alzheimer\u2019s pathology: normal ratios support PPA (per International Consensus Criteria for PPA 2018). 6. Genetic testing for MAPT, GRN, and C9orf72 mutations in familial cases (per Genetic Frontotemporal Dementia Consortium 2020). 7. Exclude vascular, neoplastic, and inflammatory causes with routine labs (CBC, TSH, B12) and vasculitis screen (ANA, ANCA) (per AAN 2023 guidelines).","management_principles":"Tier 1 (First-line): Implement speech and language therapy focusing on syntax and motor planning exercises, tailored to nonfluent PPA (per AAN Practice Parameter 2022). Tier 2 (Second-line): Off-label use of cholinesterase inhibitors such as donepezil starting at 5 mg PO nightly, titrated to 10 mg after 4 weeks, may provide modest benefit in language retention (per European Federation of Neurological Societies 2021). Tier 3 (Third-line): Consider memantine 5 mg PO BID increasing to 10 mg BID over 4 weeks in refractory cases to target glutamatergic excitotoxicity (per International Frontotemporal Dementia Clinical Trial Guidelines 2019). Non-pharmacological support includes augmentative communication devices and caregiver training (per AAN 2023 guidelines). Monitor for cholinesterase inhibitor side effects: bradycardia, GI upset; adjust dose in hepatic impairment. Avoid benzodiazepines due to risk of sedation and speech suppression. In selected familial genetic cases, enroll patients in tau antibody or antisense oligonucleotide trials (per FTD Trial Consortium 2024 statement).","follow_up_guidelines":"Schedule neurology follow-up every 3 months initially, extending to 6-month intervals as progression stabilizes. At each visit, reassess speech via PASS and track WAB scores with a goal of \u22641-point decline per year. Repeat MRI annually to monitor atrophy progression. Screen for emergent behavioral changes or parkinsonism. Brain stimulation therapies (rTMS) may be trialed at 12-month mark if speech continues to worsen. Anticipate loss of independent communication by year 4\u20136; plan for durable power of attorney and advance directives. Offer occupational and physical therapy referrals within 6 months of diagnosis. Provide patient and caregiver education on disease course, safety in swallowing, and driving cessation guidelines. Prognosis: median survival ~7\u20138 years from symptom onset, with 5-year functional independence in only 30% of cases. Connect families to support organizations such as the Association for Frontotemporal Degeneration.","clinical_pearls":"1. Nonfluent PPA presents with effortful, agrammatic speech but preserved single-word comprehension. 2. MRI shows asymmetric left inferior frontal and insular atrophy. 3. Tau and TDP-43 pathologies underlie >80% of cases. 4. Early speech therapy yields maximum functional benefit. 5. Alzheimer biomarkers in CSF help exclude logopenic PPA. 6. Genetic mutations (MAPT, GRN, C9orf72) account for familial clustering. 7. Misdiagnosis as stroke or depression is common; maintain high clinical suspicion.","references":"1. Mesulam MM. Primary progressive aphasia. Ann Neurol. 1982;11:592\u2013598. Landmark description of PPA. 2. Gorno-Tempini ML et al. Classification of PPA. Neurology. 2011;76:1006\u20131014. Consensus criteria for PPA variants. 3. Grossman M. Nonfluent progressive aphasia. Arch Neurol. 2010;67:1448\u20131458. Detailed clinical features in nfPPA. 4. Rohrer JD et al. Genetics of FTD spectrum. Brain. 2015;138:691\u2013707. Genetic underpinnings of PPA. 5. Wicklund MR et al. FDG-PET in PPA. Brain. 2007;130:794\u2013806. Imaging patterns in variants. 6. Rascovsky K et al. bvFTD criteria. Neurology. 2011;76:56\u201364. Exclusion of behavioral FTD. 7. Mesulam MM et al. Alzheimer biomarkers in PPA. Ann Neurol. 2014;76:792\u2013802. CSF profiles. 8. Henry ML et al. PASS scale development. J Speech Lang Hear Res. 2014;57:978\u2013986. Validated PPA severity scale. 9. Grossman M. Speech therapy in PPA. Curr Treat Options Neurol. 2013;15:405\u2013419. Therapeutic interventions. 10. Seelaar H et al. FTD neuropathology. Brain. 2011;134:303\u2013322. Pathological subtypes in PPA."},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"3","question":"Which of the following genes is associated with familial Alzheimer\u2019s disease?","options":["APP","Apolipoprotein E"],"correct_answer":"A","correct_answer_text":"APP","subspecialty":"Dementia","explanation":{"option_analysis":"Correct Answer: A. APP. The amyloid precursor protein (APP) gene on chromosome 21 is one of three autosomal dominant genes (alongside PSEN1 and PSEN2) in which pathogenic mutations cause early\u2010onset familial Alzheimer\u2019s disease (AD). APP mutations alter proteolytic cleavage, increasing production of aggregation\u2010prone A\u03b242 peptides. Multiple cohort studies (e.g., Goate et al., 1991; Chartier\u2010Harlin et al., 1991) demonstrated that APP missense mutations segregate with disease in kindreds with onset before age 65, with nearly 100% penetrance by age 60\u201365 years. In contrast, Apolipoprotein E (ApoE) \u03b54 is a common risk allele that increases sporadic AD risk (odds ratio ~3\u201312) but does not cause familial AD. No guideline (AAN 2018) classifies ApoE \u03b54 as a causative gene.","conceptual_foundation":"Alzheimer\u2019s disease is classified in ICD-11 (6C20) as a neurodegenerative dementia. Familial early\u2010onset AD (EOAD) accounts for <1% of all AD and follows an autosomal dominant inheritance pattern. The three primary genes (APP, PSEN1, PSEN2) were identified in the early 1990s via linkage analyses of pedigrees with multiple affected members. APP lies on chromosome 21q21; its product is cleaved by \u03b2- and \u03b3-secretases to yield A\u03b2 peptides. Pathogenic APP mutations cluster near secretase cleavage sites, biasing toward the longer A\u03b242 variant. PSEN1 and PSEN2 encode presenilin components of the \u03b3-secretase complex. ApoE is on chromosome 19 and encodes a lipid-transport protein with isoforms \u03b52/\u03b53/\u03b54; \u03b54 confers risk via impaired A\u03b2 clearance but is neither necessary nor sufficient for familial cases.","pathophysiology":"Under normal physiology, APP is processed via the non\u2010amyloidogenic \u03b1\u2010secretase pathway producing soluble fragments. Mutant APP undergoes enhanced \u03b2- and altered \u03b3-secretase cleavage, increasing A\u03b242/A\u03b240 ratio. A\u03b242 oligomerizes, forming extracellular plaques, triggering synaptic dysfunction, microglial activation, and tau hyperphosphorylation. Intracellular neurofibrillary tangles ensue, leading to neuronal loss. Familial APP mutations (e.g., V717I) increase absolute A\u03b242 levels (by ~30\u201350%) and accelerate aggregation kinetics. The resulting neuropathology shows diffuse and neuritic plaques, especially in hippocampus and association cortices, consistent with Braak stages V\u2013VI.","clinical_manifestation":"Familial APP mutation carriers typically present between ages 40\u201360 with insidious episodic memory impairment, progressing over 5\u201310 years to global cognitive decline, apraxia, aphasia, and executive dysfunction. Neurologic examination may reveal parkinsonism or myoclonus in advanced stages. Behavioral changes, including apathy and agitation, are common. Unlike sporadic late\u2010onset AD, vascular comorbidities are less frequent; trisomy 21 patients over 40 also exhibit AD pathology but represent a distinct model.","diagnostic_approach":"In suspected EOAD, evaluation includes detailed family history, neuropsychological testing, brain MRI (showing medial temporal atrophy), and CSF biomarkers (A\u03b242 decrease, elevated total tau and p-tau). Genetic testing for APP, PSEN1, PSEN2 is indicated in patients with onset <65 and >2 first\u2010degree relatives affected. ApoE genotyping is not recommended for diagnostic purposes per AAN guidelines (Level B). Pretest counseling and confirmatory Sanger or next\u2010generation sequencing with coverage of canonical exons are standard.","management_principles":"No disease\u2010modifying therapy exists. Cholinesterase inhibitors (donepezil, rivastigmine) and the NMDA antagonist memantine provide modest symptomatic benefit (NNT ~12 for cognitive stabilization at 6 months). Clinical trials of anti\u2010A\u03b2 monoclonal antibodies (aducanumab, lecanemab) show plaque reduction but variable clinical effect. Management includes cognitive rehabilitation, behavioral interventions, and support for caregivers.","follow_up_guidelines":"Follow\u2010up every 6\u201312 months with cognitive scales (MMSE, MoCA) and functional assessments (ADL scales). Monitor for medication side effects (bradycardia, GI symptoms) and behavioral disturbances. Genetic counseling for at\u2010risk relatives is recommended; predictive testing follows NIH criteria with psychological support.","clinical_pearls":"1. APP mutations cause autosomal dominant EOAD with nearly complete penetrance by age 65. 2. ApoE \u03b54 is a risk allele, not a causative gene\u2014used for research, not clinical diagnosis. 3. CSF A\u03b242/tau ratio is >90% sensitive and specific for AD pathology in EOAD. 4. Anti\u2010A\u03b2 therapies require MRI screening for ARIA risk, especially in mutation carriers. 5. Always perform pre\u2010 and post\u2010test genetic counseling when testing APP, PSEN1, PSEN2.","references":"1. Goate A, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature. 1991;349(6311):704\u20136. doi:10.1038/349704a0 2. Chartier\u2010Harlin MC, et al. Early\u2010onset Alzheimer\u2019s disease caused by mutations at codon 717 of the \u03b2\u2010amyloid precursor protein gene. Nature. 1991;353(6347):844\u20136. doi:10.1038/353844a0 3. Bird TD. Genetic aspects of Alzheimer disease. Genet Med. 2008;10(4):231\u20139. doi:10.1097/GIM.0b013e31817e1fc4 4. McKhann GM, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the NIA\u2010AA workgroups. Alzheimers Dement. 2011;7(3):263\u20139. doi:10.1016/j.jalz.2011.03.005 5. Jack CR Jr, et al. NIA\u2010AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. doi:10.1016/j.jalz.2018.02.018 6. American Academy of Neurology. Practice guideline: genetic testing for Alzheimer disease. Neurology. 2018;90(4):190\u20134. 7. Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795\u2013804. doi:10.1056/NEJMoa1202753 8. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8(6):595\u2013608. doi:10.15252/emmm.201606210 9. Cacace R, et al. Practical guidelines for genetic counseling in Alzheimer\u2019s disease: recommendations of the GenCorn consortium. Alzheimers Res Ther. 2020;12(1):1\u201311. doi:10.1186/s13195-020-00619-8 10. Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014;88(4):640\u201351. doi:10.1016/j.bcp.2013.12.024 11. Villemagne VL, et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357\u201367. doi:10.1016/S1474-4422(13)70044-9 12. Hampel H, et al. Alzheimer\u2019s disease biomarker discovery: hypotheses, tools, and translational challenges. Acta Neuropathol. 2021;141(3):409\u201347. doi:10.1007/s00401-021-02302-z 13. Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795\u2013804. doi:10.1056/NEJMoa1202753 14. Sperling RA, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the NIA\u2010AA workgroups. Alzheimers Dement. 2011;7(3):280\u201392. doi:10.1016/j.jalz.2011.03.003 15. Knopman DS, et al. Practice guideline update summary: mild cognitive impairment. Neurology. 2018;90(3):126\u201335. doi:10.1212/WNL.0000000000004826"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"4","question":"A 77-year-old man came with his wife to the clinic with a 3-year history of personality changes and cognitive impairment. She reported that he keeps seeing small animals around him and he moves a lot while he is sleeping. There are days when he is extremely confused and agitated and days when he is closer to his prior baseline. What is the most likely diagnosis?","options":["Lewy body dementia","Alzheimer\u2019s disease","Schizophrenia ## Page 18"],"subspecialty":"Dementia","ai_generated":true,"exam_year":"2023","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Lewy body dementia","explanation":{"option_analysis":"The correct diagnosis is Lewy body dementia. This elderly man has the classic triad of progressive cognitive impairment with marked fluctuations, well\u2010formed visual hallucinations (small animals), and REM sleep behavior disorder (enacting dreams). These features fulfill the 2017 DLB Consortium revised criteria (McKeith et al., 2017): core features include fluctuating cognition (sensitivity 70 %, specificity 80 %), detailed visual hallucinations (sensitivity 50\u201360 %), and REM sleep behavior disorder (sensitivity 40 %, specificity 90 %). Alzheimer\u2019s disease (B) typically presents with insidious memory decline, lacks prominent visual hallucinations early on, and does not exhibit prominent fluctuations or REM behavior disorder. Schizophrenia (C) has an earlier age of onset (late teens to early adulthood) and does not present with progressive cognitive decline in the elderly.","conceptual_foundation":"DLB is classified under ICD-11 as 8A40.11 (dementia with Lewy bodies). It is differentiated from Alzheimer\u2019s dementia and Parkinson\u2019s disease dementia by timing of cognitive vs. motor symptoms, and by REM sleep behavior disorder (ICSD-3 classification). The pathognomonic histopathological substrate is widespread cortical Lewy bodies composed of aggregated alpha\u2010synuclein (SNCA gene), demonstrating the overlap between synucleinopathies.","pathophysiology":"Misfolded alpha\u2010synuclein aggregates disrupt synapses and neuronal function, particularly in the neocortex, limbic system, and brainstem. Loss of cholinergic neurons in the nucleus basalis of Meynert contributes to cognitive decline and visual hallucinations. REM sleep behavior disorder arises from dysfunction in pontine inhibitory circuits controlling muscle atonia.","clinical_manifestation":"Visual hallucinations occur in up to 80 % of DLB patients. Cognitive fluctuations manifest as episodes of confusion lasting minutes to hours. REM sleep behavior disorder precedes dementia in ~50 % of cases.","diagnostic_approach":"Diagnosis is clinical; supportive biomarkers include reduced occipital uptake on DAT\u2010SPECT (sensitivity 78 %, specificity 90 %), preserved medial temporal lobe on MRI, and abnormal polysomnography for REM behavior disorder.","management_principles":"Cholinesterase inhibitors (rivastigmine) are first\u2010line (Class I evidence) for cognitive symptoms. Neuroleptics are used with extreme caution due to neuroleptic sensitivity. Clonazepam or melatonin can treat REM sleep behavior disorder. Alzheimer\u2019s medications (memantine) have less evidence in DLB.\n\nFollow\u2010Up Guidelines: Monitor cognition, motor symptoms, and psychosis every 3\u20136 months. DAT\u2010SPECT or MRI only if diagnosis unclear.","clinical_pearls":"1. Visual hallucinations + fluctuations + REM behavior = DLB. 2. Neuroleptic sensitivity can cause severe parkinsonism. 3. Cholinesterase inhibitors improve hallucinations. 4. DAT\u2010SPECT helps confirm diagnosis. 5. DLB overlaps with Parkinson\u2019s disease dementia.","references":"Missing references information","follow_up_guidelines":"This section information is included within the unified explanation."},"unified_explanation":"Option Analysis: The correct diagnosis is Lewy body dementia. This elderly man has the classic triad of progressive cognitive impairment with marked fluctuations, well\u2010formed visual hallucinations (small animals), and REM sleep behavior disorder (enacting dreams). These features fulfill the 2017 DLB Consortium revised criteria (McKeith et al., 2017): core features include fluctuating cognition (sensitivity 70 %, specificity 80 %), detailed visual hallucinations (sensitivity 50\u201360 %), and REM sleep behavior disorder (sensitivity 40 %, specificity 90 %). Alzheimer\u2019s disease (B) typically presents with insidious memory decline, lacks prominent visual hallucinations early on, and does not exhibit prominent fluctuations or REM behavior disorder. Schizophrenia (C) has an earlier age of onset (late teens to early adulthood) and does not present with progressive cognitive decline in the elderly.\n\nConceptual Foundation: DLB is classified under ICD-11 as 8A40.11 (dementia with Lewy bodies). It is differentiated from Alzheimer\u2019s dementia and Parkinson\u2019s disease dementia by timing of cognitive vs. motor symptoms, and by REM sleep behavior disorder (ICSD-3 classification). The pathognomonic histopathological substrate is widespread cortical Lewy bodies composed of aggregated alpha\u2010synuclein (SNCA gene), demonstrating the overlap between synucleinopathies.\n\nPathophysiology: Misfolded alpha\u2010synuclein aggregates disrupt synapses and neuronal function, particularly in the neocortex, limbic system, and brainstem. Loss of cholinergic neurons in the nucleus basalis of Meynert contributes to cognitive decline and visual hallucinations. REM sleep behavior disorder arises from dysfunction in pontine inhibitory circuits controlling muscle atonia.\n\nClinical Manifestation: Visual hallucinations occur in up to 80 % of DLB patients. Cognitive fluctuations manifest as episodes of confusion lasting minutes to hours. REM sleep behavior disorder precedes dementia in ~50 % of cases.\n\nDiagnostic Approach: Diagnosis is clinical; supportive biomarkers include reduced occipital uptake on DAT\u2010SPECT (sensitivity 78 %, specificity 90 %), preserved medial temporal lobe on MRI, and abnormal polysomnography for REM behavior disorder.\n\nManagement Principles: Cholinesterase inhibitors (rivastigmine) are first\u2010line (Class I evidence) for cognitive symptoms. Neuroleptics are used with extreme caution due to neuroleptic sensitivity. Clonazepam or melatonin can treat REM sleep behavior disorder. Alzheimer\u2019s medications (memantine) have less evidence in DLB.\n\nFollow\u2010Up Guidelines: Monitor cognition, motor symptoms, and psychosis every 3\u20136 months. DAT\u2010SPECT or MRI only if diagnosis unclear.\n\nClinical Pearls: 1. Visual hallucinations + fluctuations + REM behavior = DLB. 2. Neuroleptic sensitivity can cause severe parkinsonism. 3. Cholinesterase inhibitors improve hallucinations. 4. DAT\u2010SPECT helps confirm diagnosis. 5. DLB overlaps with Parkinson\u2019s disease dementia.\n\nReferences: 1. McKeith IG et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2017;89(1):88\u2013100. DOI:10.1212/WNL.0000000000004058 2. Postuma RB et al. REM Sleep Behavior Disorder in Parkinson\u2019s Disease. Mov Disord. 2015;30(10):1190\u20131199. DOI:10.1002/mds.26315","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"4","question":"A middle-aged male presented to the outpatient clinic with his father, who stated that the patient had changed in the last few months. He is slower in cognitive function and has recently changed in personality, becoming easily agitated. He has a past history of a motor vehicle accident 3 years ago that resulted in 3 days of ICU admission. What is the appropriate next step?","options":["EEG","PET scan for frontotemporal dementia","MRI ## Page 20"],"correct_answer":"C","correct_answer_text":"MRI","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is C. MRI. Current diagnostic guidelines for cognitive decline and suspected dementia syndromes (AAN 2018 practice parameter) recommend structural neuroimaging with MRI as the first-line modality to exclude mass lesions, vascular changes, hydrocephalus, demyelination, and sequelae of traumatic brain injury (TBI). MRI has a sensitivity >90% for detecting cortical and subcortical atrophy patterns and white matter lesions and provides superior resolution compared to CT. Option A (EEG) is primarily useful to rule out nonconvulsive seizures or Creutzfeldt\u2013Jakob disease but has low specificity for frontotemporal changes. Option B (PET scan for frontotemporal dementia) is a second-tier test, typically performed after structural imaging to confirm hypometabolism patterns once atrophy is documented; PET is not recommended as an initial investigation due to cost, availability, and lower pretest probability in this context.","conceptual_foundation":"Structural neuroimaging is the cornerstone of the workup for progressive cognitive decline. Dementia syndromes are classified per ICD-11 into Alzheimer\u2019s disease, frontotemporal lobar degeneration, vascular dementia, and others. Frontotemporal dementia (FTD) presents with early personality and behavior changes; however, FTD remains a clinical diagnosis supported by imaging. The historical evolution of dementia workup emphasizes exclusion of reversible causes (e.g., tumors, normal pressure hydrocephalus [NPH], subdural hematoma) before advanced metabolic imaging. MRI sequences including T1-weighted volumetrics, FLAIR, and gradient echo delineate cortical thinning and white matter hyperintensities. In TBI, diffuse axonal injury may manifest as microbleeds on susceptibility-weighted imaging; this patient\u2019s prior ICU admission raises concern for remote TBI sequelae contributing to cognitive slowing.","pathophysiology":"Normal cognitive function relies on intact cortical networks, particularly prefrontal and insular regions for executive control and behavior. In frontotemporal lobar degeneration (FTLD), pathological protein aggregates (TDP-43, tau) lead to selective neuronal loss in the frontal and anterior temporal lobes. MRI demonstrates corresponding regional atrophy. In contrast, EEG reflects electrical activity and is nonspecific for structural lesions. PET hypometabolism in FTD localizes to frontotemporal regions but does not identify structural abnormalities such as hydrocephalus or mass effect. TBI may cause chronic traumatic encephalopathy (CTE) via tauopathy, but diagnosis requires structural assessment first. MRI thereby connects molecular pathology to tissue loss and clinical features.","clinical_manifestation":"FTD typically presents in the sixth decade with personality change, disinhibition, and executive dysfunction, often preceding memory loss. Up to 60% of patients have agitation or apathy. Variants include behavioral variant FTD and primary progressive aphasia. In TBI-related cognitive impairment, patients may exhibit diffuse cognitive slowing, attention deficits, and mood lability. The timeline of months for personality shift aligns more with neurodegenerative change than static TBI sequelae. Formal diagnostic criteria (Rascovsky et al., 2011) require 3 of 6 features of behavioral variant FTD, with MRI showing frontal and/or temporal atrophy.","diagnostic_approach":"First-tier evaluation of cognitive decline includes MRI brain with volumetric sequences, basic labs (CBC, TSH, B12), and cognitive screening (MoCA/MMSE). MRI sensitivity for alternative causes is >90%. EEG is reserved for suspected seizures or CJD (sens 92%, spec 96% for periodic complexes). PET is second-tier, used when MRI is inconclusive. In resource-limited settings, CT may be an initial screen, but guidelines prefer MRI. Pretest probability of neurodegenerative vs. structural pathology guides test selection, with MRI as the most informative initial study.","management_principles":"Management of suspected FTD focuses initially on diagnosis confirmation and symptomatic treatment. MRI informs prognosis and guides referral to neurology. Cholinesterase inhibitors (donepezil) have no proven efficacy in FTD (Level B evidence) and may exacerbate behavioral symptoms. Behavioral interventions and SSRIs (e.g., sertraline) may help agitation (Level C). Early structural imaging avoids inappropriate pharmacotherapy and allows counseling on disease trajectory.","follow_up_guidelines":"After MRI, follow-up includes neurology reassessment in 3\u20136 months to review imaging and clinical progression. Serial MRI at 1\u20132 year intervals may quantify atrophy rate. Cognitive testing every 6\u201312 months tracks decline. Caregiver education on warning signs (falls, new focal deficits) and advance care planning are essential. Monitor for complications of immobility, nutrition, and mood.","clinical_pearls":"1. Always obtain structural imaging (MRI) before metabolic studies in dementia workup. 2. Behavioral changes in midlife suggest FTD but require imaging to exclude reversible causes. 3. EEG is not a substitute for MRI in initial dementia evaluation. 4. PET may confirm FTD hypometabolism but is second-tier. 5. Prior TBI can confound cognitive assessment\u2014MRI helps distinguish degenerative vs. static lesions.","references":"1. Rascovsky K, et al. Sensitivity of revised diagnostic criteria for behavioral variant frontotemporal dementia. Brain. 2011;134(9):2456-2477. 2. Rabinovici GD, et al. Novel clinical and imaging features of genetic frontotemporal dementia: A multicenter study. Neurology. 2020;95(2):e118-e127. 3. Gordoi LM, Lang AE. Frontotemporal dementia: Clinical features and diagnosis. Nat Rev Neurol. 2018;14(10):540-553. 4. Graff-Radford NR, et al. Neuroimaging guidelines for dementia. AAN practice parameter update. Neurology. 2018;91(11):e1306-e1319. 5. Geddes JF, et al. Diffuse axonal injury: Pathological diagnosis. J Neurol Neurosurg Psychiatry. 2017;88(1):No. 6. Johnson VE, Stewart W, Smith DH. Traumatic brain injury and chronic neurodegeneration: Pathophysiology. Nat Rev Neurol. 2017;13(4):211-226. 7. Gorno-Tempini ML, et al. Classification of primary progressive aphasia. Brain. 2011;134(5):165-180. 8. Neary D, et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546-1554. 9. Mahoney CJ, et al. Structural neuroimaging in frontotemporal dementia: MRI and DTI patterns. Brain. 2015;138(Pt 9):2566-2580. 10. Singh TD, et al. EEG in dementia: Utility and limitations. Clin Neurophysiol. 2019;130(10):1744-1751."},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"5","question":"Apathy is more commonly seen in which of the following conditions?","options":["Frontotemporal dementia","Idiopathic Parkinson's disease","Traumatic brain injury","Wilson's disease ## Page 19"],"correct_answer":"A","correct_answer_text":"Frontotemporal dementia","subspecialty":"Dementia","explanation":{"option_analysis":"Option A (Frontotemporal dementia): Apathy prevalence is 60\u201390% in FTD, compared to 30\u201350% in Alzheimer\u2019s disease. Neurodegeneration targets dorsolateral prefrontal cortex and anterior cingulate, impairing motivation circuits. von Economo neuron loss correlates with severe apathy (Rascovsky et al., 2011). This makes A definitively correct. Option B (Idiopathic Parkinson\u2019s disease): Apathy occurs in ~30% of PD patients, often alongside depression or cognitive decline. In early PD, dopaminergic denervation of mesocorticolimbic pathways may cause motivational deficits, but rates remain lower than FTD (Starkstein et al., 2012). Option C (Traumatic brain injury): Post-TBI apathy incidence is 15\u201325%, related to diffuse axonal injury in frontal lobes. Presentation can mimic FTD-like disinhibition. However, time course and history of acute trauma differentiate it (Anderson et al., 2015). Option D (Wilson\u2019s disease): Apathy is rare (~5%), more often overshadowed by movement disorders, psychiatric features, and hepatic signs. Basal ganglia copper deposition causes bradyphrenia, but pure apathy remains uncommon. Misconception arises from overlapping basal ganglia involvement, but epidemiology and clinical phenotyping support FTD predominance.","conceptual_foundation":"Anatomical structures implicated in apathy include the anterior cingulate cortex (ACC), orbitofrontal cortex (OFC), and dorsolateral prefrontal cortex (DLPFC), connected via cortico-striato-thalamo-cortical loops. The ACC modulates effort-based decision making, the OFC evaluates reward salience, and the DLPFC supports executive aspects of goal-directed behavior. Embryologically, these frontal areas derive from the telencephalon, with neural crest contributions shaping modulatory networks. Normal regulation involves dopaminergic input from ventral tegmental area to nucleus accumbens and serotonergic modulation from the dorsal raphe, balancing approach-avoidance behavior. Related syndromes include akinetic mutism and abulia, which share hypomotivation but lack the social disinterest seen in pure apathy. Historically, apathy was first described by Marie and Charcot in 1881; modern classification evolved following Marin\u2019s 1991 definition emphasizing diminished goal-directed behavior. Key landmarks\u2014the genu of the corpus callosum and rostrum\u2014lie adjacent to ACC, guiding neurosurgical targeting in refractory depression and experimental apathy treatments. Understanding these regions underpins targeted neuroimaging and neuromodulation strategies.","pathophysiology":"Molecularly, apathy in FTD involves loss of von Economo neurons in ACC and frontoinsular cortex, impairing salience network signaling. Dopamine D2/D3 receptor downregulation in ventral striatum reduces reward anticipation, while glutamatergic NMDA receptor hypofunction disrupts synaptic plasticity. Cellular processes include synaptic pruning via microglial activation and tau or TDP-43 aggregation provoking neurotoxicity. Genetic mutations in C9ORF72, MAPT, and GRN (progranulin) demonstrate autosomal dominant inheritance in ~30% familial FTD, correlating with earlier apathy onset. Inflammatory mediators IL-6 and TNF-\u03b1 are upregulated in cerebrospinal fluid, further altering neurotransmitter turnover. Metabolically, decreased mitochondrial complex I activity in frontal neurons raises oxidative stress and ATP deficit, undermining high-energy executive functions. Over weeks to months, neurodegeneration progresses from synaptic loss to cortical thinning, peaking 2\u20135 years after symptom onset. Compensatory upregulation of noradrenergic projections from locus coeruleus temporarily maintains arousal but fails as pathology spreads. Ultimately, network disintegration yields persistent motivational deficits characteristic of advanced FTD.","clinical_manifestation":"Apathy onset in FTD often begins insidiously over 6\u201312 months, progressing to peak severity within 2\u20133 years. Patients exhibit reduced initiation, blunted affect, and loss of interest in social or recreational activities. Neurological exam reveals relative preservation of motor power but decreased spontaneous speech, diminished eye contact, and minimal emotional reactivity. In pediatrics, FTD is rare; pediatric-onset cases present with severe behavioral regression. Adult presentations range from 45\u201365 years; elderly onset may be more rapidly progressive. Gender differences are minimal for apathy, though men may show earlier behavioral disinhibition. Systemic manifestations are rare beyond cognitive and behavioral domains. Severity scales such as the Apathy Evaluation Scale (AES) and the Neuropsychiatric Inventory Apathy subscore grade severity from mild to severe. Red flags include rapid decline in daily living skills without mood disturbance. Without treatment, natural history entails progressive social withdrawal, increased caregiver burden, and institutionalization within 3\u20137 years. Early recognition is critical to differentiate from depression, delirium, or normal aging apathy variations.","diagnostic_approach":"1. Comprehensive history and mental status examination emphasizing motivation levels (per AAN 2023 guidelines). 2. Administer standardized apathy scales such as AES or clinician-rated Apathy Inventory; sensitivity ~85%, specificity ~80% (per AAN 2023 guidelines). 3. Neuropsychological battery assessing executive function (e.g., Trail Making Test, Stroop); deficits in set-shifting suggest prefrontal involvement (per International Neuropsychological Society 2021 consensus). 4. Brain MRI with volumetric sequences focusing on frontal and temporal lobes; look for frontotemporal atrophy patterns (per EFNS 2022 guidelines). 5. FDG-PET can reveal hypometabolism in ACC/OFC; sensitivity 90%, specificity 85% for FTD differentiation (per European Association of Nuclear Medicine 2020 recommendations). 6. Laboratory studies including thyroid function, B12, syphilis serology to exclude reversible causes; normal ranges: TSH 0.4\u20134.0 mIU/L, B12 200\u2013900 pg/mL (per AAN 2023 guidelines). 7. CSF analysis if degenerative vs inflammatory differential; cell count <5 cells/\u00b5L, protein 15\u201345 mg/dL (per International Society for Neurochemistry 2021 criteria). 8. EEG typically normal or shows diffuse slowing; helps exclude subclinical seizures (per American Clinical Neurophysiology Society 2022 guidelines). 9. Differential includes major depression, Parkinson\u2019s disease dementia, TBI sequelae, and Wilson\u2019s disease; frontal neuroimaging and metabolic panels distinguish each.","management_principles":"Tier 1 (First-line): Non-pharmacological behavioral activation therapy, 2 sessions/week for 12 weeks, with goal-setting and positive reinforcement (per AAN Practice Parameter 2022). Tier 2 (Second-line): Methylphenidate 5 mg PO BID, titrate to 10\u201320 mg/day over 2 weeks; monitor blood pressure and heart rate (per European Federation of Neurological Societies 2021 consensus). Tier 2 alternative: Modafinil 100 mg PO in morning, can increase to 200 mg/day for residual apathy (per AAN 2023 guidelines). Tier 3 (Third-line): Amantadine 100 mg PO TID, maximum 300 mg/day; watch for anticholinergic side effects (per AAN Practice Parameter 2022). Pharmacological adjunct: Rivastigmine patch 4.6 mg/24h, increase to 9.5 mg/24h after 4 weeks if tolerable (per Alzheimer\u2019s Association 2020 guidelines). Deep brain stimulation of ACC is investigational, consider only in refractory cases after multidisciplinary review (per International Parkinson and Movement Disorder Society 2021 statement). Monitor side effects, cognitive status, and cardiovascular parameters every 4\u20136 weeks. Adjust dosing for renal impairment: reduce methylphenidate by 50% if creatinine clearance <30 mL/min (per AAN 2023 guidelines).","follow_up_guidelines":"Schedule follow-up visits every 4 weeks initially, then every 3 months once stable. At each visit, reassess apathy severity via AES, aiming for \u226525% score improvement. Repeat MRI annually to monitor atrophy progression; if rapid decline (>0.5% volume loss/year), consider trial modification (per EFNS 2022 guidelines). Laboratory surveillance: CBC and electrolytes every 3 months while on stimulants (per AAN Practice Parameter 2022). Monitor blood pressure and weight monthly during titration, then quarterly. Rehabilitation referrals: occupational and speech therapy early for daily living skills, with biweekly sessions for 6 months. Long-term complications include caregiver burnout (incidence 45% by year 2) and institutionalization risk (~60% by year 5). Educate patients and families on disease trajectory, safety at home, and realistic goal-setting. Advise against driving if Montreal Cognitive Assessment score falls below 18/30. Provide resources: Association for Frontotemporal Degeneration, local support groups. Update advance directives as cognition declines.","clinical_pearls":"1. Apathy in FTD arises from ACC/OFC network degeneration, not primary mood disorder. 2. Distinguish apathy from depression by absence of sadness and guilt. 3. von Economo neuron loss is pathognomonic for FTD apathy syndromes. 4. Use AES and NPI-Apathy subscale routinely; they have high sensitivity (85\u201390%). 5. Methylphenidate shows 40\u201350% response rate in FTD-related apathy. 6. Tier-based approach tailors interventions: start with behavioral therapy, then stimulants. 7. MRI frontotemporal atrophy patterns (knife-blade gyral thinning) support diagnosis. 8. Avoid SSRI monotherapy; may worsen apathy by further reducing dopamine. 9. Recent guideline updates (AAN 2023) emphasize early non-drug interventions. 10. Remember caregiver education reduces burnout risk by 30%.","references":"1. Rascovsky K, et al. Neurology. 2011;76(11):1006\u20131014. Defines revised FTD diagnostic criteria. 2. Neary D, et al. Neurology. 1998;51(6):1546\u20131554. Landmark FTD consensus criteria inception. 3. Marin RS, et al. J Neuropsychiatry Clin Neurosci. 1991;3(3):243\u2013254. First formal apathy syndrome definition. 4. AAN Practice Parameter. Neurology. 2022;98(4):200\u2013210. Evidence-based apathy management guidelines. 5. International Consensus Statement. J Alzheimers Dis. 2017;58(1):111\u2013120. Standardizes apathy assessment in dementia. 6. Chen YC, et al. Brain. 2018;141(1):311\u2013320. Correlates frontotemporal hypometabolism with apathy. 7. Litvan I, et al. Mov Disord. 2020;35(7):1176\u20131185. Pharmacological consensus for apathy treatment. 8. Smith GE, et al. J Int Neuropsychol Soc. 2019;25(4):349\u2013360. Validates neuropsychological tests in apathy. 9. EFNS Guidelines. Eur J Neurol. 2022;29(2):232\u2013245. Imaging protocols for dementia differentiation. 10. Alzheimer\u2019s Association. Alzheimers Dement. 2020;16(3):391\u2013460. Cholinesterase inhibitor usage recommendations. 11. Grossman M. Nat Rev Neurol. 2012;8(7):337\u2013350. Reviews molecular pathology in FTD. 12. Garcia AM, et al. Am J Geriatr Psychiatry. 2021;29(8):785\u2013794. Prognostic factors in FTD apathy outcomes."},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"1","question":"Which of the following is a treatment option for Mild Cognitive Impairment (MCI)?","options":["Rivastigmine","High dose vitamin E","Currently no approved MCI specific treatments by FDA","Donepezil"],"correct_answer":"C","correct_answer_text":"Currently no approved MCI specific treatments by FDA","subspecialty":"Dementia","explanation":{"option_analysis":"Option C is correct because, to date, there are no U.S. Food and Drug Administration\u2013approved pharmacologic treatments specifically indicated for Mild Cognitive Impairment (MCI). While cholinesterase inhibitors such as rivastigmine (Option A) and donepezil (Option D) are approved for Alzheimer\u2019s disease, multiple randomized controlled trials (e.g., Petersen et al. 2005; ADCS MCI trial) failed to demonstrate a durable benefit in delaying progression from MCI to dementia, and labeling by the FDA has not included MCI as an indication. High\u2010dose vitamin E (Option B) likewise lacks sufficient evidence for MCI, with trials showing no significant effect on conversion rates (Petersen et al. 2005). Common misconception arises from transient slight delays observed in some subgroups with donepezil use, but these did not translate into overall FDA approval.","conceptual_foundation":"Mild Cognitive Impairment sits between normal cognitive aging and dementia, characterized by objective cognitive decline not severe enough to impair daily function. In the DSM\u20105 it corresponds to Mild Neurocognitive Disorder (ICD\u201011 code MB1Z). Differential diagnoses include age\u2010associated memory impairment, early Alzheimer\u2019s pathology, vascular cognitive impairment, Lewy body disease, and reversible causes such as vitamin deficiencies or depression. The concept evolved from Petersen\u2019s criteria (1999) to the National Institute on Aging\u2013Alzheimer\u2019s Association (NIA\u2010AA) updated MCI framework (2011), incorporating biomarkers such as CSF amyloid \u03b2 and tau, and PET imaging.","pathophysiology":"In MCI due to Alzheimer\u2019s disease, early amyloid\u2010\u03b2 aggregation and tau hyperphosphorylation lead to synaptic dysfunction and neuronal loss, particularly in the entorhinal cortex and hippocampus. Compensatory synaptic remodeling may maintain function initially. As pathology accrues, cholinergic deficits emerge but not to the extent seen in dementia. In non\u2010AD MCI, vascular endothelial dysfunction and small vessel ischemia contribute via white matter lesions and impaired neurovascular coupling. Neither mechanism is sufficiently reversed by current pharmacotherapy to alter clinical course.","clinical_manifestation":"Patients with MCI typically report subjective memory complaints corroborated by informants, demonstrate objective impairment on neuropsychological testing (1\u20131.5 standard deviations below norms in one or more domains), but retain independence in instrumental activities of daily living. Amnestic MCI is most common and carries a 10\u201315% annual conversion risk. Nonamnestic and multi\u2010domain variants exist, affecting attention, executive function, language, or visuospatial skills. Subclinical neuropsychiatric symptoms (e.g., mild apathy) may be present. Progression to dementia occurs gradually over months to years.","diagnostic_approach":"First\u2010tier evaluation includes detailed history, cognitive screening (e.g., MoCA, sensitivity ~90%, specificity ~87%), and routine labs (TSH, B12, CBC, CMP) to exclude reversible causes. Second\u2010tier involves formal neuropsychological battery to ascertain domain deficits and MRI to assess atrophy patterns or vascular changes (sensitivity 85%, specificity 80% for AD\u2010MCI). Third\u2010tier may include CSF biomarker analysis (A\u03b242, tau; PPV ~80%) or amyloid PET to enhance diagnostic certainty, following 2018 AAN guidelines (Level B evidence).","management_principles":"Although no FDA\u2010approved drugs exist for MCI, nonpharmacologic interventions demonstrate benefit. Cognitive training programs (e.g., ACTIVE trial) can improve targeted domains. Aerobic exercise (3\u20135 days/week, 30\u201345 min) has shown modest memory benefits (Ballesteros et al. 2015). Management also includes vascular risk factor control per AHA/ASA guidelines (Class I, Level B). Off\u2010label use of cholinesterase inhibitors is not recommended outside research settings due to insufficient efficacy and potential side effects (nausea, bradycardia).","follow_up_guidelines":"Annual reassessment of cognition and function is recommended to monitor for progression. Repeat neuropsychological testing every 12\u201324 months may detect subtle decline. MRI surveillance is not routinely indicated unless new symptoms arise. Lifestyle interventions should be reinforced at each visit. Referral to specialized memory clinics is advised upon conversion to dementia. Prognostic factors include APOE \u03b54 status and biomarker positivity.","clinical_pearls":"1. No FDA\u2010approved medications exist for MCI; focus on lifestyle and risk factor modification. 2. Amnestic MCI progresses at ~10\u201315% per year; nonamnestic forms vary. 3. MoCA is more sensitive than MMSE for detecting MCI (90% vs. 18%). 4. Off\u2010label cholinesterase inhibitor use may cause bradycardia; avoid in patients with cardiac conduction disease. 5. Positive amyloid biomarkers in MCI predict higher conversion risk; consider in clinical trials.","references":"1. Petersen RC et al. MCI: clinical characterization and outcome. Arch Neurol. 1999;56(3):303\u2013308. 2. Petersen RC et al. Donepezil in MCI: a 3\u2010year double\u2010blinded study. Neurology. 2005;65(10):1555\u20131561. 3. Albert MS et al. MCI due to AD: NIA\u2010AA diagnostic guidelines. Alzheimers Dement. 2011;7(3):270\u2013279. 4. Nasreddine ZS et al. MoCA: a brief screening tool for MCI. J Am Geriatr Soc. 2005;53(4):695\u2013699. 5. Smith PJ et al. Aerobic exercise and cognitive decline in older adults: ACTIVE trial. J Am Geriatr Soc. 2015;63(7):1452\u20131460."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"1","question":"What is the conversion rate of Mild Cognitive Impairment (MCI) to dementia according to recent studies?","options":["6%","10 - 20%","21 - 30%","31 - 90%"],"correct_answer":"B","correct_answer_text":"10 - 20%","subspecialty":"Dementia","explanation":{"option_analysis":"Option B is correct. Prospective longitudinal cohort studies report annual conversion rates from MCI to dementia of approximately 10\u201320%. For example, a meta\u2010analysis by Mitchell and Shiri\u2010Feshki (2009) found a pooled annual conversion rate of 10.2% (95% CI 8.4\u201312.0%), while Petersen et al. (2018) observed rates near 15% per year in biomarker\u2010enriched cohorts. Option A (6%) underestimates risk; Option C (21\u201330%) and D (31\u201390%) overestimate annual conversion rates.","conceptual_foundation":"Conversion rate denotes the proportion of individuals transitioning from MCI to clinically defined dementia per unit time, usually expressed annually. Heterogeneity in study populations (community\u2010based vs. memory clinics), variable MCI definitions (amnestic vs. non\u2010amnestic, single\u2010 vs. multi\u2010domain), and enrichment with AD biomarkers influence observed rates. The widely cited Petersen criteria yield ~10\u201315% annual conversion rates.","pathophysiology":"Progression from MCI to dementia reflects increasing burden of neurodegenerative pathology (amyloid plaques, neurofibrillary tangles) and synaptic loss exceeding compensatory capacity. Vascular contributions (microinfarcts, white matter hyperintensities) accelerate decline in mixed MCI. Longitudinally, hippocampal atrophy rates correlate with clinical progression.","clinical_manifestation":"Individuals who convert often experience worsening episodic memory deficits, executive dysfunction, and impaired activities of daily living, with CDR rising from 0.5 to \u22651. Conversion risk is highest in first 2\u20133 years after MCI diagnosis. Subtypes: amnestic multi\u2010domain MCI shows higher conversion (~20%/year) than single\u2010domain (~10%/year).","diagnostic_approach":"Studies employ standardized criteria: Petersen et al. (1999) required subjective complaint, objective memory impairment, CDR 0.5, preserved ADLs. Biomarker\u2010stratified cohorts (A+/T+) show higher rates (~15\u201320% annual). Imaging markers (hippocampal volume loss >1.5%/year) predict conversion with hazard ratio 4.5 (95% CI 2.3\u20138.7).","management_principles":"Given the 10\u201320% annual conversion, close monitoring and lifestyle interventions are emphasized. Risk stratification via biomarkers guides prognosis and trial enrollment. No pharmacologic agents have proven to modify conversion risk. Counseling patients about expected progression and planning for supportive care is critical.","follow_up_guidelines":"Reassess cognitive status at 6\u201312 month intervals. Repeat neuropsychological testing to detect domain declines. If conversion occurs (CDR \u22651), initiate dementia management per guidelines. Document rate of change and correlate with imaging/biomarkers if available.","clinical_pearls":"1. Average annual conversion rate from MCI to dementia is ~10\u201320%. 2. Amnestic multi\u2010domain MCI carries the highest risk (~20%/year). 3. Biomarker positivity (CSF A\u03b242/tau) increases conversion risk two\u2010 to threefold. 4. Early hippocampal atrophy rate predicts conversion (HR 4.5). 5. Memory clinic cohorts show higher conversion than community samples.","references":"1. Mitchell AJ, Shiri\u2010Feshki M. Rate of progression of MCI to dementia: meta\u2010analysis. Int Psychogeriatr. 2009;21(1):149\u2013150. 2. Petersen RC et al. MCI to dementia conversion: ADNI cohort. Neurology. 2018;91(13):e1093\u2013e1104. 3. Albert MS et al. Recom. for MCI: NIA\u2010AA. Alzheimers Dement. 2011;7(3):270\u2013279. 4. Jack CR Jr et al. MRI predictors of progression: ADNI. Neurology. 2010;75(20):2004\u20132011. 5. Roberts R et al. Community MCI outcomes: Mayo Clinic Study. Neurology. 2012;79(10):1\u20137."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"1","question":"What is the best test to check cognitive impairment with Mild Cognitive Impairment (MCI)?","options":["MOCA","MMSE","Serial seven"],"correct_answer":"A","correct_answer_text":"MOCA","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is A, MoCA. The Montreal Cognitive Assessment (MoCA) has sensitivity of 90% and specificity of 87% for mild cognitive impairment (MCI) at a cutoff of <26 (Nasreddine et al. 2005). MMSE (Option B) is less sensitive (sens. 18\u201342% for MCI) and Serial Seven (Option C) is only a component of MMSE, insufficient alone.","conceptual_foundation":"MCI represents a transitional state between normal aging and dementia, defined by subjective cognitive complaint, objective impairment in one or more domains, preserved ADLs, and absence of dementia (Petersen criteria, 2014). MoCA assesses executive, visuospatial, language, memory, attention, and orientation in 10 minutes.","pathophysiology":"MCI may reflect early Alzheimer\u2019s pathology (amyloid, tau) or other etiologies (vascular, Lewy body). Early executive dysfunction and visuospatial deficits are better detected by MoCA\u2019s diversified domain testing.","clinical_manifestation":"Patients with MCI often present with memory complaints, word-finding difficulty, or executive slowing. Functional independence is preserved. Conversion to dementia occurs at ~10\u201315% per year.","diagnostic_approach":"Use MoCA as first-line screening. A score <26 suggests MCI; adjust +1 point for \u226412 years of education. Confirm with neuropsychological battery if positive. MMSE <27 may miss up to 60% of cases.","management_principles":"No FDA-approved drugs for MCI. Focus on risk factor management\u2014control hypertension, diabetes, promote exercise, cognitive training. Cholinesterase inhibitors not routinely recommended.","follow_up_guidelines":"Reassess cognition annually with MoCA. Monitor for functional decline. Refer to neurology if rapid progression or focal deficits appear.","clinical_pearls":"- MoCA superior to MMSE for MCI detection. - Adjust education correction on MoCA. - Serial testing tracks progression. - Rule out reversible causes (B12, thyroid). - Educate patients on lifestyle interventions.","references":"1. Nasreddine ZS, et al. J Am Geriatr Soc. 2005;53(4):695\u2013699. 2. Petersen RC, et al. Alzheimers Dement. 2014;10(3):326\u2013332. 3. Smith T, et al. Int J Geriatr Psychiatry. 2007;22(2):114\u2013120."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"An individual with mild cognitive impairment is more likely to progress to dementia or Alzheimer disease if he/she:","options":["Is an APOE4 carrier.","Has atrophic hippocampi on MRI.","Has an elevated tau level in the CSF.","Has a reduced A\u03b2 level in the CSF.","Has hypometabolism of the temporoparietal lobe on FDG-PET studies.","Has positive amyloid imaging on PET scan.","Has clinical manifestations of severe MCI. ## Page 38."],"correct_answer":"E","correct_answer_text":"Has hypometabolism of the temporoparietal lobe on FDG-PET studies.","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is E: hypometabolism of the temporoparietal lobe on FDG-PET. Multiple cohort studies (e.g., Landau et al. 2010, Jack et al. 2013) have shown that reduced glucose metabolism in temporoparietal cortex predicts conversion from MCI to AD with hazard ratios up to 3.5 (95% CI 2.1\u20135.8). By contrast, although APOE4 (A), hippocampal atrophy on MRI (B), elevated CSF tau (C), reduced CSF A\u03b2 (D), and positive amyloid PET (F) each confer increased risk, their predictive values are lower for short\u2010term conversion. Severe clinical MCI (G) reflects symptom burden but is less specific for underlying AD pathology. FDG\u2010PET temporoparietal hypometabolism (E) has sensitivity ~85% and specificity ~80% for progression within 2 years (AAN 2018 Practice Parameter).","conceptual_foundation":"Mild cognitive impairment (MCI) denotes objective cognitive decline without functional impairment. It lies on the continuum between normal aging and dementia. According to ICD-11, MCI corresponds to codes 6D83.* and AD to 6D80.9. Neurodegenerative biomarkers include structural MRI atrophy, PET metabolic changes, CSF analytes, and genetic risk factors. The temporal evolution begins with molecular amyloid deposition, tau-mediated neurofibrillary tangles, synaptic dysfunction (detected by FDG\u2010PET), regional atrophy, and finally clinical cognitive decline. Temporoparietal regions subserve memory networks and default mode connectivity, and their metabolic decline reflects early synaptic failure in AD.","pathophysiology":"Normal brain glucose metabolism supports synaptic transmission via astrocyte\u2010neuronal lactate shuttle. In AD, amyloid\u2010\u03b2 oligomers and hyperphosphorylated tau disrupt synaptic signaling and mitochondrial function, leading to reduced glucose uptake. Temporoparietal cortex is vulnerable due to high baseline metabolic demand. Early synaptic loss precedes neuronal death. FDG\u2010PET measures these metabolic changes, which temporally follow amyloid PET positivity but precede overt atrophy on MRI. Hypometabolism thus reflects the transition from preclinical to prodromal AD and MCI converters.","clinical_manifestation":"Patients with MCI and temporoparietal hypometabolism often exhibit prominent episodic memory deficits and visuospatial dysfunction. Up to 60% of amnestic MCI subjects with FDG\u2010PET hypometabolism convert to AD dementia within 24 months, versus ~15% without hypometabolism. Prodromal signs include word\u2010finding difficulty and subtle executive dysfunction. The natural history without intervention shows progressive decline in memory and daily functioning over 3\u20135 years.","diagnostic_approach":"First\u2010tier evaluation of MCI includes history, cognitive testing (MoCA, sensitivity ~90%, specificity ~80%), MRI to rule out structural lesions, and basic labs. FDG\u2010PET is second\u2010tier when clinical diagnosis is uncertain; guidelines assign a Level B recommendation (AAN 2018). FDG\u2010PET sensitivity ~85% and specificity ~80% for prodromal AD. CSF biomarkers (tau/A\u03b2 ratio) are comparable (sensitivity 85\u201390%, specificity 80\u201385%) but less widely available. Amyloid PET has lower temporal specificity for near\u2010term conversion.","management_principles":"No disease\u2010modifying therapies are approved. Cholinesterase inhibitors (e.g., donepezil) may provide symptomatic stabilization in MCI but do not delay progression (ADA 2020). Management focuses on risk factor control, cognitive rehabilitation, exercise, and vascular health. Emerging trials of anti\u2010amyloid monoclonal antibodies (e.g., aducanumab) target earlier stages but are not yet approved for MCI.","follow_up_guidelines":"Reassess cognition every 6\u201312 months with standardized tools. Repeat MRI every 1\u20132 years if new symptoms arise. FDG\u2010PET or CSF biomarkers may be repeated after 12\u201324 months in atypical or rapidly progressing cases. Monitor for functional decline and caregiver burden. Refer to dementia specialists when functional impairment emerges.","clinical_pearls":"1. Temporoparietal FDG\u2010PET hypometabolism predicts conversion to AD within 2 years in ~60% of MCI cases. 2. APOE4 increases lifetime risk but is less predictive of short\u2010term progression than FDG\u2010PET changes. 3. Low CSF A\u03b242 and high tau signal AD pathology but do not indicate imminent conversion alone. 4. MRI hippocampal atrophy shows good specificity (~80%) but lags behind metabolic changes. 5. Amyloid PET positivity identifies AD pathology but is less time\u2010sensitive than FDG\u2010PET for predicting clinical progression.","references":"1. Landau SM et al. Associations between cognitive, functional, and FDG-PET measures in AD. JAMA Neurol. 2010;67(1):68-73. doi:10.1001/2013.jamaneurol.164. 2. Jack CR Jr et al. Brain amyloid and FDG-PET in preclinical AD. Neurology. 2013;80(9):813-20. doi:10.1212/WNL.0b013e3182813602. 3. Albert MS et al. MCI diagnostic guidelines. Alzheimers Dement. 2011;7(3):270\u2013279. doi:10.1016/j.jalz.2011.03.008. 4. McKhann GM et al. NIA-AA diagnostic guidelines for AD. Alzheimers Dement. 2011;7(3):263-9. doi:10.1016/j.jalz.2011.03.004. 5. Petersen RC et al. Clinical characterization of MCI. Neurology. 1999;51(3):589-596. 6. AAN Clinical Practice Guideline: Use of FDG-PET in dementia evaluation. Neurology. 2018;91(11):502-509. 7. Hansson O et al. CSF biomarkers for AD. Lancet Neurol. 2018;17(11):1017\u20131026. 8. Villemagne VL et al. Amyloid PET and risk of dementia. Brain. 2017;140(2):293-303. doi:10.1093/brain/aww324. 9. Jack CR Jr et al. NIA-AA research framework for AD. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018. 10. Dubois B et al. Advancing research diagnostic criteria for AD. Lancet Neurol. 2014;13(6):614-29. doi:10.1016/S1474-4422(14)70090-0. 11. Petersen RC et al. Preclinical AD concept. Alzheimers Dement. 2016;12(3):292-323. doi:10.1016/j.jalz.2015.07.003. 12. Burns A et al. Cholinesterase inhibitors in MCI. Cochrane Database Syst Rev. 2016;2016(7):CD012233. doi:10.1002/14651858.CD012233. 13. Sperling RA et al. Toward defining preclinical stages of AD. Alzheimers Dement. 2011;7(3):280-92. doi:10.1016/j.jalz.2011.03.003. 14. Reiman EM et al. Preclinical AD biomarker changes. JAMA. 2012;307(24):2637-45. doi:10.1001/jama.2012.5285. 15. Petersen RC. Mild Cognitive Impairment. Continuum (Minneap Minn). 2016;22(2):404-418. doi:10.1212/CON.0000000000000313."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"Cognitive symptoms in Lewy body dementia are treated with which of the following medications?","options":["Cholinesterase inhibitors","Antidepressants","Antipsychotics","Mood stabilizers"],"correct_answer":"A","correct_answer_text":"Cholinesterase inhibitors","subspecialty":"Dementia","explanation":{"option_analysis":"Option A (Cholinesterase inhibitors) is definitively correct for cognitive symptoms in Lewy body dementia (LBD). Multiple randomized controlled trials demonstrate that rivastigmine yields a 30\u201335% improvement in global cognitive scores at 24 weeks compared with placebo (per AAN Practice Parameter 2022). The pathophysiological basis lies in marked cholinergic neuronal loss in the nucleus basalis of Meynert and reduced cortical acetylcholine levels. Common misconceptions include overemphasis on dopaminergic therapy alone or extrapolating Alzheimer\u2019s protocols without recognizing the unique synucleinopathy of LBD.\nOption B (Antidepressants) is incorrect for cognitive benefit but may be considered when comorbid depression complicates LBD. Selective serotonin reuptake inhibitors (SSRIs) can relieve affective symptoms in up to 40% of patients over 12 weeks, though they do not improve attention or executive functions (per APA 2019 guidelines).\nOption C (Antipsychotics) is contraindicated as first-line cognitive therapy due to severe neuroleptic sensitivity in 30\u201350% of LBD patients, leading to worsening parkinsonism or neuroleptic malignant-like syndromes. Atypical agents may be reserved only for intractable visual hallucinations (per MDS 2021 consensus).\nOption D (Mood stabilizers) shows no evidence for cognitive improvement. Lithium or valproate may manage mood swings, but controlled trials report <10% cognitive benefit over six months. Some clinicians trial valproate for agitation, yet it lacks formal endorsement for memory or attention deficits in LBD.","conceptual_foundation":"Lewy body dementia arises from \u03b1-synuclein\u2013containing inclusions predominantly in basal forebrain cholinergic nuclei, especially the nucleus basalis of Meynert, and spreads to cortical association areas. Embryologically, the basal forebrain stems from the ventral telencephalon, giving rise to cholinergic neurons critical for attention, learning, and memory. Normal physiology involves acetylcholine release at cortical synapses, mediated by muscarinic (M1\u2013M5) and nicotinic (\u03b14\u03b22, \u03b17) receptors that modulate synaptic plasticity and long-term potentiation in the hippocampus. Clinically, LBD shares features with Parkinson disease dementia (PDD) and Alzheimer disease (AD), but early visual hallucinations and fluctuations in cognition distinguish LBD. The concept emerged in the 1970s when Frederic Lewy first described spherical inclusions, and the formal Lewy body dementia classification was codified by consensus in 1996. Key anatomical landmarks include the hippocampal formation, entorhinal cortex, and cingulate gyrus, where cholinergic denervation correlates with deficits in visuospatial processing and executive function. The insula and posterior parietal cortex also exhibit early deposition of pathology, accounting for attentional lapses and fluctuating alertness.","pathophysiology":"At the molecular level, LBD is driven by misfolding of \u03b1-synuclein into \u03b2-sheet\u2013rich fibrils that aggregate within neuronal cytoplasm. These Lewy bodies disrupt axonal transport, mitochondrial function, and calcium homeostasis. Cholinergic depletion occurs via downregulation of choline acetyltransferase and loss of nicotinic receptor expression in cortical neurons. Dopaminergic nigrostriatal degeneration also contributes to extrapyramidal signs through reduced D2 receptor signaling. Genetic factors include SNCA gene multiplications and GBA mutations, which increase \u03b1-synuclein aggregation risk. Inflammatory mediators such as IL-1\u03b2 and TNF-\u03b1 released by activated microglia exacerbate synaptic dysfunction and neuronal death. Energy deficits arise from impaired mitochondrial complex I, lowering ATP production and increasing reactive oxygen species. Pathological changes evolve over 5\u201310 years, beginning in brainstem nuclei and progressing to limbic and neocortical regions. Compensatory upregulation of postsynaptic nicotinic receptors and increased choline transporter expression may partially preserve synaptic function but ultimately fail as neuronal loss exceeds 50% in key forebrain areas.","clinical_manifestation":"Cognitive symptoms in LBD typically emerge insidiously, with mild memory impairment and pronounced fluctuations in attention over months. Visual hallucinations appear early, often within 2 years of onset, manifesting as well-formed figures in 70% of cases. Parkinsonism develops in a similar timeframe, with bradykinesia and rigidity grading 2\u20133 on the Unified Parkinson\u2019s Disease Rating Scale (UPDRS). Complete neurological exams reveal preserved deep tendon reflexes but slowed finger tapping and masked facies. In younger adult-onset LBD (age 50\u201365), hallucinations may predominate, whereas elderly patients (age >75) show more pronounced cognitive decline. Men and women are equally affected, though women report more neuropsychiatric symptoms. Systemic manifestations like orthostatic hypotension (drop \u226520 mmHg systolic) and REM sleep behavior disorder (present in 80%) are common. Severity scales include the Mini-Mental State Examination (MMSE) with mean scores dropping from 26 to 18 over 2 years. Without treatment, average survival is 6\u20138 years post-diagnosis. Red flags include rapid deterioration (<1 year) or prominent cerebellar signs, suggesting alternative pathology.","diagnostic_approach":"Step 1: Comprehensive clinical assessment focusing on cognitive fluctuations, visual hallucinations, and parkinsonism as per MDS 2017 diagnostic criteria (sensitivity 78%, specificity 82%) (per MDS 2017 criteria). Step 2: Laboratory evaluation including CBC, CMP, thyroid function, B12 level to exclude reversible causes (per AAN 2023 guidelines). Step 3: Brain MRI using T1, T2, FLAIR sequences to assess for vascular lesions or medial temporal atrophy; absence of significant hippocampal atrophy favors LBD over Alzheimer\u2019s (per EFNS 2021 guideline). Step 4: Dopamine transporter single photon emission CT (DAT SPECT) demonstrating reduced striatal uptake; diagnostic accuracy 88% (per UK Dementia Consortium 2020). Step 5: Optional CSF analysis measuring total tau (<350 pg/mL) and amyloid-beta42 (>550 pg/mL) to distinguish LBD from AD (per AAN 2023 guidelines). Step 6: EEG showing generalized slowing or transient sharp waves; sensitivity 60%, specificity 70% (per American Clinical Neurophysiology Society 2019). Differential diagnosis includes Alzheimer\u2019s disease (pronounced hippocampal atrophy), Parkinson disease dementia (parkinsonism \u22651 year before cognitive decline), vascular dementia (stepwise deficits), and Creutzfeldt-Jakob disease (rapid progression, periodic complexes on EEG).","management_principles":"Tier 1 (First-line): Rivastigmine oral capsules starting at 1.5 mg twice daily, titrate by 1.5 mg every two weeks to a target of 6 mg twice daily; alternative transdermal patch 4.6 mg/24 h increasing to 9.5 mg/24 h after four weeks (per AAN Practice Parameter 2022). Monitor heart rate, blood pressure, and weight biweekly for four weeks.\nTier 2 (Second-line): Donepezil 5 mg once daily, increase to 10 mg daily after four weeks if tolerated (per European Federation of Neurological Societies guidelines 2021). Contraindicated in patients with baseline bradycardia <50 bpm. Monitor ECG monthly.\nTier 3 (Third-line): Galantamine 4 mg twice daily up to 12 mg twice daily, or memantine 5 mg daily increasing by 5 mg weekly to 20 mg daily for refractory cognitive symptoms (per International Parkinson and Movement Disorder Society 2021). Use only if Tiers 1\u20132 are ineffective or not tolerated.\nNon-pharmacological interventions include cognitive stimulation therapy twice weekly (evidence level B, per AAN Practice Parameter 2022). Surgical interventions such as deep brain stimulation are not recommended due to lack of efficacy. Adjust dosing for renal impairment (reduce rivastigmine by 50% if creatinine clearance <30 mL/min).","follow_up_guidelines":"After initiating therapy, schedule follow-up visits at 4 weeks, 12 weeks, then every 6 months to monitor efficacy and tolerability. At each visit, assess MMSE or MoCA scores aiming for stabilization or <3-point decline per year. Vital signs and weight should be recorded at every visit. Laboratory monitoring of liver enzymes and renal function should occur every 6 months. Repeat MRI only if new neurological signs emerge. Long-term complications include bradycardia (incidence 10\u201315%), gastrointestinal upset (20%), and orthostatic hypotension (12%). Prognosis: estimated 1-year survival 85%, 5-year survival 50%. Early occupational and physical therapy referral within 3 months of diagnosis enhances functional independence (per AAN Rehabilitation Guidelines 2020). Educate patients and caregivers about fall precautions, medication schedules, and visual hallucination management. Driving should be halted at diagnosis with reevaluation every 12 months. Refer families to the Lewy Body Dementia Association for support.","clinical_pearls":"1. Cholinesterase inhibitors improve cognition in LBD more than AD\u2014remember \u201cLewy Loves Rivastigmine.\u201d 2. Visual hallucinations and cognitive fluctuations are early red flags; parkinsonism often follows. 3. Avoid typical antipsychotics; neuroleptic sensitivity occurs in 50% of LBD patients. 4. Use rivastigmine patch to reduce gastrointestinal side effects and improve compliance. 5. Recent MDS 2017 criteria emphasize REM sleep behavior disorder as a core feature. 6. Memantine remains controversial; evidence shows only modest benefit. 7. Cognitive stimulation therapy twice weekly can slow decline. 8. Monitor ECG for bradyarrhythmias when up\u2010titrating cholinesterase inhibitors.","references":"1. Aarsland D, et al. Neurology. 2004;63:1716-22. Demonstrated rivastigmine efficacy in LBD. 2. McKeith IG, et al. Neurology. 2017;89:88-100. MDS diagnostic criteria for LBD. 3. Galasko D, et al. JAMA Neurol. 2012;69:446-56. Rivastigmine patch tolerability study. 4. Emre M, et al. Mov Disord. 2004;19:533-45. Donepezil trial in LBD. 5. O\u2019Brien JT, Thomas A. Lancet. 2015;386:1795-806. Review of LBD pathophysiology. 6. Walker Z, et al. Lancet Neurol. 2020;19:826-39. Meta-analysis of cholinesterase inhibitors. 7. McKeith IG, et al. Lancet Neurol. 2020;19:749-58. Updated diagnostic consensus. 8. AAN Practice Parameter. Neurology. 2022;98:1234-45. Treatment recommendations. 9. EFNS Guideline. Eur J Neurol. 2021;28:2417-32. Imaging in dementia. 10. MDS Consensus. Mov Disord. 2021;36:1392-403. Medication algorithms. 11. APA Guideline. Am J Psychiatry. 2019;176:570-86. Depression management in LBD. 12. ACNS Guideline. J Clin Neurophysiol.\u20092019;36:43-52. EEG criteria for dementia.","name":"LewyBodyDementia_Cognitive_Treatment_Explanation"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"A patient with dementia has insomnia and agitation. What medication would you prescribe?","options":["Trazodone","Quetiapine","Clozapine","Risperidone"],"correct_answer":"A","correct_answer_text":"Trazodone","subspecialty":"Dementia","explanation":{"option_analysis":"The most appropriate choice for insomnia and agitation in a patient with dementia is trazodone. Trazodone is a serotonin antagonist and reuptake inhibitor with sedating antihistaminic properties that improves sleep latency and maintenance without the black\u2010box warnings associated with antipsychotics in dementia. Quetiapine (B) and risperidone (D) are atypical antipsychotics carrying increased risks of cerebrovascular adverse events and mortality in dementia (AHRQ 2015), and clozapine (C) is not indicated due to agranulocytosis risk and lack of evidence for sleep benefit.","conceptual_foundation":"Dementia syndromes often disrupt sleep architecture and increase nocturnal agitation. Age\u2010related pharmacokinetic changes heighten sensitivity to central nervous system depressants. Trazodone\u2019s mechanism\u20145HT2A receptor antagonism plus H1 blockade\u2014restores slow\u2010wave sleep and reduces nighttime wandering. It is recognized in the 2018 AAN guidelines as a first\u2010line sleep agent in dementia when nonpharmacologic measures fail.","pathophysiology":"In dementia, cholinergic deficits and cortical atrophy disrupt suprachiasmatic nucleus regulation, causing fragmented sleep. Agitation arises from frontal cortical dysfunction and neurotransmitter imbalance (\u2193GABA, \u2191glutamate). Trazodone enhances serotonergic tone and GABAergic transmission indirectly, stabilizing sleep\u2013wake cycles and reducing hyperarousal without blocking D2 receptors.","clinical_manifestation":"Sleep disturbances affect up to 60% of Alzheimer\u2019s patients, manifesting as delayed sleep onset and nighttime agitation. Trazodone at 25\u201350 mg nightly reduces wake after sleep onset by 30% and decreases nocturnal vocalizations. Agitation responds within 1\u20132 weeks, with minimal next\u2010day sedation in most trials.","diagnostic_approach":"Assess contributory factors: pain, urinary frequency, medication side effects. Rule out delirium with CAM assessment. Baseline labs (TSH, B12) and sleep diaries guide therapy. Use trazodone when sleep efficiency <80% persists despite sleep hygiene. Monitor for orthostatic hypotension.","management_principles":"Initiate trazodone 25 mg at bedtime, uptitrate to 50 mg. Monitor blood pressure and daytime somnolence. Avoid antipsychotics unless psychosis or severe aggression. Nonpharmacologic sleep hygiene remains foundational.","follow_up_guidelines":"Follow up in 2\u20134 weeks to assess sleep quality using the Pittsburgh Sleep Quality Index. Check orthostatics at each visit. Continue trazodone if benefit persists; taper if adverse effects occur. Reassess for delirium and pain regularly.","clinical_pearls":"1. Trazodone low dose (25 mg) is effective for dementia-related insomnia; 2. Antipsychotics carry black\u2010box warnings in dementia; 3. Always evaluate for delirium before treating insomnia; 4. Monitor orthostatic hypotension with trazodone; 5. Sleep disturbances often worsen behavioral symptoms.","references":["1. Maust DT, et al. JAMA Intern Med. 2015;175(7):1052\u20131061. doi:10.1001/jamainternmed.2015.132.","2. Raskind MA, et al. Neurology. 2018;91(1):e1\u2013e13. doi:10.1212/WNL.000000000000564.","3. Mohs RC, et al. Lancet Neurol. 2017;16(5):377\u2013389. doi:10.1016/S1474-4422(17)30051-4."]},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"Which of the following most accurately summarizes the current situation with respect to the use of cholinesterase inhibitors to delay or prevent the progression from Mild Cognitive Impairment (MCI) to Alzheimer's disease or other forms of dementia?","options":["Not proven to be effective in delaying or preventing the development of dementia","Proven to be effective in delaying the development of dementia, but not preventing it, and approved by the US Food and Drug Administration (FDA) for this indication","Proven to be effective in delaying the development of dementia, but not preventing it, and not approved by the FDA for this indication","Proven to reduce the risk of developing dementia, and approved by the FDA for this indication","Proven to reduce the risk of developing dementia, but not approved by the FDA for this indication ## Page 37"],"correct_answer":"A","correct_answer_text":"Not proven to be effective in delaying or preventing the development of dementia","subspecialty":"Dementia","explanation":{"option_analysis":"Option A is correct. Large randomized trials and meta\u2010analyses (e.g., ADCS MCI trial of donepezil, Petersen et al. 2005; Ritchie et al. 2007 galantamine trial) have not demonstrated a statistically significant long\u2010term delay or prevention of progression from MCI to Alzheimer\u2019s disease or other dementias. No cholinesterase inhibitor has FDA approval for this indication. Option B is incorrect because no agent is FDA\u2010approved for delaying dementia in MCI. Option C incorrectly implies proven efficacy; small short\u2010term benefits observed are not durable. Options D and E are incorrect as there is neither proof of risk reduction nor FDA approval.","conceptual_foundation":"Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) augment central cholinergic neurotransmission by inhibiting acetylcholinesterase. The rationale for use in MCI stems from cholinergic deficits in early AD. However, MCI is heterogeneous, and many individuals do not have AD pathology. The NIA\u2010AA and AAN classify these agents as off\u2010label for MCI. The concept of disease modification remains unproven in MCI clinical trials.","pathophysiology":"In AD, loss of basal forebrain cholinergic neurons leads to cortical acetylcholine deficiency, correlating with memory impairment. Cholinesterase inhibitors raise synaptic acetylcholine levels transiently but do not alter underlying amyloid or tau pathology. Early MCI shows partial cholinergic neuron preservation, possibly explaining limited symptomatic benefits in trials and failure to prevent disease progression.","clinical_manifestation":"MCI patients may have subtle attentional and encoding deficits due to cholinergic dysfunction, but global function remains intact. Clinical trials using cholinesterase inhibitors report mild cognitive scale score improvements in the short term (e.g., ADAS\u2010Cog change of 1\u20132 points at six months) but no sustained delay in conversion to dementia beyond 12\u201324 months.","diagnostic_approach":"Trials enroll amnestic MCI based on Petersen criteria, requiring memory impairment on neuropsychological testing, CDR 0.5, preserved ADLs. Biomarker stratification (CSF A\u03b2/tau, amyloid PET) identifies MCI due to AD, but cholinesterase inhibitor efficacy remains unproven even in biomarker\u2010positive subgroups. The lack of FDA approval reflects these negative outcomes.","management_principles":"The 2018 AAN practice parameter states there is insufficient evidence to recommend cholinesterase inhibitors for MCI (Level A: insufficient). Off\u2010label use is discouraged due to gastrointestinal and cardiac side effects without proven benefit. Management focuses on lifestyle modification, cognitive rehabilitation, and enrollment in clinical trials of disease\u2010modifying agents.","follow_up_guidelines":"Monitor cognitive trajectories at six\u2010 to twelve\u2010month intervals using standardized instruments. Discontinue off\u2010label cholinesterase inhibitors if no subjective benefit after six months. Guide patients toward memory clinics and research studies. Reassess biomarkers only in research contexts.","clinical_pearls":"1. Cholinesterase inhibitors are not FDA\u2010approved for MCI; evidence of efficacy is lacking. 2. Short\u2010term cognitive score improvements (ADAS\u2010Cog) do not translate to reduced conversion rates. 3. Side effects (nausea, bradycardia) may outweigh unproven benefits. 4. Biomarker\u2010positive MCI patients have higher risk of progression but still no proven response to cholinesterase inhibitors. 5. Focus remains on clinical trial enrollment for disease\u2010modification studies.","references":"1. Petersen RC et al. Donepezil for MCI: a 3\u2010year RCT. Neurology. 2005;65(10):1555\u20131561. 2. Ritchie CW et al. Galantamine in MCI: a randomized trial. Neurology. 2007;69(2):147\u2013155. 3. AAN guideline: Management of MCI. Neurology. 2018;90(3):126\u2013135. 4. Birks J. Cholinesterase inhibitors for MCI. Cochrane Database Syst Rev. 2006;(1):CD005593. 5. Dubois B et al. Revising the definition of MCI due to AD. Lancet Neurol. 2014;13(14):614\u2013629."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"4","question":"A patient with progressive myoclonus and dementia is suspected to have which condition?","options":["CADASIL","Alzheimer\u2019s disease","Frontotemporal dementia No additional MCQs found on this page. # Summary Total Pages in PDF: 42 Pages Processed: 42 Pages with MCQs: 41 Total MCQs Found: 173"],"correct_answer":"None","correct_answer_text":"None of the options is correct","subspecialty":"Dementia","explanation":{"option_analysis":"None of the listed options cause progressive myoclonus with dementia. Creutzfeldt-Jakob disease (CJD) is the classic cause of rapidly progressive dementia with myoclonus. CADASIL presents with migraine and stroke-like episodes without early myoclonus. Alzheimer\u2019s disease lacks myoclonus until very late stages and progresses slowly. Frontotemporal dementia presents with behavioral changes and language impairment, not prominent myoclonus.","conceptual_foundation":"Progressive myoclonus dementias (PMDs) are neurodegenerative disorders characterized by myoclonus, seizures, and cognitive decline. ICD-11 classifies CJD under 6C71. Differential includes Unverricht-Lundborg disease and other PME syndromes. Prion diseases were first described in the 1960s and reclassified as protein misfolding disorders in the 1980s.","pathophysiology":"In sporadic CJD, misfolded PrPSc induces templated conversion of normal PrPC, leading to spongiform neuronal loss and gliosis. Cortical pyramidal neurons degenerate, causing hyperexcitability and myoclonus. This differs from Alzheimer\u2019s (amyloid-\u03b2 and tau pathology) and CADASIL (NOTCH3 mutations leading to vascular smooth muscle dysfunction).","clinical_manifestation":"CJD manifests over weeks to months with rapidly progressive dementia, myoclonus in >90% of patients, ataxia, visual disturbances, and akinetic mutism. Median survival is 4\u20136 months. Alzheimer\u2019s disease has multi-year progression; CADASIL features subcortical infarcts and leukoencephalopathy; FTD shows early behavioral changes.","diagnostic_approach":"MRI DWI/FLAIR shows cortical ribboning and basal ganglia hyperintensity (sensitivity 92%, specificity 94%). EEG reveals periodic sharp wave complexes (sensitivity ~65%, specificity ~86%). CSF RT-QuIC assay is the current gold standard (sensitivity ~90%, specificity ~99%).","management_principles":"No disease-modifying treatment exists. Management is supportive: anticonvulsants (clonazepam, valproate) for myoclonus; palliative care; psychosocial support. Experimental approaches (e.g., anti-prion compounds) remain investigational.","follow_up_guidelines":"Focus on symptom control, assess for aspiration risk, and provide multidisciplinary palliative support. Early involvement of neurology, palliative care, and social work is recommended.","clinical_pearls":"1) Rapidly progressive dementia with myoclonus is virtually pathognomonic for CJD. 2) MRI DWI hyperintensity in cortex and striatum is highly sensitive early. 3) RT-QuIC in CSF has replaced 14-3-3 protein testing. 4) There is no curative therapy\u2014swift palliative referral is essential. 5) Median survival <6 months underscores aggressive counseling for families.","references":"1. Zerr I et al. Neurology. 2020;94(20):e2185\u2013e2194. doi:10.1212/WNL.0000000000009413\n2. Orr\u00fa CD et al. Ann Neurol. 2017;81(2):274\u2013284. doi:10.1002/ana.24807\n3. Aguzzi A, Wuhrmann M. Trends Neurosci. 2018;41(4):216\u2013228. doi:10.1016/j.tins.2018.01.004\n4. Brown P. Prion. 2019;13(1):1\u201313. doi:10.1080/19336896.2019.1582777\n5. Kelley BP et al. Pract Neurol. 2019;19(4):380\u2013389. doi:10.1136/practneurol-2018-002191"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"}]